PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC - Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia Nov 01, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/MRJ865. CME/MOC/NCPD/CPE/AAPA credit will be available until October 17, 2025.

Changing the Future for Families With HoFH: Long-Term Benefits of Early Diagnosis and Treatment for Homozygous Familial Hypercholesterolemia

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Family Heart Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

April W. Armstrong, MD, MPH - Staying on Target Against Moderate to Severe Psoriasis: Strategies for Achieving Sustained Benefits Through TYK2 Inhibition Oct 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RJG865. CME/MOC/AAPA/IPCE credit will be available until October 22, 2025.

Staying on Target Against Moderate to Severe Psoriasis: Strategies for Achieving Sustained Benefits Through TYK2 Inhibition

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

Matthew C. Breeggemann, MD / John C. Lieske, MD - Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management Oct 22, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EZY865. CME credit will be available until October 9, 2025.

Stepping Stones on the Path to a Healthier Future for Patients With Primary Hyperoxaluria Type 1: Expert Perspectives on Ensuring Timely Diagnosis and Appropriate Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Professor Stephen Johnston, MA, PhD - How to Make Multifactorial Clinical Decisions in HR+, HER2- EBC and MBC: Guiding Precision Amid Growing Complexity Oct 22, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SQE865. EBAC/CME/MOC/AAPA/IPCE credit will be available until November 1, 2025.

How to Make Multifactorial Clinical Decisions in HR+, HER2- EBC and MBC: Guiding Precision Amid Growing Complexity

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Arndt Vogel, MD, PhD - Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease Oct 22, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HFK865. CME/MOC credit will be available until October 3, 2025.

Strengthening the Immunotherapy Paradigm in Biliary Tract Cancer: Standardizing Team-Based Strategies With Immune Checkpoint Inhibitors in Advanced Disease

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Christopher D. Still, DO, FACP, FTOS - Optimizing Obesity Management Before and After Bariatric Surgery: The Role of Antiobesity Pharmacotherapy to Reduce Weight and Obesity-Related Comorbidities Oct 22, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RDF865. CME credit will be available until October 3, 2025.

Optimizing Obesity Management Before and After Bariatric Surgery: The Role of Antiobesity Pharmacotherapy to Reduce Weight and Obesity-Related Comorbidities

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

Guillermo Garcia-Manero, MD - Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care Oct 22, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/SZU865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.

Resetting Standards in MDS: New Principles for Integrating Innovative Therapy Into Risk-Adapted Care

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This educational activity is supported through medical education grants from Bristol Myers Squibb and Geron.

Disclosure information is available at the beginning of the video presentation.

Suresh S. Ramalingam, MD, FACP, FASCO - Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC Oct 04, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/BVU865. EBAC/CME credit will be available until October 7, 2025.

Elevating Expectations, Broadening Impact: How to Leverage Immunotherapy and EGFR-Targeted Therapy to Improve Outcomes in Unresectable Stage III NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

William G. Wierda, MD, PhD - Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care Oct 04, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/THK865. CME/MOC/NCPD/CPE credit will be available until October 3, 2025.

Exceeding Expectations in CLL: Workshops on Targeted Standards, Sequential Options, and Emerging Therapeutics for Team-Based Care

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.

Disclosure information is available at the beginning of the video presentation.

Shannon N. Westin, MD, MPH, Ramez N. Eskander, MD - Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XJE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 24, 2025.

Rethinking and Refining Endometrial Cancer Care in the Modern Age of Precision Medicine: How to Translate Clinical Evidence Into Meaningful Improvements for Patients

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical educational grants from AstraZeneca, GSK, and Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).

Disclosure information is available at the beginning of the video presentation.

Roy S. Herbst, MD, PhD - Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/CGJ865. CME/MOC credit will be available until October 9, 2025.

Elevating Care in Resectable Stage I-III NSCLC: Targeted Therapy and Immunotherapy at the Forefront of Multimodal Treatment Strategies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Komal Jhaveri, MD, FACP - Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RFN865. CME/MOC/NCPD/AAPA credit will be available until September 23, 2025.

Embracing Progress, Transforming Treatment, Empowering Patients: Harnessing the Potential of TROP2-Targeted ADC Therapy in TNBC and HR+, HER2- Breast Cancer

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Onyema Ogbuagu, MD, FACP, FIDSA - Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/WHB865. CME/CE/AAPA credit will be available until September 24, 2025.

Adjusting HIV Treatment for ART-Experienced People With HIV: Switching ART to Address Antiretroviral Resistance, Adverse Events, and Adherence Barriers

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity has been supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Naval Daver, MD, Tapan Kadia, MD - Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics Oct 02, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/HGC865. CME/MOC/NCPD/CPE credit will be available until October 5, 2025.

Opportunity Knocks in AML: Guidance on Achieving Truly Personalized Care in Challenging Populations with Modern Therapeutics

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Daiichi Sankyo, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Kura Oncology, Inc., and Syndax.

Disclosure information is available at the beginning of the video presentation.

Marc S. Sabatine, MD, MPH - Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care Sep 23, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CXZ865. CME/AAPA credit will be available until September 17, 2025.

Emerging Options for Targeting PCSK9 in Hypercholesterolemia Management: Visualizing New Routes to Individualized Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Stephanie L. Graff, MD, FACP, FASCO - Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes Sep 23, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AGR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until September 16, 2025.

Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer: Practical Training on Individualizing CDK4/6 Inhibitor Treatment to Enhance Adherence, Quality of Life, and Outcomes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Marwan Noel Sabbagh, MD, FAAN, FANA - From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer’s Disease Sep 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.

From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer’s Disease

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant by Eisai Inc.

Disclosure information is available at the beginning of the video presentation.

April W. Armstrong, MD, MPH - All Things Considered in Psoriasis Management: Looking at the Role of Biologic Therapies in a Holistic Approach Sep 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GMW865. CME/CE/AAPA/IPCE credit will be available until September 3, 2025.

All Things Considered in Psoriasis Management: Looking at the Role of Biologic Therapies in a Holistic Approach

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Lilly.

Disclosure information is available at the beginning of the video presentation.

Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH - Pharmacist-Led RSV Immunization Strategies: Leveraging Trust to Overcome Vaccine Hesitancy Sep 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CPE information, and to apply for credit, please visit us at PeerView.com/MFD865. CPE credit will be available until September 20, 2025.

Pharmacist-Led RSV Immunization Strategies: Leveraging Trust to Overcome Vaccine Hesitancy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported by an independent medical education grant from GSK.

Disclosure information is available at the beginning of the video presentation.

Hope S. Rugo, MD, FASCO - Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer Sep 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TSZ865. CME/MOC/NCPD/CE/AAPA/IPCE credit will be available until August 28, 2025.

Exchanging Ideas on How to Navigate Patient-Centric Clinical Decisions in Integration of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Sara M. Tolaney, MD, MPH - Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC Sep 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until August 29, 2025.

Critically Focusing Decision-Making and Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBC: Modeling Best Practices for Assessing Risk, Selecting Patients for Adjuvant CDK4/6i Therapy, and Fostering Treatment Adherence/Persistence

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Bradley J. Monk, MD, FACS, FACOG - Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment Aug 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YQP865. CME/MOC credit will be available until August 25, 2025.

Advancing Immunotherapy: Revolutionizing Cervical Cancer Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

John E. Anderson, MD - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal Aug 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/USQ865. CME/NCPD/AAPA credit will be available until August 15, 2025.

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Stacey B. Trooskin, MD, PhD, Robert G Gish, MD - A Modern Take on Hepatitis Immunization: Overcoming Today's Hurdles With Recent Guidelines and Practical Strategies Aug 21, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SHN865. CME/NCPD/CPE/AAPA/IPCE credit will be available until August 14, 2025.

A Modern Take on Hepatitis Immunization: Overcoming Today's Hurdles With Recent Guidelines and Practical Strategies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported by an independent medical education grant from GSK.

Disclosure information is available at the beginning of the video presentation.

P. Barton Duell, MD - Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies Aug 20, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.

Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Vanita R. Aroda, MD - Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs Aug 15, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.

Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

Angela Lamarca, MD, PhD, MSc - Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting Aug 15, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EUX865. CME credit will be available until August 6, 2025.

Prioritising Patient-Centric Care in Biliary Tract Cancer: Leveraging Immunotherapy Platforms to Overcome Challenges in the Advanced Setting

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Hussein Tawbi, MD, PhD - Renovating Frontline Care for Metastatic Melanoma: Guidance on Upgrading to Combination Immunotherapy Standards Across Disease Presentations Aug 15, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RQT865. CME/MOC/AAPA/IPCE credit will be available until August 4, 2025.

Renovating Frontline Care for Metastatic Melanoma: Guidance on Upgrading to Combination Immunotherapy Standards Across Disease Presentations

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

Jamy D. Ard, MD, FTOS - Breaking Through Biases: Building Skills for Collaborative Weight Management in Primary Care and Treating Obesity as a Chronic Disease Jul 26, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/TBR865. CME/NCPD/AAPA credit will be available until July 17, 2025.

Breaking Through Biases: Building Skills for Collaborative Weight Management in Primary Care and Treating Obesity as a Chronic Disease

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Ticiana Leal, MD - Achieving Optimal SCLC Care With Established and Innovative Therapies: Latest Evidence, Key Ongoing Trials, and Practical Considerations for Real-World Practice Jul 26, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HXN865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.

Achieving Optimal SCLC Care With Established and Innovative Therapies: Latest Evidence, Key Ongoing Trials, and Practical Considerations for Real-World Practice

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical educational grants provided by Amgen, AstraZeneca, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

Maissaa Janbain, MD, MSCR - Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches Jul 18, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/GXU865. CME/MOC/NCPD/IPCE credit will be available until July 11, 2025.

Clotting the Gaps in VWD Care: Elevating Diagnostic Awareness and Treatment Planning With Modern Therapeutic Approaches

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from CSL Behring.

Disclosure information is available at the beginning of the video presentation.

Hussein Tawbi, MD, PhD / Prof. Christian Blank, MD, PhD - Deploying the Immune GAMBIT Against Melanoma: Guidance on Advances and Medical Breakthroughs With ImmunoTherapy Jul 18, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BYP865. CME credit will be available until July 5, 2025.

Deploying the Immune GAMBIT Against Melanoma: Guidance on Advances and Medical Breakthroughs With ImmunoTherapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

Naval Daver, MD - Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics Jul 18, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YGR865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

Unleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through independent educational grants from AbbVie, Astellas, Bristol Myers Squibb, Daiichi Sankyo, Inc., Kura Oncology, Inc., and Rigel Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Joyce O’Shaughnessy, MD - Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BEX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 2, 2025.

Rising to the Challenges of Early and Advanced HR+ Breast Cancer: Examining Complex Evidence to Inform Clinical Decisions

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Living Beyond Breast Cancer, and GRASP. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Genentech, a member of the Roche Group, and Lilly.

Disclosure information is available at the beginning of the video presentation.

Pier Luigi Zinzani, MD, PhD - Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/QHV865. CME/MOC credit will be available until July 17, 2025.

Stepping Forward to Transform MCL Management: Guidance on the Selection and Use of BTKi Platforms as First-Line Therapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Paolo Ghia, MD, PhD - Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UFU865. CME/MOC credit will be available until July 15, 2025.

Opening With Innovation in CLL: The Practicalities and Potential of Finite Therapy With BTKi Platforms

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Kathleen M. Buchheit, MD / Stella Lee, MD - Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEC865. CME/MOC/CC/AAPA credit will be available until July 4, 2025.

Precision Learning for Precision Medicine: What You Need to Know About Hitting the Type 2 Target With Biologic Treatment for CRSwNP

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Benjamin M. Greenberg, MD, MHS - Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/HXG865. CME credit will be available until June 27, 2025.

Mastering Diagnosis and Navigating the Sea of Targeted Treatments in NMOSD: Practical Guidance on Optimizing Patient Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure information is available at the beginning of the video presentation.

Stephen V. Liu, MD - Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024 Jul 16, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TFK865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Lilly, and Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Barbara Burtness, MD - Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQB865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

Progress Meets Innovation in Head and Neck Cancer: Perspectives on Modern Immunotherapy and Novel Therapeutic Mechanisms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Coherus BioSciences, Inc., and Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Sundar Jagannath, MD, FASCO - Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KQE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

Extending Innovation From Lymphoma to Myeloma: The Next Wave of Bispecific Antibody Breakthroughs for Clinical Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Peter Voorhees, MD - Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VRK865. CME/MOC/AAPA/IPCE credit will be available until July 1, 2025 .

Three Rs for Modern Myeloma Care: Delivering the Right Treatment for the Right Patient at the Right Time With Antibody and BCMA Platforms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Prof. Mohamad Mohty, MD, PhD - Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QTT865. CME credit will be available until July 18, 2025.

Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi.

Disclosure information is available at the beginning of the video presentation.

Jaime Almandoz, MD, MBA, FTOS / Safia Khan, MD - Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight/Obesity Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/SRY865. CME/MOC credit will be available until June 20, 2025.

Cases in Practice: Prioritizing Weight Loss for People With Sleep Disorders and Overweight/Obesity

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Sandip Patel, MD - Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early-Stage NSCLC: A Guide to Patient Assessment, Treatment Selection, and Multidisciplinary Collaboration Across the Disease Continuum Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZUT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

Illuminating the Path With Immunotherapy for Metastatic, Locally Advanced, and Early-Stage NSCLC: A Guide to Patient Assessment, Treatment Selection, and Multidisciplinary Collaboration Across the Disease Continuum

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

Komal Jhaveri, MD, FACP - Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SBE865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

Accelerating Therapeutic Progress in HER2+ and HER2-Low Breast Cancer: State of the Science and Guidance for Individualized Clinical Decisions

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure information is available at the beginning of the video presentation.

Petros Grivas, MD, PhD - On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZDU865. CME/NCPD/AAPA/IPCE credit will be available until June 25, 2025.

On Target: Integrating Trop-2-Directed Therapeutics for Urothelial Carcinoma With Precision

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity has been supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Ruben A. Mesa, MD, FACP - CONTROL Myelofibrosis: Current Options, New Treatment Principles, and Opportunities to Leverage JAKi Platforms and Novel MOAs Jul 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AQJ865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2025.

CONTROL Myelofibrosis: Current Options, New Treatment Principles, and Opportunities to Leverage JAKi Platforms and Novel MOAs

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported by independent medical education grants from Bristol Myers Squibb, Geron, GSK, and Incyte Corporation.

Disclosure information is available at the beginning of the video presentation.

Petros Grivas, MD, PhD - Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care Jun 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MBD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.

Maximizing the Role of ADCs in Urothelial Carcinoma: Practical Tips for Patient Selection, Safety Management, and Collaborative Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program has been supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Nicole Lamanna, MD - Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations Jun 26, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UNN865. CME credit will be available until June 11, 2025.

Redefining Frontlines in CLL: Key Questions on the Role of CIT, BTKi Standards, and Innovative BTKi Combinations

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Manish A. Shah, MD, FASCO - Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms Jun 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/VTE865. CME/MOC/NCPD/AAPA credit will be available until July 2, 2025.

Catalysts for Change in Gastric and GEJ Cancer: Digesting New Evidence and Future Directions of Care With Innovative Immunotherapy and Targeted Platforms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Hope For Stomach Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Astellas, BeiGene, and Bristol Myers Squibb.

Disclosure information is available at the beginning of the video presentation.

Amit Bar-Or, MD, FRCPC / Jiwon Oh, MD, PhD, FRCPC - Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS Jun 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/UCT865. CME/NCPD/CPE/IPCE credit will be available until June 29, 2025.

Taking a Closer Look at Each Patient: Exploring Novel Biomarker and Imaging Strategies in MS

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Yelena Y. Janjigian, MD - Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC Jun 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JPD865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 30, 2025.

Precision Tactics in HER2-Positive GI Malignancies: Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Cholangiocarcinoma Foundation, and the Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure information is available at the beginning of the video presentation.

William Anderson, MD - Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options Jun 19, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/HGM865. CME/MOC/NCPD/CPE/AAPA credit will be available until June 13, 2025.

Improving Outcomes for Pediatric Patients With Uncontrolled Moderate-to-Severe Asthma Using a Collaborative Approach: Recognition, Referral, and Management in the Era of Targeted Treatment Options

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Kun "Kevin" Xiang, MD, PhD - Anticoagulation Therapy in NVAF: A Quality Improvement Initiative Jun 19, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/MXE865. CME/MOC/NCPD/CPE credit will be available until June 12, 2025.

Anticoagulation Therapy in NVAF: A Quality Improvement Initiative

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Disclosure information is available at the beginning of the video presentation.

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting Jun 19, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD/NCPD/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/WUM865. CME/MOC/CPD/NCPD/CPE/AAPA credit will be available until June 21, 2025.

Safeguarding Patients With HR+, HER2-, High-Risk, Early Breast Cancer: A Practical Roadmap for CDK4/6 Inhibition in the Adjuvant Setting

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM Jun 19, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/ZKT865. CME/CE/AAPA credit will be available until June 11, 2025.

Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Monica Gandhi, MD, MPH - Adapting HIV Treatment for People With Substance Use Disorder Jun 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/VCQ865. CME/MOC/CE/AAPA credit will be available until June 4, 2025.

Adapting HIV Treatment for People With Substance Use Disorder

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Rohit Loomba, MD, MHSc - Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH? Jun 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RNX865. CME credit will be available until June 19, 2025.

Experts vs AI: Who Is Better at Monitoring and Treating MASLD and MASH?

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

Prof. Mohamad Mohty, MD, PhD / Caitlin Costello, MD - Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM Jun 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/CAN865. CME/CPD credit will be available until 5 June 2025.

Five Steps for Integrating BCMA Bispecific Innovations: From Clinical Data to Clinical Practice in RRMM

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Pfizer.

Disclosure information is available at the beginning of the video presentation.

Riad Salem, MD, MBA / Mark Yarchoan, MD - Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit Jun 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TCK865. CME/MOC credit will be available until June 14, 2025.

Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Interventional Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Sarah Hayward, PharmD, BCOP / Ambar Khan, PharmD, BCOP - A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care Jun 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/ZPE865. CME/CPE/IPCE credit will be available until May 27, 2025.

A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Jessica Donington, MD - Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches Jun 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/WFQ865. CME/MOC/AAPA credit will be available until June 7, 2025.

Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Suzanne Lentzsch, MD, PhD / Joshua Richter, MD - “Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets Jun 03, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/PHX865. CME credit will be available until May 23, 2025.

“Four-Ward” Progress in NDMM: New Developments With CD38 Antibody Quadruplets

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Nicholas J. Short, MD - Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies and MRD-Guided Strategies Across Disease Settings May 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/XKA865. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.

Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational funding provided by Amgen.

Disclosure information is available at the beginning of the video presentation.

Oliver Sartor, MD - On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer May 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QSV865. CME credit will be available until May 23, 2025.

On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Blue Earth Diagnostics, Lantheus Medical Imaging, and Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations May 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/FRR865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.

Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Jamie Carroll, APRN, CNP, MSN - Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education May 24, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at PeerView.com/USZ865. NCPD/ILNA/AAPA credit will be available until May 8, 2025.

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and The Chrysalis Initiative. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure information is available at the beginning of the video presentation.

Marianne Davies, DNP, ACNP, AOCNP, FAAN / Beth Sandy, MSN, CRNP, FAPO - Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care May 20, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at PeerView.com/XRX865. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical education grants from AstraZeneca, Bristol Myers Squibb, and Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Jonathan A. Bernstein, MD - Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria May 20, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FTH865. CME credit will be available until May 5, 2025.

Chasing the Itch: Exploring the BTK Inhibitor Frontier In Chronic Urticaria

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Jonathan A. Bernstein, MD - BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment May 10, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WQU865. CME credit will be available until May 6, 2025.

BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Saakshi Khattri, MBBS, MD, FAAD, FACR - Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors May 10, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/VEX865. CME/AAPA credit will be available until April 24, 2025.

Interdisciplinary Approaches to Management of Immune-Mediated Inflammatory Diseases: Addressing Shared Pathophysiology With JAK Inhibitors

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Crohn's and Colitis Foundation, National Eczema Association, and Spondylitis Association of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AbbVie.

Disclosure information is available at the beginning of the video presentation.

Joseph K. Han, MD, Seth J. Isaacs, MD - Biologics in CRSwNP: Putting a Paradigm Shift Into Practice May 08, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AMJ865. CME/MOC/CC/AAPA/IPCE credit will be available until May 6, 2025.

Biologics in CRSwNP: Putting a Paradigm Shift Into Practice

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Disclosure information is available at the beginning of the video presentation.

A. Michael Lincoff, MD - Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy May 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/MVU865. CME credit will be available until April 25, 2025.

Exploring the Evidence: Improving Cardiovascular Outcomes and the Role of Weight Loss Pharmacotherapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO - Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platform May 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/CWA865. CME/CPE/IPCE credit will be available until May 2, 2025.

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Disclosure information is available at the beginning of the video presentation.

Lecia V. Sequist, MD, MPH - Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals May 06, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJP865. CME/MOC/AAPA/IPCE credit will be available until April 16, 2025.

Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Carlos G. Romo, MD, Aimee Sato, MD - Precision and Progress Against NF1: Solutions for Better Outcomes With MEKi and Multimodal Care for NF1 pNF and Other Tumors Apr 25, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/XSH865. CME/MOC credit will be available until May 2, 2025.

Precision & Progress Against NF1: Solutions for Better Outcomes With MEKi & Multimodal Care for NF1 pNF and Other Tumors

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Alexion Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

Olalekan Oluwole, MBBS, MPH - Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy Apr 25, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/HKJ865. CME/NCPD credit will be available until April 15, 2025.

Democratizing the CAR-T Experience: The Principles and Practice of Outpatient Cellular Therapy

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Laura S. Dominici, MD, FACS - Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment Apr 25, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/YGX865. CME/MOC/CC credit will be available until April 21, 2025.

Unraveling the Complex Choices in Early Breast Cancer: A Roadmap to Informed Multidisciplinary Decisions About Assessment and Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Apr 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FYP865. CME credit will be available until April 26, 2025.

The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Eisai Inc.

Disclosure information is available at the beginning of the video presentation.

Richard K. Bogan, MD, FCCP, FAASM - Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment Apr 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UVZ865. CME/MOC credit will be available until April 9, 2025.

Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Avadel CNS Pharmaceuticals, LLC.

Disclosure information is available at the beginning of the video presentation.

Jennifer Wargo, MD, MMSc - New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy Apr 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NQH865. CME/MOC/AAPA/IPCE credit will be available until April 21, 2025.

New Chapters in the Immunotherapy Story for Melanoma: Collaborative Care and Next Steps With Adjuvant and Neoadjuvant Therapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through educational grants from Bristol Myers Squibb and Merck & Co., Inc.

Disclosure information is available at the beginning of the video presentation.

Meghan C. Thompson, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care Apr 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WBS865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until April 4, 2025.

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Prof. Dr. med. Stephan Stilgenbauer - Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations Apr 10, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.

Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal Mar 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025.

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Sergio A. Giralt, MD, FACP - Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies Mar 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Krina Patel, MD, MSc - Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses and Enduring Efficacy Mar 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/QQW865. CME/NCPD credit will be available until March 21, 2025.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Zack DeFilipp, MD - Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches Mar 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TGK865. CME/MOC credit will be available until March 20, 2025.

Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Incyte Corporation.

Disclosure information is available at the beginning of the video presentation.

Roy F. Chemaly, MD, MPH, FIDSA, FACP / Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT - Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents Mar 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure information is available at the beginning of the video presentation.

Prof. Mohamad Mohty, MD, PhD / Christine N. Duncan, MD - Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management Mar 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Disclosures
Prof. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.
Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.

Medical Director
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC Mar 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.

The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Sandip Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.
Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.

Faculty/Planner
Tina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca and Bristol Myers Squibb.

Faculty/Planner
John V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.
Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Taofeek K. Owonikoko, MD, PhD - Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic Mar 26, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FUR865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner
Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.
Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Amy Shapiro, MD - A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations Mar 14, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Joshua Sabari, MD - Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon Mutations: How to Navigate the Expanding Options and Increasing Complexity Mar 14, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SKH865. CME/MOC/AAPA/IPCE credit will be available until March 20, 2025.

Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Faculty/Planner
Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.
Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.

Faculty/Planner
Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.
Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in Lilly.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer Mar 14, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.

Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Faculty/Planner
Marina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.
Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.

Faculty/Planner
Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.

Faculty/Planner
Zosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Reshma L. Mahtani, DO - A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights Mar 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.

A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Reshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.
Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Alok A. Khorana, MD, FACP, FASCO - REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism Mar 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CGE865. CME/MOC/AAPA/IPCE credit will be available until February 28, 2025.

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Santosh L. Saraf, MD - Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions Mar 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/QHE865. CME/AAPA credit will be available until February 21, 2025.

Activating Better Care in SCD: Guidance on Novel PKR Agents, Other Innovative Therapies, and Modern Care Transitions

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Sickle Cell Disease Association of America, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Santosh L. Saraf, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agios Pharmacueticals, Inc.; Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk, Inc.; and Pfizer.
Grant/Research Support from Global Blood Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management Feb 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.

Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosures
R. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.

CME Reviewer

Ramil Goel
Assistant Professor of Medicine
Division of Cardiovascular Medicine
Electrophysiology Section
University of Florida College of Medicine
Gainesville, Florida

Ramil Goel, MD, FHRS, has no relevant financial relationships to disclose.

Jessica Donington, MD / Jonathan D. Spicer, MD, PhD, FRCSC - A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC Feb 27, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/QRX865. CME/MOC/CC/AAPA credit will be available until February 27, 2025.

A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Jessica Donington, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.

Co-Chair/Planner
Jonathan D. Spicer, MD, PhD, FRCSC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Chemocentryx; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Protalix Biotherapeutics; Regeneron; and Xenetic Biosciences.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; CLS Therapeutics; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; and Protalix Biotherapeutics.

Faculty/Planner
Patrick M. Forde, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Ascendis Pharma A/S; AstraZeneca; Bristol Myers Squibb; CureVac SE; F-star Therapeutics Inc.; Flame Pharmaceuticals Pvt Ltd; Fosun Pharma USA Inc.; G1 Therapeutics, Inc.; Genelux Corporation; Genentech, Inc.; Gritstone bio, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Synthekine; Tavotek Biotherapeutics; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; BioNTech SE; Bristol Myers Squibb; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Brendon M. Stiles, MD - Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC Feb 21, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/WFZ865. CME/MOC credit will be available until February 27, 2025.

Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Brendon M. Stiles, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; Regeneron; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.

Faculty/Planner
Balazs Halmos, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; AstraZeneca; Bristol Myers Squibb/Bristol Myers Squibb Foundation; F. Hoffmann-La Roche Ltd; Galvanize Therapeutics, Inc.; Genentech, Inc.; Medtronic; and Pfizer.
Grant/Research Support from Bristol Myers Squibb/Bristol Myers Squibb Foundation.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum Feb 21, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/THZ865. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.

Synergizing for Success in HCC: Immunotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Lipika Goyal, MD, MPhil, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alentis Therapeutics AG; Basilea Pharmaceutica; Black Diamond Therapeutics, Inc.; Blueprint Medicines Corporation; Eisai Inc./H3Biomedicine; Exelixis, Inc.; Genentech, Inc.; Incyte Corporation; Kinnate Biopharma Inc.; Merck & Co., Inc.; QED Therapeutics; Relay Therapeutics; Servier Pharmaceuticals; Sirtex Medical Ltd; Surface Oncology; Taiho Oncology, Inc.; and TransThera Biosciences.
Data Safety Monitoring Board for AstraZeneca.

Co-Chair/Planner
Riad Salem, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bard Pharmaceuticals; Boston Scientific Corporation; Cook Medical; Eisai Inc./Merck & Co., Inc.; and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Ghassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches Feb 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.

Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Blue Faery: The Adrienne Wilson Liver Cancer Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This educational activity is supported through independent educational grants from AstraZeneca, Eisai Inc., Exelixis, Inc., Merck & Co., Inc., and Novocure, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Ghassan Abou-Alfa, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Autem Therapeutics; Berry Genomics; BioNTech; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Incyte; Ipsen Biopharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Neogene Therapeutics; NewBridge Pharmaceuticals; Novartis Pharmaceuticals Corporation; Servier Laboratories; Tempus; Vector; and Yiviva.
Grant/Research Support from Agenus Inc.; Arcus Biosciences, Inc.; AstraZeneca; BioNTech; Bristol Myers Squibb; Elicio Therapeutics Inc; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Helsinn Healthcare SA; Parker Institute for Cancer Immunotherapy; Pertzye; Puma Biotechnology, Inc.; QED Therapeutics; and Yiviva.

Faculty/Planner
Anthony El-Khoueiry, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Exelixis, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Merck & Co., Inc.; Qurient; and Senti Biosciences.
Grant/Research Support from Astex Pharmaceuticals; AstraZeneca; Auransa Inc.; and Fulgent Pharma.

Faculty/Planner
Ahmed Omar Kaseb, MD, CMQ, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck & Co., Inc.; Pfizer; and Tvardi Therapeutics.

Faculty/Planner
Stacey M. Stein, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Eisai Inc.; Exelixis, Inc.; and Genentech, Inc.
Data Safety Monitoring Board for Aethlon Medical, Inc.and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Planner
Andrea Wilson Woods
President & Founder, Blue Faery

Andrea Wilson Woods has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca and Humanise Health.

Meghan C. Thompson, MD, Catherine C. Coombs, MD - From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care Feb 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HGE865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 16, 2025.

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.

Co-Chair/Planner
Catherine C. Coombs, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Mingsight Pharmaceuticals, Inc.; and Octapharma USA, Inc.
Grant/Research Support from Lilly.
Speaker for AbbVie Inc.; AstraZeneca; BeiGene, Inc.; and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Anjali Tiku Owens, MD - Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes Feb 09, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.

Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.
Grant/Research Support from Bristol Myers Squibb.

Faculty/Planner
Neil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.
Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Joshua Sabari, MD - Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC Feb 09, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/KYJ865. CME/MOC/CC credit will be available until January 24, 2025.

Mastering the Testing for Common and Uncommon EGFR Mutations to Guide EGFR-Targeted Therapy in Advanced NSCLC

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
The activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey Jan 31, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANR865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 16, 2025.

Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche AG; and Pfizer.

Co-Chair/Planner
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences; Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.; Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

John L. Marshall, MD - Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team Jan 31, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RBK865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 11, 2025.

Hitting the Benchmarks in mCRC: A Precision Medicine Quality Initiative for the Care Team

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
John L. Marshall, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.
Grant/Research Support from Arcos; AstraZeneca; Bayer Corporation; Caris Life Sciences; Merck & Co., Inc.; Oradose; Pfizer; Seagen Inc.; Taiho Oncology, Inc.; Takeda Pharmaceutical Company Limited; and Zcurex.
Other Financial or Material Support Executive role for Indivumed GmbH.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Prof. John G. Gribben, MD, DSc - Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management Jan 31, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YUZ865. CME/MOC credit will be available until December 31, 2024.

Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.

Support
This activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosures
Prof. John G. Gribben, MD, DSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen and Gilead Sciences/Kite.
Grant/Research Support from AstraZeneca.

John N. Allan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene, Inc.; Epizyme, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LAVA Therapeutics; Lilly; Pharmacyclics LLC; and TG Therapeutics, Inc.
Grant/Research Support from BeiGene, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Speaker for AbbVie; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to Institution.
Honoraria from Brazilian Association of Hematology; Curio Science; Dava Oncology; Hemotherapy and Cellular Therapy (ABHH); Intellisphere LLC; Massachusetts Medical Society; MJH Life Sciences; Phillips Group Oncology Communications; and VJHemOnc.

Larry Marion has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Erika Hamilton, MD - Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies Jan 31, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/GHA865. CME/MOC/AAPA credit will be available until January 6, 2025.

Mastering the Art of Precision in the Treatment of HR+ Early and Metastatic Breast Cancer: Risk Assessment, Prognostic Testing, and Selection and Sequencing of Therapies

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Lilly, and Olema Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).
Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).

Faculty/Planner
Komal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.
Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.

Faculty/Planner
Hope S. Rugo, MD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Daiichi Sankyo, Inc.; Mylan/Viatris Inc.; Napo Pharmaceuticals, Inc.; and Puma Biotechnology, Inc.
Grant/Research Support from AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Pfizer; Pionyr Immunotherapeutics; Sermonix Pharmaceuticals; and Stemline Therapeutics.

Faculty/Planner
Paolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; and Lilly.
Grant/Research Support from AstraZeneca.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

María Díez Campelo, MD, PhD - Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment Jan 17, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/BWR865. CME/MOC credit will be available until December 31, 2024.

Exploring Unmarked Territory in MDS: Taking Command and Enhancing Care With Team-Based Diagnosis and Treatment

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.

Disclosures
María Díez Campelo, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Agios Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; GlaxoSmithKline; Hemavant Sciences; Novartis; and Syros Pharmaceuticals, Inc.

Rory M. Shallis, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Curio Bioscience; Gilead Sciences, Inc.; Rigel Pharmaceuticals, Inc.; and Servier Pharmaceuticals.

Aditi Shastri, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kymera Therapeutics; and Rigel Pharmaceuticals, Inc.
Grant/Research Support from Kymera Therapeutics.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Taofeek K. Owonikoko, MD, PhD - Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZZA865. CME/MOC/AAPA credit will be available until January 2, 2025.

Harnessing the Power of the Latest Clinical and Research Advances in SCLC: How to Accelerate Progress and Improve Patient Outcomes With Current and Emerging Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; G1 Therapeutics, Inc.; GenCART; Heat Biologics Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; PharmaMar; Takeda Pharmaceutical Company Limited; Xcovery; and Zentalis Pharmaceuticals.
Grant/Research Support from Aeglea BioTherapeutics; Amgen Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; Cardiff Oncology, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; Incyte; Ipsen Pharma; Loxo Oncology/Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Turning Point Therapeutics, Inc.; United Therapeutics Corporation; and Y-mAbs Therapeutics, Inc.

Faculty/Planner
Hossein Borghaei, DO, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Axiom; Bayer Corporation; BeiGene, Inc.; BerGenbio; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Da Volterra; Daiichi Sankyo, Inc.; EMD Serono, Inc.; Genentech, Inc.; Genmab A/S; Grid Therapeutics; Guardant Health; IO Biotech, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; Pfizer; PharmaMar; Puma Biotechnology; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen Inc.; Bristol Myers Squibb; and Lilly.
Data Safety Monitoring Board for Incyte; Novartis Pharmaceuticals Corporation; SpringWorks Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; and University of Pennsylvania: CAR T Program.

Faculty/Planner
Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Nikhil C. Munshi, MD - Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.

Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Nikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.
Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.

Faculty/Planner
Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Prof. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.
Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.
Speaker for Jazz Pharmaceuticals, Inc.
Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.

Faculty/Planner
Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Sara A. Hurvitz, MD, FACP - Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.

Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Sara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.
Speaker for Curio and OncLive.
Stock Shareholder in RomTech, spouse.

Faculty/Planner
Javier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.
Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.
Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.

Faculty/Planner
Paolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.
Grant/Research Support from AstraZeneca.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Jorge Plutzky, MD - At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DDA865. CME credit will be available until December 26, 2024.

At the Heart of Obesity: Evidence-Based Strategies for Managing Obesity to Reduce Cardiovascular Risks With Weight Loss Pharmacotherapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Jorge Plutzky, MD, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Shmuel Shoham, MD - Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/JXH865. CME credit will be available until December 31, 2024.

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosures
Shmuel Shoham, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adagio Therapeutics, Inc.; Adamis Pharmaceuticals Corporation; Immunome; Karius, Inc.; Pfizer; and SCYNEXIS, Inc.
Grant/Research Support from Ansun Biopharma; Cidara Therapeutics, Inc.; F2G; Octapharma USA, Inc.; and Zeteo Biomedical LLC.

Ghady Haidar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca and Karius, Inc.
Grant/Research Support from Allovir; AstraZeneca; Karius, Inc.; and National Institutes of Health (NIH).
Speaker for International AIDS Society and MDOutlook.

Carol Ann Huff, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Janssen Pharmaceuticals, Inc. and Sanofi.

Haleh Simi has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Jonathan Corren, MD / Mario Castro, MD - Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.

Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Jonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.

Co-Chair/Planner
Mario Castro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.
Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.
Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.
Stock Shareholder in Aer Therapeutics.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Professor Chloe Orkin - Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YHX865. CME/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Getting Personal: Reassessing HIV Management to Better Individualize Treatment Across the Ages

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Professor Chloe Orkin has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.
Grant/Research Support from Gilead Sciences, Inc. and ViiV Healthcare group of companies.
Speaker for Gilead Sciences, Inc.; GSK; Merck Sharp & Dohme; and ViiV Healthcare group of companies.

Patient Advocate/Planner
Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Patient Advocate/Planner
Donald Young has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Steven Brem, MD - Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches Jan 12, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.

Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Steven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Manmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.
Grant/Research Support from Seagen Inc.
Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.

Faculty/Planner
Michelle Kim, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Blue Earth Diagnostics.

Patient/Planner
JB Bird has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

April W. Armstrong, MD, MPH / Tina Bhutani, MD, MAS - Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life Jan 04, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/DJC865. CME/AAPA credit will be available until January 6, 2025.

Staying in the Clear When Managing Psoriasis: Utilizing Biologics to Improve Cutaneous Outcomes in Difficult to Treat Areas, Prevent Psoriatic Disease Progression, and Safeguard Quality of Life

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Parexel International Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals Pte Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; Leo Pharma Inc.; Lilly; Pfizer; and UCB, Inc.

Co-Chair/Planner
Tina Bhutani, MD, MAS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; Sun Pharmaceutical Industries Ltd; and UCB, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Castle Biosciences, Inc.; CorEvitas, LLC; Dermavant Sciences, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Stefano Del Prato, MD - Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making Jan 04, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024.

Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd.
Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Benjamin Levy, MD - Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer Dec 28, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.

Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Benjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.

Faculty/Planner
Charu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.
Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.

Faculty/Planner
Rebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.

Faculty/Planner
Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.
Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.
Data Safety Monitoring Board for Candel Therapeutics.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

PD Dr. med. Luc Biedermann - Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape Dec 28, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RGF865. CME/MOC/AAPA credit will be available until December 27, 2024.

Targeted Biologic Therapy in Eosinophilic Esophagitis: Practical Strategies for a Changing Therapeutic Landscape

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
PD Dr. med. Luc Biedermann has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; EsoCap AG; Janssen-Cilag AG; Lilly; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.
Speaker for AbbVie Inc.; Bristol Myers Squibb; Dr. Falk Pharma GmbH; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited.

Co-Chair/Planner
Jonathan Spergel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARS Pharmaceutical; DBV Technologies; Kaleo, Inc.; ReadySetFood; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Matthew A. Gubens, MD, MS, FASCO - Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care Dec 27, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.

Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.

Faculty/Planner
Jessica Donington, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.

Faculty/Planner
Elaine Shum, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from DELFI Diagnostics.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Yelena Y. Janjigian, MD - Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making Dec 21, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EGP865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until December 12, 2024.

Equitably Empowering Our Upper GI Cancer Patients Using Plain Language Tools to Improve Outcomes With Immunotherapeutic Regimens Through Informed Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported through an educational grant from Bristol Myers Squibb.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Yelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck & Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.
Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck & Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.
Stock Shareholder in Inspirna, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Neal D. Shore, MD, FACS - Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum Dec 21, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UAR865. CME/MOC/AAPA credit will be available until December 31, 2024.

Under Pressure to Improve Prostate Cancer Care: Unlocking the Power of Advanced Therapeutics to Enhance Outcomes Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent medical educational grants from Astellas and Pfizer, Inc., AstraZeneca, Exelixis, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Neal D. Shore, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Accord Healthcare; Alessa Therapeutics; Amgen Inc.; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Aurora Biosciences; Bayer Corporation; BioProtect Ltd.; Boston Scientific Corporation; Bristol Myers Squibb; CG Oncology; Clarity Pharmaceuticals Ltd; Dendreon Pharmaceuticals LLC; Exact Images; Ferring Pharmaceuticals; FIZE Medical; Foundation Medicine, Inc.; F. Hoffmann-La Roche Ltd./Genentech Inc.; GenesisCare; ImmunityBio; Incyte Corporation; Invitae Corporation; Janssen Pharmaceuticals, Inc.; Lantheus; Lilly; MDX; Merck & Co., Inc.; Minomic International Ltd; Myovant Sciences Ltd; Myriad Genetics, Inc.; Nonagen Bioscience; Novartis Pharmaceuticals Corporation; Nymox Pharmaceutical Corporation; Pacific Edge; Palette Life Sciences, Inc.; Pfizer; Photocure; PlatformQ; ProFound Therapeutics; Promaxo; Propella Therapeutics, Inc.; Protara Therapeutics Inc.; Sanofi/Genzyme; Specialty Networks; Telix Pharmaceuticals; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

Faculty/Planner
Alicia K. Morgans, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Advanced Accelerator Applications (AAA); Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Lantheus; Merck & Co., Inc.; Myovant Sciences Ltd.; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Telix Pharmaceuticals Limited.
Grant/Research Support from Astellas Pharma Inc.; Bayer Corporation; Myovant Sciences Ltd.; Pfizer; and Sanofi.

Faculty/Planner
Ashley E. Ross, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; BillionToOne Inc.; Blue Earth Therapeutics; and Janssen Pharmaceuticals, Inc.
Grant/Research Support from Astellas/Pfizer/Sumitovant/Myovant; Bayer Corporation; Blue Earth Therapeutics; and Lantheus.
Speakers Bureau participant with Bayer HealthCare Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Blue Earth Therapeutics; Lantheus; and Veracyte, Inc.

Faculty/Planner
Matthew R. Smith, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ambrx; Astellas Pharma US, Inc.; Bayer Corporation; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

W. Troy Donahoo, MD, FTOS - Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change Dec 14, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/PZM865. CME/NCPD/AAPA credit will be available until November 26, 2024.

Obesity as a Chronic Disease: Practicing What We Preach to Overcome Stigma and Inspire Change

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosures
W. Troy Donahoo, MD, FTOS, has no financial interests/relationships or affiliations in relation to this activity.

Amy J. Sheer, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Actors of Health Care Theatre have nothing to disclose.

Medical Directors
Angela McIntosh, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Margery Tamas, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Darren McGuire, MD, MHSc - Translating Data Into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes Dec 12, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UGE865. CME credit will be available until December 5, 2024.

Translating Data into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Darren McGuire, MD, MHSc, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support in the form of clinical trial leadership for AstraZeneca; CSL Behring; and Esperion Therapeutics, Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care Dec 12, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.

Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Roxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.
Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).
Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.
Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.

Co-Chair/Planner
Jeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.
Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Thomas G. Martin, III, MD - The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms Dec 12, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.

The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Thomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.

Faculty/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care Dec 06, 2023

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.

Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.
Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.

Co-Chair/Planner
Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.
Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care Dec 06, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.

Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.
Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner
Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Horizon CME and OncLive.

Faculty/Planner
Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Incyte.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM Dec 01, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024.
Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Co-Chair/Planner
Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application Dec 01, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.
FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from argenx US, Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.
Faculty/Planner
Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

James D. Berry, MD, MPH - Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.
Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.
Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.
Data Safety Monitoring Board for Sanofi.
Co-Chair/Planner
Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.
Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Eric Marsh, MD, PhD - Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UDJ865. CME credit will be available until November 20, 2024.
Honing Diagnostic and Management Skills: The Role of the Pediatrician in the New Era of Rett Syndrome Management
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Eric Marsh, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc. and Stoke Therapeutics.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Curaleaf, Inc.; Epygenix Therapeutics, Inc.; Marinus Pharmaceuticals, Inc.; Stoke Therapeutics; and Takeda Pharmaceutical Company Limited.
Faculty/Planner
David N. Lieberman, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.; Anavex Life Sciences Corp.; and Jazz Pharmaceuticals, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Nirav Shah, MD, MS / Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD - Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GYD865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until November 26, 2024.
Reviving the BTK Target in MCL: Recalibrating the Treatment Sequence With Non-Covalent BTK Inhibitors in R/R Disease
Covalent BTK inhibitors (cBTKi) have transformed the management of mantle cell lymphoma (MCL). However, their efficacy as second-line therapies is often hindered by intolerance and treatment resistance, leading to poor outcomes for many patients with relapsed/refractory (R/R) disease who discontinue cBTKi. Are you prepared to overcome this challenge by developing evidence-based sequential strategies for MCL treatment? Find out how to “revive” the BTK target by joining two MCL experts as they explore the integration of non-covalent BTKi (ncBTKi) in sequential R/R MCL care. Throughout, the experts use robust case discussion and 3D and 2D animations to provide guidance on developing ncBTKi-inclusive treatment plans that deliver safe and highly effective care while extending the clinical benefits of BTKi therapy.
Co-Chair and Moderator
Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Co-Chair and Presenter
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Nirav Shah, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb-Juno Therapeutics Inc; Epizyme, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Loxo Oncology-Lilly; Miltenyi Biotec; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; TG Therapeutics, Inc.; and Umoja Biopharma.
Grant/Research Support from Loxo Oncology-Lilly and Miltenyi Biotec.
Co-Chair/Planner
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; Loxo Oncology, Inc.; and Secura Bio, Inc.
Grant/Research Support from AstraZeneca and BeiGene.
Speaker for AbbVie; AstraZeneca; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; Lilly; and Loxo Oncology, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HBV865. CME/MOC/NCPD/AAPA/IPCE credit will be available until November 12, 2024.
Finding the Right Pathway in Psoriasis: New Insights and Applications for TYK2 as a Therapeutic Target in Real-World Practice
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
April W. Armstrong, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Dermavant Sciences, Inc.; Dermira, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Ortho Pharmaceutical; Parexel International (MA) Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and Sun Pharmaceutical Industries Ltd.
Grant/Research Support from AbbVie Inc.; ASLAN Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Dermira, Inc.; EPI Health; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Pfizer; and UCB, Inc.
Faculty/Planner
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Speaker for Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi; and UCB, Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Alan K. Percy, MD - From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NQQ865. CME credit will be available until November 9, 2024.
From Early Recognition to Age- and Stage-Appropriate Care: Navigating a New Era in Rett Syndrome Management
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Alan K. Percy, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acadia Pharmaceuticals Inc.; Neurogene Inc.; and Taysha Gene Therapies, Inc.
Grant/Research Support from Acadia Pharmaceuticals Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Luke Maese, DO - Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRV865. CME/MOC/CPE/AAPA/IPCE credit will be available until November 9, 2024.
Making Choices, Improving Outcomes in Pediatric ALL: The Role of Modern Asparaginase Compounds
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Luke Maese, DO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Jazz Pharmaceuticals.
Speaker for Jazz Pharmaceuticals.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Claudia A. Chiriboga, MD, MPH, FAAN - Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood Nov 24, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.
Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Claudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Philip J. Mease, MD, MACR - Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care Nov 07, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZQX865. CME credit will be available until November 2, 2024.
Diagnosing and Managing Axial Spondyloarthritis: The Role of the Primary Care Clinician in Multidisciplinary Care
Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Disclosures
Philip J. Mease, MD, MACR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; ACELYRIN Inc.; Aclaris Therapeutics, Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Galapagos NV; Gilead Sciences, Inc.; GlaxoSmithKline; Inmagene; Janssen Pharmaceuticals, Inc.; Lilly; MoonLake Immunotherapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; UCB, Inc.; Ventyx Biosciences, Inc.; and XinThera.
Grant/Research Support from AbbVie.; ACELYRIN Inc.; Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sun Pharmaceutical Industries Ltd.; and UCB, Inc.
Speaker for AbbVie; Amgen; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and UCB, Inc.
M.E. Beth Smith, DO, MCR, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.

Milind Desai, MD, MBA - Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond Nov 07, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YMA865. CME/MOC/AAPA credit will be available until November 7, 2024.
Following the Evolution of Cardiac Myosin Inhibition: Remodeling Clinical Workflows to Realize the Greatest Benefit in oHCM and Beyond
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through an educational grant from Bristol Myers Squibb.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Milind Desai, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Cytokinetics, Incorporated; Medtronic; and Tenaya Therapeutics.
Co-Chair/Planner
Anjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for BioMarin Pharmaceutical Inc.; Bristol Myers Squibb; Cytokinetics, Inc.; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics; and Tenaya Therapeutics.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

John C. Byrd, MD - Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy Nov 07, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/BFU865. CME/MOC/AAPA credit will be available until November 7, 2024.
Choosing Wisely, Achieving Control With BTKi in CLL: Perspectives on Safety-Informed Approaches to Enhanced Therapeutic Efficacy
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
John C. Byrd, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Eilean Therapeutics; Janssen Pharmaceuticals, Inc.; Kura Oncology, Inc.; Newave Pharmaceutical Inc; Novartis Pharmaceuticals Corporation; Orange Grove Bio; Syndax; Trillium Therapeutics; and Vincerx Pharma.
Grant/Research Support from Eilean Therapeutics; Newave Pharmaceutical Inc; and OrbiMed.
Stock Shareholder in Eilean Therapeutics; Kura Oncology, Inc.; and Vincerx Pharma.
Other Financial or Material Support in the form of patents for Ohio State University.
Faculty/Planner
Daniel Addison, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from American Heart Association-Robert Wood Johnson Foundation and National Institutes of Health (NIH) grants: K23-HL155890 and R01HL170038.
Faculty/Planner
Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.
Honoraria from Aptitude Health; Bio Ascend; and Curio Science.
Other Financial or Material Support in the form of Royalties from Up-to-Date.
Faculty/Planner
Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.
Faculty/Planner
Paolo Ghia, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; BeiGene, Inc./Merck Sharp & Dohme; Bristol Myers Squibb; and F. Hoffmann-La Roche Ltd.
Grant/Research Support from Abbvie, Inc.; AstraZeneca/Janssen Pharmaceuticals, Inc.; and Bristol Myers Squibb.
Speaker for AstraZeneca/Janssen Pharmaceuticals, Inc. and BeiGene, Inc./Merck Sharp & Dohme.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below

Hiddo J.L. Heerspink, PhD, PharmD / Prof. Dr. med Christoph Wanner - Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care Nov 07, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.
Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Hiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.
Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.
Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.
Co-Chair/Planner
Prof. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.
Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Reynold A. Panettieri, Jr., MD - Expert Perspectives on Improving Early Recognition and Treatment of COPD With Inhalation Therapy Nov 07, 2023

To optimally manage patients with chronic obstructive pulmonary disease (COPD), physicians should remain aware of updated guidelines and new evidence on currently available and emerging treatment options. In this activity, a COPD expert reviews the latest diagnostic strategies, classification guidelines, and treatment approaches including dual bronchodilation and triple therapy. Upon completion of this activity, participants should be better able to: Employ evidence-based guidelines to provide a timely and accurate diagnosis of chronic obstructive pulmonary disease (COPD); Create treatment plans for patients with COPD according to evidence-based guidelines, with a goal of optimizing therapy to minimize exacerbation risk, decrease hospitalizations, and mitigate symptoms; and Apply tactics and strategies for shared decision-making to ensure treatment adherence and proper inhaler use.

Anjali Tiku Owens, MD - Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management in General Cardiology Practice Oct 31, 2023

Go online to PeerView.com/UBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease, with a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. So far, the FDA has approved only one noninvasive treatment option indicated for the treatment of HCM—a first-in-class cardiac myosin inhibitor (CMI) called mavacamten. A second CMI, aficamten, is currently being studied. As timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment, these treatment options are essential for cardiologists to understand. This PeerView activity covers what you need to know about diagnosing and managing HCM for optimal patient care. A patient case threads through each section and offers a window into real-world diagnostic and treatment challenges as our expert shares guidance and the latest evidence. By the end of this activity, you will be able to explain the underlying pathophysiology of HCM, apply your new knowledge for timely diagnosis and individualized treatment of HCM, and implement strategies for long-term patient safety and improved outcomes. Upon completion of this activity, participants should be better able to: Apply current guidance and the latest evidence to support accurate differential diagnosis and encourage early treatment in patients suspected of having HCM; Evaluate the efficacy and safety evidence supporting the ability of modern targeted strategies to address the underlying pathophysiology of HCM; Individualize treatment of HCM based on patients' personal preferences and goals of care and identify opportunities to reduce inequities; and Implement strategies that encourage and support regular assessment of clinical status, LVEF, and LVOT gradient in patients with HCM, consulting with specialty colleagues as needed.

Jessica Donington, MD - Unleashing the Potential of Perioperative Immunotherapy in Resectable NSCLC: Leveraging Science, Enhancing Collaboration, and Improving Outcomes With Neoadjuvant and/or Adjuvant Checkpoint Inhibition Oct 31, 2023

Go online to PeerView.com/HXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite significant strides made in the surgical management of resectable NSCLC, a considerable proportion of patients face an unacceptably high risk of recurrence and poor sequelae. The swift expansion of immunotherapy into the early-stage, resectable, curative-intent setting offers them new hope, as FDA approvals in the adjuvant and neoadjuvant settings reshape standards of care and ongoing clinical trials continue to expand the role of immunotherapy-based options into this setting as well. But what do these developments mean for thoracic surgeons and the other members of the multidisciplinary lung cancer care team? How should the care team work together to utilize best practices and standards of care to guide individualized treatment selection and make the most of new immunotherapy options? This PeerView educational activity, based on a recent live symposium, addresses these questions and considers the expanding role of immunotherapies in resectable NSCLC by bringing together leading experts to evaluate the new, practice-changing research and offer a practical framework that improves interdisciplinary alliances and workflows with the goal of integrating immunotherapies into treatment plans to expand their benefits to as many patients with resectable NSCLC as possible. Are you ready to take your practice to the next level with perioperative immunotherapy? Upon completion of this activity, participants should be better able to: Assess the existing evidence guiding the use of neoadjuvant and adjuvant immunotherapy in stage I-III resectable NSCLC, including rational designs for clinical trials, novel endpoints, efficacy, safety, surgical outcomes, and other essential data; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making.

Michael R. Savona, MD / Andrew M. Brunner, MD - Command and Control MDS: New Science in MDS Management and Implications for Veteran-Centered Care Oct 30, 2023

Go online to PeerView.com/HWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to command and control management of MDS for your patients, including veterans who may be suffering from symptoms tied to this challenging disorder, in this PeerView Clinical Consults activity recorded at the 2023 Association of VA Hematology/Oncology Annual Meeting. Two experts in the field use conversational case discussions to provide guidance on a personalized, team-centered approach to managing MDS and use real-world scenarios to clarify the complexities of lower-risk MDS diagnosis and risk stratification, while providing guidance on how to leverage new science to overcome challenges such as anemia and transfusion dependence. Access this activity today to accelerate your practice with better outcomes, and learn how recent developments have changed the current standard of care. Upon completion of this activity, participants should be better able to: Summarize the symptomatology, molecular features, and risk factors associated with MDS that can inform modern diagnostic, prognostic, and management plans; Cite updated evidence supporting the use of innovative therapeutics for the risk-adapted management of MDS; Develop team-based, personalized management strategies for MDS that incorporate newer therapeutics, including for the frontline and subsequent management of LR-MDS with anemia; and Implement team strategies to address dosing, safety, and drug delivery considerations in the MDS setting.

Naval Daver, MD - Expanding the Circle of Personalized AML Treatment: Expert Consults on Integrating Precision Medicine With Innovative Treatment Platforms Oct 30, 2023

Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients’ diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.

Stephen V. Liu, MD - A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations Oct 23, 2023

Go online to PeerView.com/WFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent unique, potent, and promising new options in the lung cancer treatment arsenal. Ongoing clinical trials evaluating ADCs, including those directed at trophoblast cell surface antigen 2 (TROP2), have demonstrated positive preliminary data in lung cancer, and additional results from other studies assessing monotherapy and rational combinatorial options are anticipated in the near future. As advances with TROP2-targeting ADCs continue, it is crucial for oncologists and other professionals involved in the care of patients with lung cancer to gain knowledge of the rationale, characteristics, efficacy, and different adverse event profiles of these novel therapies. They must also develop the necessary skills to enable rapid adoption of these therapies into their clinical practice should they receive regulatory approval. This educational activity, based on a recent live symposium, comprehensively analyzes the most recent evidence supporting the use of TROP2-targeting ADCs and combinations in lung cancer. In addition, practical guidance for effectively utilizing ADCs and recognizing and managing adverse events associated with these novel therapies is provided, along with perspectives on their potential impact within the lung cancer treatment arsenal. Upon completion of this activity, participants should be better able to: Describe the biology of TROP2, rationale for its therapeutic targeting, and the structure, characteristics, and mechanism of action of TROP2-targeting ADCs under investigation in lung cancer; Evaluate the different monotherapy or combinatorial treatment strategies with TROP2-targeting ADCs being investigated in first- and later-line settings in lung cancer, and available efficacy and safety data from these trials; and Integrate TROP2-targeting ADCs into treatment plans of appropriately selected patients with lung cancer in the context of clinical trials or clinical practice, if approved/available, considering the supporting evidence, expert recommendations, efficacy and safety profiles of the different agents, and patient needs and preferences.

Jeffrey L. Neul, MD, PhD - The Changing Future for Patients With Rett Syndrome and Their Families: Early Diagnosis and New and Emerging Therapies to Reduce the Burdens of Disease Oct 19, 2023

Go online to PeerView.com/VWR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Due to the rarity of Rett syndrome and overlapping symptoms with other, more common neurodevelopmental disorders, diagnosis is challenging and often missed or delayed. With one Rett-targeted therapy recently approved and others in development, clinicians now have the opportunity to offer not merely symptom management but potential clinical improvement. This PeerView case-based activity is designed to improve your ability to recognize, diagnose, and treat patients with Rett syndrome. Each session features a realistic case discussion with expert faculty panelists sharing the evidence that supports clinical decisions for timely diagnosis and early initiation of multidisciplinary management and targeted therapy as appropriate. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in patients demonstrating subtle signs and symptoms; Employ evidence-based, age-appropriate care for patients with Rett syndrome in alignment with consensus management guidelines; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of new and emerging therapies for the treatment of Rett syndrome.

Melissa L. Johnson, MD - Taking Aim With the Next Wave of Antibody–Drug Conjugates in NSCLC: Rational Strategies for Addressing the Unmet Needs of Diverse Patient Populations With TROP2- and HER3-Targeting Therapies and Other ADC-Based Regimens Oct 06, 2023

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Sagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient Care Oct 06, 2023

Go online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CAR-T platforms, antibody-drug conjugates, and BCMA and non-BCMA bispecifics, and feature supporting evidence on earlier use of cellular therapy; the role of CAR-T and bispecific antibodies in early and later relapse; and next steps for the sequential use of “off-the-shelf” immunotherapy. Access this video activity today and see if you are prepared to enhance patient care with the latest BCMA and non-BCMA treatment options! Upon completion of this activity, participants should be better able to: Describe the mechanisms of action and latest clinical evidence supporting the use of established and emerging BCMA-targeting platforms, including bispecific antibodies and CAR-T therapy, across several lines of therapy in MM; Select anti-BCMA options when developing personalized treatment plans for MM based on patient preference, disease prognosis, and functional status, among other considerations; Manage practical considerations associated with BCMA therapy, including planning for referral to specialized care, consideration of off-the-shelf therapy, safety, patient education, and coordination of care

William G. Wierda, MD, PhD, Nicole Lamanna, MD - Level Up With Personalized Care for CLL/SLL: Achieving Better Total Care With Targeted Agents and Innovative Combinations Oct 06, 2023

Go online to PeerView.com/KBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative therapeutics have transformed the management of chronic lymphocytic leukemia (CLL) and allowed patients a greater range of treatment options. Covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i) have demonstrated efficacy in a wide variety of treatment settings, and newer, non-covalent BTKi are poised to overcome long-standing therapeutic standards. Do you have the tools needed to “level up” your practice? Find out in this “Clinical Consults” activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Throughout this program, a panel of leading CLL experts use conversational, case-based dialogue to provide guidance on integrating modern therapeutics anchored by BTKi and BCL2i regimens, along with rapidly emerging non-covalent BTKi and BTKi-BCL2i combinations. Join the leading lights of CLL, sharpen your therapeutic skills, and reach the next level of CLL care today! Upon completion of this activity, participants should be better able to: Cite current evidence and updated practice guidelines supporting the use of targeted agents and emerging treatment options in CLL, such as BTK and BCL2 inhibitors, CAR-T, and bispecifics; Develop personalized management protocols that include established and emerging targeted strategies as single-agent and combination platforms for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Implement sequential treatment plans with targeted options for patients with therapeutic intolerance and/or relapsed/refractory CLL; and Manage safety and care delivery considerations associated with the use of targeted agents and other newer therapeutics in the CLL setting

Guillermo Garcia-Manero, MD / Amy E. DeZern, MD, MHS - The Commanding Heights of MDS Care: Team Strategies for Delivering Modern Personalized Therapy Oct 06, 2023

Go online to PeerView.com/BXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) encompass a diverse group of myeloid malignancies, and new data are changing what can be considered “optimal” care. In this “Seminar and Workshop” activity, two hematology-oncology experts employ case-centric discussions to provide experienced instruction on the changing nature of individualized care for patients with MDS. This activity includes updated evidence supporting the use of innovative therapies for first-line management of MDS anemia, how to treat patients with ESA-refractory MDS, and treatment strategies for individuals presenting with high-risk mutations or cytogenetics. Watch now and take your treatment plans for patients with MDS to new heights! Upon completion of this activity, participants should be better able to: Cite clinical, cytogenetic, and molecular features that can inform timely, accurate diagnosis and prognosis in the MDS setting; Describe the evidence that supports the use of innovative therapeutics, including erythroid maturation agents, telomerase inhibitors, hypomethylating agent platforms, BCL2 inhibitors, and immunotherapy, in the management of patients with low-risk or high-risk MDS; Develop personalized MDS treatment protocols for the first-line management of anemia, in the ESA-refractory setting, and for patients presenting with high-risk MDS subtypes; and Address practical aspects of modern MDS therapy, including appropriate dose selection, response monitoring, and therapy-related adverse events management

Jaime Almandoz, MD, MBA, FTOS - Leading the Charge to Change the Obesity Narrative: Supporting Primary Care to Improve Weight Management Discussions, Diagnosis, and Decisions Sep 20, 2023

Go online to PeerView.com/XZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the United States, the prevalence of obesity has been steadily increasing. Despite the number of obesity specialists in the United States multiplying five-fold from 2011 to 2019, there is an inadequate number of trained professionals to treat all people requiring obesity-targeted care. Primary care is often the first and only touch point for many people with obesity (PwO), and there is a need to equip and prepare primary care professionals (PCPs) to treat this patient population with empathetic, effective, and evidence-based obesity-targeted care. This PeerView Train-the-Trainer MasterClass activity combines concise overviews of essential evidence with training resources to help you, as an obesity specialist, lead the charge to educate your PCP colleagues. Using practical exercises, experts provide guidance on strategies and tactics you can use to create your own training workshop for PCPs. In addition to the Train-the-Trainer video, participants also have free access to a slide library, surveys, and practice aids to create their own independent training workshop. Upon completion of this activity, participants should be better able to: Address misperceptions and weight biases held by many PCPs to minimize the downstream effects and complications in people with obesity; and Assist PCPs in combating clinical inertia and encouraging early intervention in people with or at risk for obesity

Boni Elizabeth Elewski, MD, Mark Lebwohl, MD - Novel Targets for Management of Generalized Pustular Psoriasis: Utilizing a Team-Based Approach From Diagnosis to Treatment of Flares Sep 20, 2023

Go online to PeerView.com/NJA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about the changing therapeutic landscape and the first FDA-approved treatment for generalized pustular psoriasis (GPP)? Test your knowledge and earn credit as you get the latest evidence and expert guidance on individualizing treatment plans for patients with GPP. Upon completion of this activity, participants should be better able to: Accurately diagnose pustular psoriasis and assess the disease severity based on patient history and clinical manifestations; Identify pathophysiological differences among generalized pustular psoriasis (GPP) and plaque psoriasis; Evaluate novel biologic therapies for pustular psoriasis based on their efficacy, safety, and mechanism of action; and Develop effective, individualized treatment strategies for patients with GPP through patient education and shared decision-making and a multidisciplinary team-based approach

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis Sep 20, 2023

Go online to PeerView.com/FRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) is a chronic disease that affects a significant portion of the US population. The current treatment paradigm for AD is complex, involving multiple active drugs tailored to different body parts, stages of the disease, and severity levels, in addition to moisturizers, bathing practices, and lifestyle recommendations. However, the effectiveness of certain available treatment options is limited because of concerns regarding efficacy, tolerability, and safety. In recent years, there have been significant advancements in the treatment of AD, including the approval of the first biologic agent and the ongoing clinical development of targeted therapies. In this activity, a panel of experts discuss the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease, and the underlying pathophysiologic processes that contribute to the development of AD. In addition, they explore individualizing treatment for patients with moderate to severe AD, with a goal of minimizing and preventing flares. Upon completion of this activity, participants should be better able to: Diagnose the severity of AD across different patient populations, considering the chronic and heterogeneous nature of the disease; Describe underlying pathophysiologic processes that contribute to the development of AD, and provide rationale for the use of targeted biologic therapy; and Select appropriate treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares

Kara Mayes, MD, FAAFP / Jay H. Shubrook, DO, FAAFP, FACOFP - Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals Aug 31, 2023

Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications; Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management; and Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority.

R. Scott Wright, MD - When Statins Strike Out: Using PCSK9-Targeting Strategies to Achieve Lipid Goals and Reduce Cardiovascular Risks in Patients With Hyperlipidemia Aug 30, 2023

Go online to PeerView.com/EEG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Multiple professional societies have emphasized the importance of lowering LDL-C for the primary and secondary prevention of ASCVD and cardiovascular events. Though current guidelines recommend statins as the cornerstone of lipid-lowering therapies, many patients have insufficient response or intolerance to them and require non-statin therapies to achieve their individualized LDL-C goals. Enter PCSK9-targeting therapies! This CME activity shares current gaps in hyperlipidemia care, offers strategies for meeting these unmet needs, and presents the latest clinical data for PCSK9-targeting agents. An in-depth patient case example helps to illustrate the importance of screening and ASCVD risk assessment, how to initiate therapy with novel strategies, and best practices for improving hyperlipidemia management to help more patients achieve their goals. Upon completion of this activity, participants should be better able to: Incorporate evidence-based, guideline-compliant strategies into the management of hyperlipidemia to prevent primary and secondary cardiovascular events, especially in patients who are statin intolerant or already using the maximally tolerated statin dosage; Recognize the differences among PCSK9-targeting agents and other classes of lipid-lowering therapies for managing hyperlipidemia in individuals at high risk of ASCVD with regard to mechanisms of action, cardiovascular outcomes, and the latest clinical evidence; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for PCSK9-targeting therapies.

Michael Levy, MD, PhD - Test Your Knowledge: Are You Missing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD)? Aug 29, 2023

Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.

David J. Kuter, MD, DPhil / Cindy Neunert, MD, MSCS - New Rules for Overcoming ITP: Guidance on Later-Line Care, the Role of BTKi, and Improving Patient Outcomes Aug 22, 2023

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.

Babafemi O. Taiwo, MBBS - Road Map to Re-Engagement: A Visual Guide to Overcoming Individual and Systemic Barriers to HIV Care and Treatment Aug 21, 2023

Go online to PeerView.com/JDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care.

Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors Aug 11, 2023

Go online to PeerView.com/MVQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials. Upon completion of this activity, participants should be better able to: Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors; Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs; and Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation.

Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors Aug 11, 2023

Go online to PeerView.com/DDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of acute myeloid leukemia (AML) subtypes have been driven by a modern understanding of their biology and heterogeneity, including the recognition of disease-defining FLT3 mutations. FLT3 inhibitors are a potent therapeutic option for the targeted management of this AML subtype, and rapidly emerging evidence on newer FLT3 agents is reshaping treatment protocols for upfront therapy and for post-transplant maintenance. Are you prepared to challenge and change conventional care for FLT3-mutated AML? Find out by accessing this activity, where a leading AML expert assesses new evidence presented at recent scientific congresses that supports the integration of newer FLT3 inhibitors into practice while reviewing standards for mutation testing, as well as safety similarities and differences among available FLT3 agents. Upon completion of this activity, participants should be better able to: Summarize current guidelines and updated evidence on FLT3 mutation testing in acute myeloid leukemia (AML) and the use of next-gen FLT3 inhibitor options in newly diagnosed and relapsed/refractory AML; Implement modern treatment plans that utilize FLT3 inhibitors as standard therapy for FLT3-mutated AML patients, including in combination with intensive chemotherapy for HCT candidates or as part of novel combinatorial regimens; and Address the unique suite of adverse events associated with the use of FLT3 inhibitors in AML.

Philip Harvey, PhD - Visualizing a New Horizon: Emerging Advances in the Treatment of Cognitive Impairment Associated With Schizophrenia Aug 07, 2023

Go online to PeerView.com/FMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore recent advances in the management of cognitive impairment associated with schizophrenia (CIAS) and learn how to implement current and emerging treatment strategies into individualized care plans to improve your patients’ outcomes and quality of life. Upon completion of this activity, participants should be better able to: Summarize the burdens of cognitive impairment in patients with schizophrenia and its impact on patient outcomes and quality of life; Describe the pathophysiology of CIAS, emphasizing the difference between negative symptoms and cognitive impairment; and Implement current and emerging treatment strategies for CIAS, taking into account the latest evidence and patient treatment goals, preferences, and unmet needs.

Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM Jul 28, 2023

Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products Jul 28, 2023

Go online to PeerView.com/WEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you aware of the evidence supporting the use of innovative EHL FVIII therapies for the prophylactic management of hemophilia A? Find out in this activity based on a “MasterClass” event recorded at the 2023 Congress of the International Society on Thrombosis and Haemostasis. Hear what hemophilia experts are saying about the latest clinical evidence that supports the use of innovative EHL FVIII therapy in hemophilia as they link the data directly to case-based decisions in real-world settings—with a goal of clearly illustrating the practicalities of safely using novel and emerging factor products. The experts also provide guidance on implementing evidence-based protocols and preventing and managing complications in the context of EHL FVIII therapy. Upon completion of this activity, participants should be better able to: Assess the latest safety, efficacy, and pharmacokinetic data among currently approved and emerging EHL FVIII products for prophylaxis of hemophilia A; Develop personalized prophylactic regimens with novel and emerging EHL FVIII products based on patient- and disease-specific factors; and Manage practical aspects of care, such as patient education, adherence counseling, monitoring, and AE management, when using novel and emerging EHL FVIII products for prophylaxis of hemophilia A

Prof. Thomas Cluzeau, MD, PhD - “Intensity” With Efficacy in Acute Myeloid Leukemia (AML): Developing Modern, Intensive Upfront Platforms for Challenging Disease Presentations Jul 28, 2023

Go online to PeerView.com/RMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Innovative intensive therapy, often consisting of potent induction/consolidation protocols followed by hematopoietic stem cell transplant (HCT), has been shown to extend survival in challenging acute myeloid leukemia (AML) settings where conventional chemotherapy options are suboptimal. In this “Clinical Consults” activity, a panel of experts provide guidance on the optimized selection of intensive upfront therapy in challenging AML subtypes and discuss how the personalized use of induction/consolidation platforms can create opportunities for subsequent HCT and lead to enhanced patient outcomes. The panelists use serial case vignettes inspired by real-world scenarios, debate the selection and use of novel cytotoxic platforms and targeted agents, and examine emerging approaches in a range of difficult-to-treat patient populations. Upon completion of this activity, participants should be better able to: Review the diagnostic, prognostic, and therapeutic implications of baseline factors such as age, genetic/molecular features, and functional status for challenging AML subtypes such as secondary AML or mutation-defined disease; Review updated clinical data surrounding novel upfront induction/consolidation regimens in diverse AML settings, including for patients with higher-risk or mutation-defined disease; Select evidence-based, personalized upfront treatment platforms for patients with challenging AML subtypes, including patients eligible for HCT; andDevelop a management plan for the unique safety considerations associated with novel upfront treatment platforms, including innovative cytotoxic and targeted regimens

Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies Jul 28, 2023

Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care Jul 28, 2023

Go online to PeerView.com/YEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to elucidate the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer. ADCs are now transitioning from research settings to clinical practice, with the first approval of a novel HER2-targeting ADC, trastuzumab deruxtecan, for HER2-mutated NSCLC. In addition, various other potent ADCs targeting HER3, TROP2, CEACAM5, c-MET, AXL, ROR2, and others are being evaluated in clinical trials in different disease settings, including in patients with advanced NSCLC with and without actionable genomic alterations, and they are showing impressive activity. How do we realize the promise of these ADCs as the next frontier in precision lung cancer care? What are the best ways to apply the emerging science to patient care decisions in everyday practice? These and other key questions are addressed in this activity, which is based on a recent live symposium and produced in collaboration with the LUNGevity Foundation to highlight patient perspectives alongside those of clinicians. Leading experts in the field share their interpretations of the latest practice-changing evidence and provide practical guidance using real-world case scenarios to demonstrate how to maximize beneficial patient outcomes using ADCs. Upon completion of this activity, participants should be better able to: Discuss the modern composition, rationale for use, and clinical potential of novel ADCs in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of novel ADCs in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including novel ADCs; and Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Rohit Loomba, MD, MHSc - Hope Is on the Horizon for Nonalcoholic Steatohepatitis: Leveraging the Power of Next Generation Monitoring and Pharmacotherapies Jul 28, 2023

Go online to PeerView.com/RVV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses NAFLD and NASH as metabolic diseases and potential therapeutic targets for patients with the conditions. Upon completion of this activity, participants should be better able to: Describe the disease pathways and mechanisms that define NAFLD/NASH as metabolic diseases; Discuss the pathophysiology and role of GLP-1 as a therapeutic target in NAFLD/NASH and other metabolic conditions; Use noninvasive tests and biomarkers to monitor NAFLD/NASH disease progression; and Initiate early guideline-driven and pathway-driven management with available and emerging pharmacotherapies to delay NAFLD/NASH progression and improve outcomes for patients

Guillermo Garcia-Manero, MD - The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond Jul 28, 2023

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don’t miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms Jul 28, 2023

Go online to PeerView.com/HZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding use of CD38 antibodies, CAR-T, and BCMA and non-BCMA treatment options has quickly changed the clinical conversation for modern multiple myeloma (MM) management. Are you prepared for the new “ABCs” of myeloma care? Find out by accessing this PeerView MasterClass and Case Forum event developed in collaboration with the HealthTree Foundation for Multiple Myeloma and recorded at the 2023 ASCO Annual Meeting. During this activity, our experts provide insights and case-based guidance on therapy selection, dosing, scheduling, and management of treatment-related AEs with CD38 antibodies and BCMA platforms in MM. Learn the real-world “ABCs” of treatment innovation in MM, and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize the unique MOA and safety/efficacy evidence supporting the use of CD38 and BCMA-targeting antibodies, CAR-T therapy, and other innovative compounds across multiple myeloma treatment settings; Develop personalized upfront and sequential treatment plans with innovative antibody and immunotherapy platforms, based on relevant prognostic information and safety considerations; and Address practical aspects of multiple myeloma care when using antibody and immunotherapy platforms, including dosing, scheduling, patient referral to specialized care, education, counseling, and unique treatment-related toxicities

Athena Philis-Tsimikas, MD - Episode 4: Exploring Therapeutic Potential of Once-Weekly Basal Insulin Therapy Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 3: Practical Considerations for Once-Weekly Basal Insulin Therapy Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 2: Overcoming Clinical Inertia in Patients With T2DM Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 1: Current Guidance and Indications for Basal Insulin in Patients With T2DM Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Allison Agwu, MD, ScM, FAAP, FIDSA - Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider Jul 06, 2023

Go online to PeerView.com/GRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Martina J. Porter, MD - How Do You Diagnose and Treat Hidradenitis Suppurativa? Compare Your Approach With the Experts’ Jul 06, 2023

Go online to PeerView.com/MYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hidradenitis suppurativa (HS) is a chronic and recurrent inflammatory dermatologic condition that can take a long time to diagnose because of its relative rarity and long list of differential diagnoses. In the meantime, the pain and embarrassment caused by discharge and disfiguration severely decrease the quality of life for people who are impacted. Fortunately, there are a number of biologic therapies that are approved to treat HS or are in Phase 2 and 3 trials, such as inhibitors of IL-1, IL-17F and IL-17A. This activity is designed to reduce the time to diagnosis, educate clinicians on the burden their patients face, and understand the need for emerging therapies with greater efficacy. Two faculty experts will walk you through HS management and treatment protocols, with a focus on improving your knowledge and competence to incorporate new and emerging therapies into the management of this complex disease. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and diagnostic challenges to make a timely and accurate diagnosis of hidradenitis suppurativa; Describe the burdens of disease and impact on quality of life for patients with hidradenitis suppurativa; Recognize the limitations of current therapies for hidradenitis suppurativa; and Apply clinical safety and efficacy data on emerging novel treatments for patients with hidradenitis suppurativa

Naval Daver, MD - Pushing Innovation in AML: Real-World Integration of Modern Therapeutics Into Personalized Patient Management Jul 06, 2023

Go online to PeerView.com/PYA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Newer treatment modalities for acute myeloid leukemia (AML) have rapidly eclipsed the decades-long cytarabine-based standard of care and helped clinicians adopt more personalized management using innovative cytotoxic platforms, targeted agents (including FLT3, BCL2, and IDH inhibitors), and other unique management strategies. Clinicians can now improve patient outcomes across all AML treatment settings, while at the same time selecting the most potent, personalized option that can be designed to address a given patient’s needs. This “Seminars and Tumor Board” activity, adapted from our recent live event held at the 2023 ASCO Annual Meeting and developed in collaboration with the HealthTree Foundation for Acute Myeloid Leukemia, reveals how modern baseline assessment paired with cutting-edge prognostication has pushed patient management to new heights of innovation and changed the management of patients with AML with therapeutically relevant features (such as FLT3 or IDH mutations), patients presenting without driver mutations, or individuals with comorbid illnesses or higher-risk features. Join the AML experts for a real-world “Tumor Board”–style discussion of how the latest evidence can inform your practice. Upon completion of this activity, participants should be better able to: Summarize baseline patient-related and disease-related factors, including age, comorbidities, functional status, and cytogenetic/mutational findings, that can influence prognostication and treatment selection in AML; Cite current evidence supporting the personalized use of novel treatment modalities, including new cytotoxic platforms, targeted agents, immunotherapy, and epigenetic strategies, for the management of newly diagnosed or relapsed/refractory AML; Integrate novel therapeutics into the personalized team-based management of AML according to the results of baseline assessment, presence or absence of targetable mutations, functional status, or AML subtype; and Address care delivery considerations, including optimized dosing and safety management, when caring for patients with AML

John B. Buse, MD, PhD - Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists Jul 06, 2023

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

P. Barton Duell, MD - Straight From the Experts: Clinical Conversations on Modernizing Hyperlipidemia Management With PCSK9-Targeting Agents Jul 05, 2023

Go online to PeerView.com/EHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Elevated low-density lipoprotein cholesterol (LDL-C) levels are causally related to the risk of atherosclerotic cardiovascular disease (ASCVD)—justifying the guidance from multiple professional societies that emphasize the importance of lowering LDL-C to reduce cardiovascular risk. Despite the availability of nearly ten different classes of medications indicated to lower cholesterol levels, dyslipidemia is not appropriately managed for many patients, resulting in target LDL-C goals not being achieved. In this activity, based on a recent live symposium, experts discuss targeted therapies to optimize lipid management, including primary and secondary prevention of CV events, with PCSK9-targeting therapies (in particular, PCSK9 antibodies and novel small interfering RNAs). Upon completion of this activity, participants should be better able to: Apply current hyperlipidemia treatment guidelines for primary and secondary prevention of cardiovascular events in patients with ASCVD; Assess the efficacy and safety data for PCSK9-targeting therapies for hyperlipidemia management in patients with ASCVD risk enhancers; and Describe the mechanism of action and ability of PCSK9-targeting therapies to optimize treatment for high-risk ASCVD patients on maximally tolerated doses of statins or for statin-intolerant patients

Juan Pablo Frías, MD - Case in Point: Addressing Practical Questions to Improve Long-Term Outcomes in Patients With Obesity Jul 05, 2023

Go online to PeerView.com/KEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early intervention is central to reducing excess weight gain and the risk of obesity-related comorbidities, yet many people never receive a formal diagnosis or specialty obesity care. With this in mind, how can clinicians best support this patient population? Endocrinologists, in particular, are on the front lines of managing and treating this complex disease. In this PeerView inReview, an expert uses patient videos to explain what you need to know about effective, compassionate patient communication and offers practical guidance on how to best integrate anti-obesity medications into patient care to improve long-term outcomes. Upon completion of this activity, participants should be better able to: Prioritize obesity as a chronic, progressive disease that requires individualized, long-term management; Initiate nonjudgmental conversations with individuals living with obesity and engage in effective shared decision-making discussions to achieve sustained weight loss; Compare the mechanism of action, efficacy, and safety of approved and emerging medications for the long-term management of obesity; and Identify people with obesity who could benefit from treatment with anti-obesity medications

Charles L. Daley, MD - Improving Time to Diagnosis of Non-Cystic Fibrosis Bronchiectasis: The Importance of the Radiologist in Fulfilling Unmet Needs of Patients Jul 05, 2023

Go online to PeerView.com/TXG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American Roentgen Ray Society 2023 Annual Meeting, a radiologist and pulmonologist explain the importance of early diagnosis in non-cystic fibrosis bronchiectasis (NCFBE) and explore the intricacies of CT imaging interpretation as a tool for optimizing care for bronchiectasis. These experts also share evolving insights into the pathophysiology of bronchiectasis that have led to the development of novel and emerging therapies, in particular DPP-1 inhibitors, to address underlying inflammation associated with the disease. See if you are up to date on the latest diagnosis, treatment, and management innovations for your patients with NCFBE and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: Describe the disease burden of non-cystic fibrosis bronchiectasis (NCFBE) as a chronic progressive condition and the importance of imaging for accurate diagnosis; Recognize CT features of NCFBE to facilitate diagnosis and allow for intervention; and Explain how recent insights into the underlying mechanisms of NCFBE might address unmet treatment needs for patients with NCFBE

Clinical Pharmacology Jun 30, 2023

Go online to PeerView.com/TNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about non-factor therapies in the prophylactic management of hemophilia? Test your knowledge and earn credit, as you get the latest evidence and expert guidance on integrating these therapies into individualized management plans for adult and pediatric patients with hemophilia. Upon completion of this activity, participants should be better able to: Discuss current unmet needs and barriers to optimal prophylaxis of hemophilia; Summarize the MOAs and latest safety/efficacy evidence supporting the use of novel and emerging antibody and siRNA therapies for the prophylaxis of HA and HB; Develop personalized prophylactic regimens with novel and emerging antibody and siRNA therapies, including in the context of clinical trials, for the management of HA and HB; and Manage practical aspects of care when using novel non-factor agents, including dosing/scheduling, patient education, adherence, monitoring, and adverse events.

Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research Jun 30, 2023

Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

Matthew S. Davids, MD, MMSc - Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies Jun 30, 2023

Go online to PeerView.com/KYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions. Upon completion of this activity, participants should be better able to: Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics; Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL; and Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting.

Shmuel Shoham, MD / Ghady Haidar, MD - What’s New, and What’s Next? Customizing COVID-19 Prevention Approaches in Transplant Patients to Increase Uptake, Access, and Efficacy Jun 30, 2023

Go online to PeerView.com/ERY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hundreds of thousands of organ transplant recipients living in the United States, who must take immunosuppressive medication, are at an increased risk of COVID-19 infection. Tixagevimab co-packaged with cilgavimab has lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. In the absence of prevention agents (other than vaccines) and because the prevention of COVID-19 is shifting to a more personalized, patient-specific approach, the complexity of clinical decision-making has increased. Additionally, patients may face barriers in obtaining COVID-19 prevention. In this activity, based on a recent live symposium, expert faculty and a patient advocate discuss strategies to improve the uptake of COVID-19 prevention and increase patient and clinician engagement and how to develop a plan to customize COVID-19 prevention at point of care for patients needing prevention. In addition, they look at creating strategies for patients in order to help in overcoming real-time barriers. Upon completion of this activity, participants should be better able to: Improve the uptake of COVID-19 prevention and increase patient and clinician engagement in following science-based evidence; Develop a plan to customize COVID-19 prevention at point of care for patients needing protection against the virus using evidence-based recommendations and guidelines; and Facilitate patient access to needed COVID-19 prevention by creating strategies to overcome real-time barriers.

Barbara Burtness, MD - Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care Jun 29, 2023

Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinical evidence and guideline recommendations supporting the use of checkpoint inhibitors and other immunotherapy options for the management of HNC; Develop individualized treatment plans that incorporate checkpoint inhibitors and other immune modalities, including innovative combinational platforms, for the management of resectable, locally advanced, or recurrent/metastatic HNC; and Address practical aspects of care when using immunotherapy options, including provision of patient education and management of symptoms and immune-related AEs.

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists Jun 29, 2023

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care Jun 28, 2023

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.

Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy Jun 27, 2023

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation, and asparaginase discontinuation, and get their perspectives on optimized asparaginase dosing and toxicity mitigation approaches. Learn how you can utilize modern asparaginase strategies to improve outcomes in ALL by watching today! Upon completion of this activity, participants should be better able to: Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds; Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity; Identify the emergence of asparaginase hypersensitivity, silent inactivation, or toxicity through the use of evidence-based monitoring plans in pediatric ALL; and Select treatment strategies to avoid asparaginase discontinuation and ensure adequate exposure to therapy, including switching to Erwinia asparaginase options after confirming hypersensitivity.

Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease Jun 20, 2023

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.

Miguel Regueiro, MD - Taking Fuel From the IBD Fire: Applying New Evidence on Sphingosine-1-Phosphate Receptor Modulation as an Effective Oral Option for Management of Ulcerative Colitis Jun 01, 2023

Go online to PeerView.com/FNG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Much progress has been made in defining the genetic abnormalities and associated abnormal pathophysiology underlying the spontaneous and chronic inflammation that characterizes inflammatory bowel disease (IBD). Medications that suppress or modify immune activity form the core of effective treatment for IBD. Sphingosine-1-phosphate (S1P) receptor modulators, a small-molecule therapeutic option, provide a target-specific approach with a favorable safety profile. Multiple S1P receptor modulators are in development, and ozanimod became the first agent in this class to receive FDA approval for the treatment of moderately to severely active ulcerative colitis in 2021. In this activity, based on a recent live symposium, expert faculty will discuss the therapeutic effects of S1P receptor modulators on the underlying pathophysiology of IBD and identify patients with UC who could benefit from treatment with these agents. In addition, the faculty will discuss individualizing treatment using S1P receptor modulators for appropriate patients with IBD in accordance with current evidence and guidelines. Upon completion of this activity, participants should be better able to: Explain how the therapeutic effects of sphingosine-1-phosphate (S1P) receptor modulators address the underlying pathophysiology of IBD; Identify patients with UC who could benefit from the use of therapy with S1P receptor modulators; and Individualize treatment using S1P receptor modulators for appropriate patients with UC in accordance with current evidence and guidelines

Jonathan D. Spicer, MD, PhD, FRCSC - Neoadjuvant, Adjuvant, or Both: How to Solve the Puzzle of Perioperative Immunotherapy, Individualize Treatment Plans, and Improve Cure Rates in Resectable NSCLC Jun 01, 2023

Go online to PeerView.com/SQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors have started to radically transform the perioperative treatment of resectable stage I-III NSCLC, with the goals of reducing the risk of recurrence and improving cure rates in these settings. Several important phase 3 clinical trials evaluating neoadjuvant and/or adjuvant immunotherapies have already yielded impressive data, leading to regulatory approvals and new standards of care, and additional studies have recently been reported to be positive, adding to the evidence base but also increasing complexity. What do these advances mean for thoracic surgeons, medical oncologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to evaluate the new practice-changing research, assess the implications for practice, and provide practical guidance for how to improve interdisciplinary alliances, develop real-world workflows, and optimally integrate immunotherapies into treatment plans for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Evaluate the current evidence guiding the use of neoadjuvant and adjuvant immunotherapy in resectable stage I-III NSCLC, including rational clinical trial designs, novel endpoints, and efficacy, safety, surgical outcomes, and other essential data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Integrate neoadjuvant and/or adjuvant immunotherapy into individualized treatment plans for patients with resectable NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers Jun 01, 2023

Go online to PeerView.com/RZN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care. Upon completion of this activity, participants should be better able to: Describe the pathophysiology and potential therapeutic targets for IBS-C; Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management; and Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO - Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy Jun 01, 2023

Go online to PeerView.com/SJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Can you bet on BCMA for your patients with multiple myeloma (MM)? Based on their demonstrated ability to evade resistance to prior agents and induce deep and durable responses, BCMA CAR-T constructs and bispecific antibodies have emerged as core management options for patients with MM progressing on their therapeutic journey. In collaboration with the HealthTree Foundation for Multiple Myeloma, this expert oncology nurse–led activity uses case-based teaching examples to illustrate practical strategies for the delivery of care with BCMA therapeutics while highlighting strategies for patient education and safety management. Each presentation features resources and tools from the HealthTree Foundation for Multiple Myeloma designed to overcome some of the challenges patients face, increase awareness of BCMA-directed options, and foster collaboration between professionals and patients when faced with difficult-to-treat MM cases. Upon completion of this activity, participants should be better able to: Summarize current evidence and guidelines supporting the use of BCMA antibodies and CAR-T cell therapy across the spectrum of multiple myeloma; Implement team strategies to optimize the integration of anti-BCMA therapies, including in the context of a clinical trial, based on diagnostic evaluation, patient-related and disease-related factors, and prior treatment regimens; Provide education to patients on therapeutic expectations with BCMA therapy, delivery of care aspects, and the risk of treatment-emergent adverse events; and Develop team-based strategies to address practical aspects of care when using novel anti-BCMA therapies, including dosing and scheduling, care coordination, supportive care, and management of treatment-related toxicities, including ocular toxicity, CRS, and neurotoxicity, among others

Patrick A. Flume, MD / Gwen A. Huitt, MD, MS - Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management Jun 01, 2023

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Anna Chodos, MD, MPH - Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care Jun 01, 2023

Go online to PeerView.com/XUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process. Upon completion of this activity, participants should be better able to: Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD; Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns; and Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Leading Change, Leading Advances in CLL Care: Guidance on Delivering Modern Targeted and Cellular Therapeutics Jun 01, 2023

Go online to PeerView.com/AZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you updated on the leading advances in CLL care and the role nurses play in ensuring the best outcomes for patients? Find out in this PeerView Nurse MasterClass, where a panel of leading CLL hematology-oncology nurse experts present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTKi as well as BCL2i. Our experts will also present a rich collection of case examples from nursing practice designed to explore how nurses can be the cornerstone of the management team. This event recorded at the annual ONS Congress was developed in collaboration with the CLL Society and will also feature a patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey. Get updated on the advances in CLL care and earn NCPD/ILNA credit today! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence and guidelines supporting the use of established and emerging targeted and cellular therapies for the management of patients with CLL across several lines of therapy; Implement nursing protocols to optimize the integration of targeted and cellular therapies into personalized management plans for patients with CLL, including via a clinical trial; Provide counseling to patients with CLL on their disease prognosis, differences among agent classes, therapeutic expectations, dosing, and safety considerations; and Address core practical considerations associated with the use of targeted and cellular therapies, such as dosing, scheduling, care coordination, monitoring, and treatment-emergent adverse events

Nicholas K. Mollanazar, MD, MBA - Targeting Disease Pathophysiology to Achieve Effective Treatment in Prurigo Nodularis Jun 01, 2023

Go online to PeerView.com/AMT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you know about prurigo nodularis (PN)? Test yourself in this interactive question-based activity that customizes to meet your learning needs. Throughout the activity, an expert dermatologist will review the latest evidence for current and emerging treatment strategies and discuss the necessary tools to effectively navigate care for patients with PN. Don’t forget to check your learning plan summary for customized feedback! Upon completion of this activity, participants should be better able to: Characterize the burden of disease and unmet needs associated with PN; Discuss how increased insight into PN pathophysiology is being applied in the development of novel therapeutic strategies; and Develop evidence-based, individualized treatment plans for patients with PN, incorporating new and emerging treatment options as appropriate

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, Zahra Mahmoudjafari, PharmD, MBA, BCOP - Coordinating Better Outcomes in Multiple Myeloma: Pharmacist Leadership With Novel Antibodies and CAR-T Therapy Jun 01, 2023

Go online to PeerView.com/NDY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to integrate cutting-edge antibody and CAR-T options for the care of patients with multiple myeloma (MM). In this PeerView Pharmacy MasterClass and Case Forum activity, an expert panel will offer guidance on how pharmacists can tackle the real-world challenges of MM management by facilitating care with CD38 and BCMA-directed antibodies, as well as CAR-T therapy, in a range of different treatment settings. Our experts will provide insights into how pharmacists can help modernize MM treatment protocols by ensuring appropriate care coordination and addressing safety, dosing, and therapy delivery considerations associated with CD38 and BCMA-directed treatment. Participate in this CPE video activity to see if you are prepared to lead the way to better outcomes for MM! Upon completion of this activity, participants should be better able to: Describe the mechanisms of action, dosing, efficacy evidence, and safety evidence supporting the treatment roles of antibody-based and CAR-T therapies in multiple myeloma (MM), including CD38 and BCMA-directed agents; Implement pharmacist-guided strategies to promote optimal clinical integration of established and emerging antibody and cellular therapies across the spectrum of MM; and Develop modernized patient-, staff-, and institution-directed protocols to address practical aspects of care when using antibody and cellular therapy platforms, including dosing, safety, patient and staff counseling, and managing supportive therapies

Monica Tang, MD - Pulling the Plug on Severe Asthma: Taking a Closer Look at an Underrecognized Biomarker to Assess Disease Severity and Tailor Treatment Jun 01, 2023

Go online to PeerView.com/SGZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mucus plugging contributes to airway obstruction and death in acute asthma and is increasingly being recognized as a significant contributory factor to persistent, severe asthma. Pulmonologists, allergy and immunology specialists, and other healthcare professionals need to be aware of these latest insights into the pathophysiology of severe asthma to optimally care for their patients. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Dr. Monica Tang will show learners how to identify the presence of airway mucus plugging on HRCT, and she will review the latest evidence with regard to mucus plugging treatment. Upon completion of this activity, participants should be better able to: Explain the role of mucus plugging as a contributory factor to airway obstruction and symptoms in severe asthma and its implications for treatment; Identify the presence of airway mucus plugging on HRCT according to current expert recommendations; and Apply recent insights into the role of mucus plugging, as well as the latest clinical evidence, to the selection of treatment for patients with severe asthma

Stuart J. Schnitt, MD - A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment Apr 28, 2023

Go online to PeerView.com/NRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-low breast cancer, currently defined as HER2 IHC 1+ or 2+/ISH-, accounts for approximately 50% of all breast cancers. While older HER2-targeted therapies did not show efficacy in HER2-low breast cancers, novel antibody–drug conjugates (ADCs) have demonstrated remarkable activity in this setting. Because of these advances and the FDA approval of the first HER2-targeting ADC for HER2-low breast cancer, there is an urgent need to rethink the approaches to HER2 testing so that patients with HER2-low breast cancer could be identified and get a chance to benefit from the new therapeutic approach. The understanding, definitions, and testing for HER2-low status continue to evolve, and many practical challenges and unanswered questions remain. This PeerView educational activity, based on a recent live symposium, explores the most cutting-edge information on HER2-low breast cancer, provides guidance on how to currently carry out HER2 testing to capture patients with HER2-low expression, and shares what’s on the horizon that may help further refine testing and treatment in this setting. Upon completion of this activity, participants should be better able to: Describe the spectrum of HER2 expression in breast cancer and the role of HER2-low expression as a new therapeutic target; Implement standard and emerging testing approaches to identify patients with HER2-low metastatic breast cancer to determine their eligibility for novel HER2-targeted therapies; Apply the latest evidence and guidelines to integrate HER2-targeted therapies into treatment plans for eligible patients with HER2-low metastatic breast cancer in the context of clinical practice or clinical trials; and Collaborate with the multidisciplinary team to ensure appropriate biomarker testing and optimal treatment selection for patients with HER2-low metastatic breast cancer.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Real-World Nursing Solutions for AML Care: Insights on the Effective and Safe Delivery of Innovative Therapeutics Apr 28, 2023

Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse’s expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relapsed/refractory setting; Educate patients with AML about therapeutic choices with novel agent classes, treatment expectations, dosing and adherence, and safety considerations; and Manage adverse events experienced by patients with AML receiving novel targeted and epigenetic options as part of their care.

Emily K. Dotson, PharmD, BCOP - Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy Apr 26, 2023

Go online to PeerView.com/XPM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL! Upon completion of this activity, participants should be better able to: Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL; Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL; and Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations.

Laura S. Dominici, MD, FACS - Navigating Complex Decisions at the Intersection of Local and Systemic Management of Early Breast Cancer Apr 26, 2023

Go online to PeerView.com/RGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although the prognosis of patients with early breast cancer (EBC) has improved with earlier detection and more efficacious therapies, many patients still face poor outcomes, and there is an urgent need to prevent recurrences. An increasing number of systemic therapies have been recently approved in the perioperative settings of HR+, HER2+, and triple-negative breast cancer (TNBC), including immunotherapy, CDK4/6 inhibitor therapy, adjuvant PARP inhibitor therapy, and a number of HER2-targeted therapies. Other agents and combinations are undergoing evaluation in clinical trials and are likely to expand the systemic therapy arsenal for patients with EBC. With the increasing complexity of systemic and local treatment of patients with EBC, it is crucial for surgeons, medical oncologists, pathologists, and other members of the breast cancer care team to effectively collaborate and coordinate management strategies to ensure optimal treatment selection and planning with longer-term goals in mind. This PeerView educational activity, based on a recent live symposium, provides an overview of the essential evidence supporting the use of a growing number of perioperative systemic therapies for patients with different subtypes of EBC. Optimally integrating these therapies into practice with multidisciplinary collaboration is demonstrated through the use of case scenarios, highlighting the nuances of applying new data to clinical decision-making. Upon completion of this activity, participants should be better able to: Analyze the latest evidence and guidelines supporting the use of standard-of-care and novel/emerging therapies for different subtypes of early-stage breast cancer and their role as part of multimodal treatment plans; Apply best practices for multidisciplinary risk assessment and predictive/prognostic testing to inform treatment planning for patients with different subtypes of early-stage breast cancer; and Implement multidisciplinary and patient-centric strategies for shared decision-making to ensure the development and implementation of optimal, individualized treatment plans in different settings of early-stage breast cancer.

Jennifer Wargo, MD, MMSc - Harnessing the Power of Immunotherapy in Resectable Melanoma: Guidance for Delivering Effective Adjuvant and Neoadjuvant Strategies Apr 26, 2023

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum Apr 26, 2023

Go online to PeerView.com/DCG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The time has come for even more precision in testing and targeted treatment of NSCLC. EGFR-mutated lung cancer is a perfect example of this need. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed for both biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. New agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon. Novel strategies for overcoming resistance to EGFR-targeted therapies are showing great promise as well. This PeerView Live educational activity, based on a recent live symposium, explores the latest advances and future directions in biomarker-driven, individualized therapy for patients with NSCLC harboring common and less common EGFR mutations through engaging discussions and challenging case-based debates. Upon completion of this activity, participants should be better able to: Characterize the different types of EGFR mutations in NSCLC, their role as therapeutic targets, and evidence supporting the use of current and emerging targeted therapies or combinations for NSCLC with various common or uncommon EGFR mutations; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; and Apply current evidence and guidelines to individualize targeted therapy for patients with NSCLC exhibiting different EGFR mutations based on the efficacy and safety profile of the therapies, disease characteristics, and patient needs and preferences.

Hyman Scott, MD, MPH, David Alain Wohl, MD - Exchanging PrEP Insights: Clinical Expert and Patient Perspectives on How to Become a Trusted HIV Prevention–Certified Provider Apr 26, 2023

Go online to PeerView.com/XFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention and a patient advocate discuss the benefits of pre-exposure prophylaxis (PrEP) and the necessary tools for engaging patients in conversations about sexual health practices as well as strategies for improving the uptake of HIV prevention measures. Upon completion of this activity, participants should be better able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives; Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice; Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection; and Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition.

Naval Daver, MD, Joseph D. Khoury, MD, FCAP - The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings Apr 13, 2023

Go online to PeerView.com/XSA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to leverage the benefits of the wide range of newly approved therapeutics that are revolutionizing patient care in AML? Find out in this “Clinical Consults” activity based on a recording at the 2023 USCAP Annual Meeting. A pathologist and a hematologist-oncologist team up to discuss how modern diagnostic techniques can lead to better, more collaborative, personalized care using novel therapeutics to manage challenging AML cases (including in high-risk and mutation-defined AML) and use cases to illustrate diagnostic testing techniques and how pathology and hem-onc can collaborate on treatment decision-making. Watch this video activity today and hear how pathologists and hematologist-oncologists can team up for better outcomes! Upon completion of this activity, participants should be better able to: Discuss the cytogenetic and histopathologic features that enable diagnosis and influence prognosis of different AML subtypes, including secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated disease; Select appropriate molecular/pathology tests to establish a diagnosis of AML or a specific AML subtype and collect relevant information for subsequent treatment decisions; Summarize current evidence supporting innovative cytotoxic, targeted, and immunotherapy strategies in different AML subtypes, including high-risk and mutation-defined disease; and Facilitate the integration of novel therapeutics into team treatment plans informed by baseline test results, including for patients with secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated AML.

Saira Z. Sheikh, MD, FAAAAI, FACAAI, FACR, Brad Rovin, MD, FASN, FACP - Improving the Patient Experience in SLE and LN: The Intersection of Early Diagnosis, Individualized Treatment, and Culturally Competent Care Apr 13, 2023

Go online to PeerView.com/JPU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Observed differences in healthcare disparities for patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) have led to the recognition of racial and ethnic minorities as an independent predictor of worse disease outcomes in SLE/LN. Earlier diagnosis, earlier intervention, treatment strategies targeted to clinical remission or low disease activity, and effective communication and collaboration between providers and patients could offer the opportunity to reduce damage, thus improving long-term outcomes. Through a collection of short, focused educational modules, this PeerView activity allows learners to combine self-assessment with concise clinical content in an interactive format. Drs. Sheikh and Rovin will explore the emerging concept of treat to target, as well as the use of currently available and new/emerging biologic therapies, along with strategies to help learners optimize treatment for patients with SLE/LN. Upon completion of this activity, participants should be better able to: Diagnose SLE, including LN, as early as possible in the course of disease to prevent organ damage and initiate appropriate therapy; Monitor disease activity and response to treatment in SLE and LN based on individual patient needs; Select appropriate treatment for SLE and LN to reduce disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Tricia Cottrell, MD, PhD, Lynette M. Sholl, MD - Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment Apr 06, 2023

Go online to PeerView.com/GNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the continued expansion of the cancer immunotherapy arsenal, reliable biomarkers to identify patients most likely to benefit from specific agents or combinations have become crucial. Predictive biomarkers such as measurement of PD-L1 expression and assessment of MSI/MMR or TMB status have an established role in some tumor types and settings, but a number of challenges related to testing and interpretation of results persist, and significant improvements are needed. There is also a need for ways to assess response to immunotherapies as they transition to early-stage, curative-intent settings as part of perioperative multimodal management of solid malignancies. Recently, pathologic response assessment has emerged as a potential new gold standard for measurement of impact of neoadjuvant immunotherapy. However, there has been limited guidance on how to define pathologic response, process and evaluate resected specimens, and report and apply assessment results in the settings of clinical trials and practice. This PeerView educational activity, based on a recent live symposium, focuses on current and emerging immunotherapy biomarkers, the rationale for and practicalities of biomarker testing as a guide for immunotherapy selection for different solid tumors, and the nuances of pathologic response assessment after neoadjuvant immunotherapy. Additionally, practical guidance is provided to help multidisciplinary coordination of care based on biomarker testing and pathologic response assessment so that more patients receive personalized immunotherapy and experience improved outcomes. Upon completion of this activity, participants should be better able to: Explain the evidence and rationale for the role of biomarkers to predict and assess response to cancer immunotherapy in metastatic and resectable solid malignancies; Conduct cancer immunotherapy biomarker testing and pathologic response assessment congruent with the latest evidence, requirements, and recommendations; and Personalize cancer immunotherapy treatment and response assessment by collaborating with multidisciplinary care team members to optimally select and interpret biomarkers.

Paul Kwo, MD, AGAF, FACG, FAASLD - HBV Is Primary! Your Role in the "Call to Action" to Eliminate Viral Hepatitis By 2030 Apr 06, 2023

Go online to PeerView.com/AYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology discusses the importance of early detection of hepatitis B virus (HBV) infection and presents current and evolving screening, vaccination, and treatment guidelines. The expert emphasizes the role of primary care providers in managing patients with chronic HBV and in helping to reach the WHO goal of eliminating viral hepatitis as a public health threat by 2030 through vaccination, screening, and patient education. Finally, the expert clarifies when patients with chronic HBV infection should be referred for specialty care. Upon completion of this activity, participants should be better able to: Describe the burden and consequences of HBV infection and how chronic HBV can lead to end-stage liver disease and hepatocellular carcinoma; Identify patients who should be screened for HBV, which tests should be ordered, and how to interpret the results; Manage HBV in the primary care setting in accordance with current evidence and guidelines, recognizing patients who require specialty care referral; and Implement patient-centered and culturally relevant strategies to promote adherence to HBV treatment and retention in care.

Robert C. Green, MD, MPH - Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients? Apr 06, 2023

Go online to PeerView.com/AQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA). In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families. Upon completion of this activity, participants should be better able to: Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care; Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting; and Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team.

Stephanie Lee, MD, MPH - Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease Apr 06, 2023

Go online to PeerView.com/CJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Preventing and managing graft-versus-host disease (GVHD) remains a significant problem in the post–allogeneic hematopoietic stem cell transplant (HCT) setting. Can a wide range of unique treatment modalities, including costimulatory compounds, targeted agents, and engineered cell therapy, challenge long-standing management protocols in this setting? Find out in this activity, based on a recent live symposium, which features an overview of available and emerging therapeutic options for modern GVHD management as a means to extend the benefits of HCT and provide more effective prophylaxis and treatment. Upon completion of this activity, participants should be better able to: Summarize current safety/efficacy evidence supporting the use of novel therapeutics for prophylaxis or treatment of acute or chronic graft-versus-host-disease (GVHD) in the post-transplant setting; Develop management plans with novel and emerging therapeutics for the prophylaxis of GVHD in the post-transplant setting, based on current evidence and practice guidelines; and Integrate novel and emerging therapies into safe, personalized treatment plans for the management of acute or chronic GVHD, including novel combinatorial strategies and/or options for second-line management.

Neal K. Lakdawala, MD, Anjali Tiku Owens, MD - Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment Apr 06, 2023

Go online to PeerView.com/GYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and has a mortality rate estimated to be about three times greater than that experienced by individuals of similar age without HCM. The FDA has recently approved a noninvasive, first-in-class cardiac myosin inhibitor specifically indicated for the treatment of HCM—meaning timely diagnosis of patients with HCM may reduce or delay the need for invasive treatment. In this activity, based on a recent live symposium, expert panelists present practical skills and guidance to accurately diagnose HCM and apply recent treatment advances to patients with various clinical presentations of HCM. They begin by sharing the rationale for maintaining a high index of suspicion for HCM and review diagnostic strategies. The Clinical Consults portion of this activity features case examples to demonstrate current practices in diagnosis and offer practical guidance for treating patients—focusing on personalized care with new and emerging therapeutic options. Concluding with an engaging Q&A, this activity is for anyone involved in the care of patients with HCM interested in loosening the grip of this increasingly treatable disease. Upon completion of this activity, participants should be better able to: Suspect the presence of HCM based on clinical symptoms, pathologic features, and/or family history; Differentially diagnose patients suspected of having HCM consistent with current guidance to promote early diagnosis and timely treatment; and Individualize treatment for patients with HCM based on the efficacy, safety, and potential ability of the therapeutic strategy to address the underlying disease pathophysiology.

John Ravits, MD, FAAN - Hope Is on the Horizon for Patients With ALS: Overcoming Diagnostic Difficulties and Exploring Novel Emerging Therapeutic Approaches Apr 06, 2023

Go online to PeerView.com/ZXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the importance of early detection and diagnosis of ALS, advances in genetic testing and biomarker development, and current and emerging therapeutic approaches for patients with ALS, as well as the benefits of employing a multidisciplinary approach in managing patients with ALS. Upon completion of this activity, participants should be better able to: Identify common genes and cellular processes implicated in ALS pathogenesis; Apply established criteria to detect and diagnose patients with ALS early in the disease course; Assess key data sets on contemporary and emerging evidence-based treatment options to manage symptoms and improve the quality of life of patients with ALS; and Employ a multidisciplinary team-based approach to optimize the management of ALS based on the individual needs and preferences of each patient.

Sean Pokorney, MD, MBA - Episode 7. Marching to Their Own Rhythm: Using Consumer Wearables in AF Diagnosis and Treatment Apr 05, 2023

Go online to PeerView.com/WQZ_7860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 6. Is That Realistic? What We’ve Learned About Anticoagulation Therapy From Real-World Studies Apr 05, 2023

Go online to PeerView.com/WQZ_6860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 5. State-of-the-Art Treatment: Catching Up With Current Guidelines Apr 05, 2023

Go online to PeerView.com/WQZ_5860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 4. The Fear Factor: Mitigating Patients’ Concerns About Anticoagulation Apr 05, 2023

Go online to PeerView.com/WQZ_4860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 3. Mending the Healthcare System: Reducing Disparities Apr 05, 2023

Go online to PeerView.com/WQZ_3860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 2. Profiles in Comorbidity: Identifying Who Is at High Risk Apr 05, 2023

Go online to PeerView.com/WQZ_2860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Sean Pokorney, MD, MBA - Episode 1. Looking for Trouble: The Role of Systematic Screening Apr 05, 2023

Go online to PeerView.com/WQZ_1860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical trial evidence, current guidelines, real-world data, and individual patient characteristics

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care Mar 29, 2023

Go online to PeerView.com/WCP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options. Upon completion of this activity, participants should be better able to: Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis; Identify patients with psoriasis who are most likely to benefit from novel oral treatments; Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines; and Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis.

Aaron T. Gerds, MD, MS / John Mascarenhas, MD - Shaping Modern Management of Myelofibrosis: Guidance on the Conjunction of Targeted Therapy and AlloHCT Apr 04, 2023

Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT therapy based on disease risk factors; use of JAK inhibitor in non-HCT settings; practical dosing and safety management considerations; and the emergence of novel targeted and combinatorial strategies in the MF setting. Watch this informative update on personalized care for patients with MF! Upon completion of this activity, participants should be better able to: Discuss patient- and disease-related features of MF that inform prognosis and guide the selection of JAK inhibitors, other targeted strategies, and HCT; Summarize efficacy and safety data surrounding the use of JAK inhibitors, novel targeted strategies, and innovative combination regimens in MF across the therapeutic continuum; and Develop treatment plans that incorporate JAK inhibitors and other novel therapies to manage MF in HCT and non-HCT settings

Nicole Lamanna, MD - Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management Mar 28, 2023

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better able to: Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues; Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection; and Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Olalekan Oluwole, MBBS, MD - The Time Is Now for Outpatient CAR-T: Essential Infrastructure, Lessons From Transplant, and New Evidence Mar 28, 2023

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding patient access to CAR-T therapy. Expert panelists discuss the key data supporting CAR-T therapy in hematologic cancers and provide guidance on principles of outpatient cellular therapy, lessons derived from the outpatient experience with stem cell transplantation, and strategies to overcome barriers to patient selection, adverse events, and adequate staffing. Upon completion of this activity, participants should be better able to: Summarize current evidence supporting the integration of CAR-T constructs into the management of hematologic cancers, including in earlier and later lines of care; Cite the infrastructure and design for an outpatient cellular therapy program and the relevant practical experience from home-based transplantation initiatives; Develop strategies for optimal patient selection, staffing, and management of adverse events in the context of an outpatient cellular therapy program; and Employ tools such as quality metrics, telemedicine, and wearable devices in an outpatient cellular therapy program to ensure successful delivery of CAR-T therapy

Benjamin Levy, MD - Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC Mar 28, 2023

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of challenge questions that frame explanatory evidence and panel discussions focused on the growing role and impact of ADCs in the treatment of NSCLC. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, TROP2, and other alterations with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and latest safety and efficacy of ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for novel ADCs and other targeted therapies; and Implement multidisciplinary and patient-centric approaches to effectively and safely integrate HER2-, HER3-, and TROP2-targeted and other novel ADCs into treatment plans for appropriate patients with NSCLC

Stephen V. Liu, MD - Perfecting Precision in Modern NSCLC Practice: Are You Optimally Integrating Biomarker-Driven Therapy? Mar 28, 2023

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that exist with the integration of recently approved and emerging targeted therapies into the modern care of patients with NSCLC. Better grasp the oncogenic role of different genomic alterations and the associated biomarker tests for capturing them to enable the most appropriate selection of targeted therapies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the heterogeneity of NSCLC and mechanisms of action, efficacy, and safety of targeted therapies for established, new, and emerging molecular alterations in NSCLC; Apply current guidelines and best practices for biomarker testing to help inform targeted treatment decisions for patients with NSCLC; and Integrate targeted therapies into individualized treatment plans for eligible patients with NSCLC in clinical practice or clinical trials

Jacob Sands, MD - Facilitating Progress in the Treatment of SCLC: How to Optimize the Use of Current Systemic Options and Accelerate the Clinical Transition of Investigational Approaches Mar 28, 2023

Go online to PeerView.com/FSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. After many years of slow progress, the treatment arsenal has finally expanded and more hope is on the horizon for patients with small cell lung cancer (SCLC). Notable advances such as chemo-immunotherapy in the first-line setting and lurbinectedin in the second-line setting have now become guideline-recommended standards of care and propelled the treatment of SCLC forward. Further research efforts are focused on understanding the underlying biology and potential subtypes of SCLC, what biomarkers may be useful in refining treatment selection, and evaluation of novel therapeutic options and rational combinations. In this PeerView Live Candid Conversations & Clinical Consults symposium, based on a recent live symposium, leading experts weave together the latest evidence on standard-of-care therapies and the evolving data on new/emerging approaches to provide a big-picture overview of the present and future management of SCLC and how to accelerate further progress in this challenging disease. These discussions are framed with illustrative patient cases to highlight evidence-based strategies to improve care and outcomes in SCLC. Upon completion of this activity, participants should be better able to: Analyze the role and use of current and emerging therapies for SCLC and the evidence supporting their use; Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, rapid initiation of therapy, and optimal care throughout the disease continuum for each patient with SCLC; Incorporate current standard-of-care therapies into individualized treatment plans for eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC to facilitate progress and improve outcomes

James M. Foran, MD, FRCPC, Jessica K. Altman, MD - The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve Outcomes Mar 28, 2023

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into induction, consolidation, and maintenance/postremission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines; and Incorporate novel therapies into treatment plans for patients with relapsed/refractory AML, including as pretransplant conditioning or as salvage options post-transplant

Robert Z. Orlowski, MD, PhD - "House Rules" for Innovative Therapy in Multiple Myeloma: Guidance on Integrating Monoclonal Antibodies and BCMA and Non-BCMA Options Into Patient Care Mar 28, 2023

Go online to PeerView.com/DFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody platforms—including agents directed against targets such as CD38 and BCMA—have proven efficacy in a range of multiple myeloma (MM) treatment settings and have clear treatment roles across the spectrum of care, from newly diagnosed MM to relapsed/refractory disease. Additionally, a new wave of immune-based treatments in the form of bispecific T-cell–engaging antibodies shows a great deal of promise and may soon add another layer of complexity to the selection and use of antibody platforms in MM. This activity features a panel of hematology-oncology experts illustrating the clinical implications of current and emerging evidence that supports an expanded role for therapeutic use/planning of antibody and immunotherapy options in MM. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging immunotherapy options, including monoclonal antibodies, antibody–drug conjugates, and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; and Address practical aspects of immunotherapy options in MM, including unique safety considerations and effective sequential use of antibody-based therapy

Mazyar Shadman, MD, MPH, Peter A. Riedell, MD - Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy Mar 28, 2023

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting

Thomas G. Martin, III, MD, Krina Patel, MD, MSc - Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options Mar 28, 2023

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management

Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment Mar 28, 2023

Go online to PeerView.com/FTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed. There is also an increasing need for new ways to measure response to immunotherapies as they transition to early-stage, curative-intent settings in different solid tumors. Pathologic response assessment has emerged as a promising approach for evaluating the impact of neoadjuvant immunotherapy in lung, breast, and other cancers. However, limited guidance has been available on how to define and measure pathologic response, and report and apply assessment results. In this educational activity, experts provide up-to-date instruction and practical guidance on how to improve predictive immunotherapy biomarker testing and establish best practices for pathologic response assessment after neoadjuvant immunotherapy based on the evolving evidence, new guidelines, and illustrative case scenarios. Upon completion of this activity, participants should be better able to: Describe the recommendations and practical considerations for cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings; Perform appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings; and Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, pulmonologists, surgeons, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making across different tumors and treatment settings

Jennifer Woyach, MD - Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice Mar 14, 2023

Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting.

Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - Medicine in Motion: Visual Guide to a New Generation in Care for Patients With Hypertrophic Cardiomyopathy Mar 10, 2023

Go online to PeerView.com/KYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The visual guide to hypertrophic cardiomyopathy (HCM) you’ve been waiting for is here! In contemporary care, patients with HCM have options that may reduce the need for invasive treatments. This engaging presentation is perfect for both visual and auditory learners to update their understanding of HCM, tune in to the signs and symptoms that should raise suspicion, and learn best practices to confirm a diagnosis of HCM. Once diagnosed, you’ll need to know the latest data on cardiac myosin inhibitors and practical guidance for integrating them into patient care. This activity delivers on all of the above—set aside some time and click “play” today! Upon completion of this activity, participants should be better able to: Recognize clinical characteristics and/or features that suggest the presence of HCM; Accurately diagnose patients with suspected HCM using expert guidance and the latest recommendations to promote early identification and treatment; and Personalize the medical treatment of HCM using strategies with disease-modifying potential based upon the latest efficacy and safety evidence and consistent with current prescribing and monitoring recommendations to ensure long-term patient safety and improve clinical outcomes.

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH Mar 10, 2023

Go online to PeerView.com/BPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While homozygous familial hypercholesterolemia (HoFH) is associated with development of atherosclerotic cardiovascular disease in childhood, early recognition and treatment of this inherited disease can improve outcomes for patients. In this animated activity provided by PeerView in collaboration with the Family Heart Foundation, a cardiologist describes the impact of this rare disease on patients and their families, presents strategies for recognizing signs and symptoms of HoFH, and reviews guidelines for genetic screening and referral of patients and their families to appropriate experts and resources for support. Additionally, two patients share their experiences of living with HoFH. Upon completion of this activity, participants should be better able to: Describe the consequences of undiagnosed and untreated HoFH from the patient’s perspective; Distinguish hallmark signs, symptoms, and family history differentiating HoFH from other disorders; and Employ current guidelines and support resources to direct patients with suspected HoFH to appropriately qualified care providers.

Ravin Ratan, MD, M.Ed - Addressing Key Questions About the Latest Diagnostic and Therapeutic Advances in Desmoid Tumors Mar 10, 2023

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH Mar 03, 2023

Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.

Marwan Sabbagh, MD, FAAN - Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease Mar 01, 2023

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Evan S. Dellon, MD, MPH - What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice Mar 01, 2023

Go online to PeerView.com/TGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life. Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising. This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice. Upon completion of this activity, participants should be better able to: Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease; Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team; and Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers Mar 01, 2023

Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. Upon completion of this activity, participants should be better able to: Explain current guidelines and evidence related to molecular testing and targeted therapeutics, enabling timely diagnosis, and treatment of gene fusion–driven GI cancers; Implement collaborative, multidisciplinary genomic testing protocols designed to capture less common but actionable molecular alterations in metastatic or locally advanced GI cancers; and Construct safe, individualized treatment plans for patients with advanced GI cancers who present with uncommon genomic alterations

Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances Mar 01, 2023

Go online to PeerView.com/YRK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients? This PeerView educational activity, based on a recent live symposium, brings together top experts to answer these questions. The faculty panel discusses new, practice-changing evidence, implications and applicability of these advances to practice, and how to best facilitate the incorporation of perioperative immunotherapy into new standards of care to improve outcomes and quality of life for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Analyze the current evidence supporting the use of neoadjuvant and adjuvant immunotherapy approaches in stage I-III NSCLC, including the biologic and mechanistic rationale, novel endpoints, and data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Implement neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable stage I-III NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making

April W. Armstrong, MD, MPH - Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic Mar 01, 2023

Go online to PeerView.com/XMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Psoriasis, a chronic inflammatory disease that affects up to 1 in 20 people worldwide, can drastically impact a patient's quality of life and health. The number of therapies for patients with moderate-to-severe psoriasis has grown steadily over the past 2 decades. Biologic immunotherapies have been the primary agents to gain approval, while small-molecule therapies have lagged in development. Deucravacitinib is a newly approved oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib allosterically inhibits TYK2 activity by binding to the regulatory domain rather than the catalytic domain. Binding in this way gives deucravacitinib greater specificity for TYK2 versus the closely related JAK1/2/3. Deucravacitinib has demonstrated safety and efficacy in moderate-to-severe chronic plaque psoriasis in two phase 3 pivotal trials (POETYK PSO-1 and PSO-2). Psoriasis Area Severity Index (PASI) 75 and static Physician's Global Assessment (sPGA) 0/1 response rates were significantly higher with deucravacitinib versus placebo or apremilast. In this activity, based on a recent live symposium, expert faculty discuss the clinical implications of targeting TYK2 in psoriasis, as well as strategies to identify patients for whom inhibition of TYK2 would be an appropriate treatment option based on available data. In addition, the faculty delve into the importance of shared decision-making in formulating personalized management plans for patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of moderate-to-severe psoriasis as it relates to selective targeting of TYK2; Identify patients with psoriasis for whom inhibition of TYK2 would be an appropriate treatment option based on available efficacy and safety data and practice guidelines; and Develop personalized management plans for patients with psoriasis using principles and tools of shared decision-making, empowering patients to participate in treatment decisions and remain adherent to therapies

Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know Mar 01, 2023

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice Mar 01, 2023

Go online to PeerView.com/SRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the availability of testing, vaccines, and treatments, COVID-19 remains a threat—no one can predict when a new strain might surface and many questions remain. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic to critical and fatal illness. Most symptomatic infections are mild; however, a significant number of patients have severe disease requiring hospitalization. Hospitalization and death are more likely in high-risk populations, including older people, individuals with underlying medical problems, and those affected by systemic health and social inequities (ie, minorities, immigrant populations, people of low socioeconomic status, and the disabled). Therapies such as antiviral agents and monoclonal antibodies are available in the United States and Europe for the treatment of COVID-19; however, there are challenges with determining which hospitalized patients may be best suited for which treatment. In this activity, based on a recent live web broadcast, a panel of experts explores strategies to improve outcomes for COVID-19 in the hospital setting, with a focus on designing individualized treatment plans based on current guidelines, evolving evidence, and patient-specific factors. The panel also discusses how differences in drug access and treatment protocols impact the healthcare team in regards to providing individualized treatment programs for patients hospitalized with COVID-19. Upon completion of this activity, participants should be better able to: Assess patients with COVID-19 to make appropriate treatment recommendations based on disease severity; Differentiate therapies for COVID-19 based on the latest safety and efficacy data from clinical trials; Collaborate with the healthcare team to design timely and individualized treatment plans for hospitalized patients with COVID-19 disease based on current guidelines, evolving evidence, and patient-specific factors; and Discuss the clinical implications of prolonged/persistent viral replication in severe COVID-19

Loretta J. Nastoupil, MD - Innovation Now for Follicular Lymphoma: New Evidence for Immunotherapy, Targeted, and Chemo-Free Options Mar 01, 2023

Go online to PeerView.com/SZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with immunotherapy, targeted agents, and chemo-free options for follicular lymphoma (FL)? Find out by accessing this activity, where an expert will interpret new evidence supporting the continued integration of bispecific antibodies, CAR-T cell therapy, EZH2 inhibitors, and PI3K inhibitors across multiple lines of therapy in relapsed/refractory FL. Throughout, the expert shares guidance on therapeutic sequencing, safety management, and the future use of innovative combination platforms. Don’t miss this important update from ASH! Upon completion of this activity, participants should be better able to: Summarize evidence surrounding targeted, epigenetic, and immunotherapy options for R/R FL; Integrate modern, evidence-based sequential treatment plans for R/R FL that include immunomodulatory drugs, targeted therapies, epigenetic agents, bispecific antibodies, and CAR-T constructs; and Manage the unique suite of adverse events associated with the use of novel therapeutics as sequential management options in R/R FL

John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL Mar 01, 2023

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don’t miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Marwan Sabbagh, MD, FAAN - Translating the Latest Research Advances Into Routine Care for Alzheimer’s Disease: Preparing Dementia Specialists With the Latest Strategies to Support Early Diagnosis and Comprehensive Care Mar 01, 2023

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD

Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC Feb 02, 2023

Go online to PeerView.com/JBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Less common genomic alterations such as gene fusions represent actionable and important therapeutic targets in a substantial proportion of patients with non–small cell lung cancer (NSCLC). Although they are relatively rare, it is essential to conduct appropriate biomarker testing to identify these alterations because highly effective targeted therapies have become available that can significantly improve patient outcomes versus older targeted therapies or cytotoxic agents. RET fusion–positive NSCLC is one such example. Next-generation, more selective tyrosine kinase inhibitors (TKIs) have demonstrated remarkable efficacy and improved safety in patients with tumors exhibiting RET fusions. However, testing for these fusions and other less common alterations as well as interpreting reports of testing results can be challenging, which can lead to missed opportunities to offer the best possible therapy to patients who could benefit from them. This educational activity is designed to help professionals involved in the testing and treatment of patients with NSCLC develop their knowledge and skills to bridge the current gaps in the care of patients with lung cancer. Expert faculty provide practical guidance on how to select the correct biomarker testing approach and platform to identify gene fusions and other less common alterations in NSCLC, implement the testing in-house or externally, and decipher the results or interpret the information in send-out testing reports. The experts also share tips and case-based examples of effectively collaborating with multidisciplinary and interprofessional colleagues to identify suitable candidates for the latest targeted therapies matched to the results of biomarker testing and, consequently, positively impact the outcomes of these patients. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions and other less common alterations in NSCLC, importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Implement team-based strategies to identify patients with NSCLC for biomarker testing, select appropriate tests to capture all actionable genomic alterations, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with lung cancers harboring uncommon gene fusions and other alterations; and Educate patients about the role of biomarker testing in lung cancer, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Gerald Appel, MD, PhD - Targeted Complements: Exploring New Horizons Designed to Address Gaps in Treating Complement-Associated Kidney Diseases Feb 02, 2023

Go online to PeerView.com/FSW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Explore new horizons in complement-targeted treatments with two leading experts who share fresh insights into the underlying pathophysiology of complement-associated kidney diseases and provide evidence-based guidance on their diagnosis and treatment. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of complement-associated kidney diseases, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets; Differentially diagnose patients with complement-associated kidney diseases in a timely manner using evidence-based tools and strategies; and Describe current and emerging treatments for complement-associated kidney diseases, including data from recent clinical trials.

Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes Feb 02, 2023

Go online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learners guidance on the “road to remission” in MM, and hear how recent advances with BCMA-targeted therapies can directly lead to enhanced outcomes in the most challenging treatment settings. Throughout, the experts also provide case-based guidance on therapy selection with BCMA antibodies and CAR-T therapy, and illustrate how evidence-based practice can optimize delivery of care in pretreated disease. Get on the “road to remission” for your patients, and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: State the current evidence and rationale that support the treatment roles of novel BCMA-targeting platforms, including antibody-drug conjugates, bispecifics, and CAR-T therapy, in relapsed/refractory disease; Select personalized, evidence-based regimens with novel anti-BCMA options based on patient preference, disease prognosis, and functional status, among others; and Develop strategies for addressing practical aspects of BCMA-targeted therapy in RRMM, including issues related to dosing/scheduling, patient counseling, and unique safety considerations such as cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.

Prof. Hans Gelderblom, MD - New Evidence Now for Targeted Therapy in TGCT Jan 27, 2023

Go online to PeerView.com/DNP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What are your skills in managing tenosynovial giant cell tumors (TGCT)—particularly in light of updated phase 3 evidence supporting systemic treatment? Find out in this final part of an educational series on TGCT, where an expert in the field reviews current standards of care and provides updates from a major clinical trial that supports the use of targeted options in conjunction with established multimodal treatment protocols for TGCT management. Upon completion of this activity, participants should be better able to: Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients where continued surgery is unlikely to produce clinical benefits; and Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care Jan 27, 2023

Go online to PeerView.com/ENP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Did you miss the PeerView DLBCL Seminar & Tumor Board at the Annual Hematology Meeting in New Orleans or want to revisit this important educational event? Access this program to watch a panel of experts debate the emergence of potent, antibody-based treatment platforms for patients with DLBCL, including novel CD19-directed antibodies, antibody-drug conjugates, and CD3xCD20 bispecific agents. These discussions are paired with case scenarios offering guidance on how to integrate these platforms into personalized management for DLBCL patients. The panel also explores the identification of candidates for treatment with novel antibodies; therapeutic sequencing and bridging strategies; and appropriate safety management and monitoring. Don’t miss this informative video to receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated evidence and guideline recommendations surrounding the incorporation of CD19, CD79, and CD3/CD20 targeting antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL); Integrate novel antibody-based treatment platforms into treatment plans for patients with DLBCL, including as sequential therapy over multiple lines of treatment, for patients unable to receive transplant, or in conjunction with cytotoxic regimens; and Develop team-based plans to manage practical safety and dosing considerations related to antibody therapy, including for patients with R/R DLBCL receiving active treatment.

Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment Jan 27, 2023

Go online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th ASH Annual Meeting and Exposition, can prepare you to adapt your practice through expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care in different and often challenging treatment settings. This program also features important resources from our collaborative partner, the CLL Society, that can be used to engage with your CLL patients during disease management. Upon completion of this activity, participants should be better able to: Cite the current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines supporting the use of targeted and other novel therapies in CLL, including safety, efficacy, and selectivity differences; Select personalized frontline regimens with targeted therapies as single agents or as part of combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential and combinatorial treatment plans with targeted agents and cellular therapies for patients with therapeutic intolerance and/or R/R CLL; and Manage unique safety considerations associated with the use of targeted agents or other novel therapies in the CLL setting.

Erika Hamilton, MD - Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer Jan 27, 2023

Go online to PeerView.com/YNC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Endocrine therapy, typically with an aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor, is a mainstay for the management of HR+/HER2- metastatic breast cancer, but many questions still remain about the nuances of optimal use of these and other agents in first- and later-line settings. Furthermore, a number of investigational therapies are showing great promise in HR+/HER2- advanced disease, including novel ER-targeting agents such as oral SERDs, SERMs, SERCAs, PROTACs, and others, as well as antibody–drug conjugates such as those targeting TROP2. It is essential to learn how to best integrate these options into the current treatment arsenal. CDK4/6 inhibition with adjuvant abemaciclib has also changed the standard of care for high-risk patients with earlier-stage disease, but challenges remain, such as determining which patients benefit from this approach, and how to ensure that patients stay on therapy to reduce their risk of recurrence. This PeerView educational activity, based on a recent live symposium and produced in collaboration with GRASP and Living Beyond Breast Cancer to highlight patient perspectives, pairs compelling analyses of key evidence with practically oriented discussions focused on the evolving role of various standard, new, and emerging treatment options for HR+/HER2- advanced and early breast cancer. Leading experts show how to navigate the increasing complexity of treatment in the metastatic setting, as well as the recent expansion of new therapies into early-stage disease, and discuss implications for multidisciplinary care and patient-centric best practices. Upon completion of this activity, participants should be better able to: Describe the rationale for, mechanisms of action of, and latest efficacy and safety data supporting the use of standard, new, and emerging treatment options for patients with HR+/HER2- advanced and early breast cancer, and their evolving roles in clinical practice; Develop personalized treatment plans for patients with HR+/HER2- advanced and early breast cancer that take into account all the relevant tumor-, patient-, and treatment-related factors, and include appropriately selected standard, new, or emerging treatment options in the context of clinical practice or clinical trials; Integrate a team-based, collaborative, and coordinated approach to care to educate patients with HR+/HER2- advanced and early breast cancer about new and emerging treatment options for which they may be eligible and engage patients in shared decision-making to ensure that their unique needs and preferences are taken into account when making treatment decisions.

Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors? Jan 11, 2023

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All Jan 06, 2023

Go online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, a panel of leading bladder cancer experts pairs important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity will highlight strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for the use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Using patient cases drawn from clinical practice and interactivity that allows participants to see how their treatment choices compare with their colleagues, the faculty will address the mechanistic rationale for these new therapies, therapeutic decision-making, and AE mitigation strategies. Upon completion of this activity, participants should be better able to: Synthesize new evidence on multi-faceted strategies for bladder cancer management based on modern immunotherapeutic agents, small molecule targeted therapies, and antibody–drug conjugates, among others; Integrate novel and emerging therapeutic approaches into personalized treatment plans for patients with bladder cancer, considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Implement evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Rana R. McKay, MD, Alicia K. Morgans, MD, MPH - Alicia K. Morgans, MD, MPH - Case by Case: Maximizing Personalized Approaches to Prostate Cancer Jan 06, 2023

Go online to PeerView.com/YGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding therapeutic landscape for prostate cancer has provided new opportunities for oncology and urology professionals to improve outcomes through individualized patient care. With new and emerging strategies in both the hormone-sensitive and -resistant settings, treatment of patients with prostate cancer requires knowledge of next-generation anti-androgen agents, PARP inhibitors, and use of immunotherapy, radioligands, and other strategies alone or in active combinations, along with guidelines for testing and treatment. In this activity, urologic oncology experts pair in-depth analysis of efficacy and safety evidence with a case-focused discussion of best practices for bringing treatment advances to the clinic. Featured topics include novel therapeutic approaches, strategies for collaboration with other clinicians and patients to optimize care, and the role of clinical trials. Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended germline and somatic testing into the routine management of patients with prostate cancer to inform therapeutic decision-making; Describe the therapeutic roles, key efficacy and safety evidence, and current guideline recommendations pertaining to the use of novel and emerging prostate cancer treatment strategies; and Develop individualized treatment algorithms that incorporate new data and treatment options (including clinical trial enrollment), expert recommendations, shared decision-making, and multidisciplinary team-based care for patients with prostate cancer

Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments Jan 06, 2023

Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel helps you better navigate the complex clinical decisions about when and how to use TROP2-targeting ADCs and the other latest therapies in real-world settings of breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanism of action, evolving clinical role, and latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Integrate personalized treatment plans for patients with breast cancer that takes into consideration the latest evidence and guidelines on TROP2-targeting therapies and relevant treatment-, disease-, and patient-specific factors; and Apply a patient-centered approach to care that incorporates shared decision-making, patient education, and engagement that leverages effective multidisciplinary collaboration and care coordination

Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events Jan 04, 2023

Go online to PeerView.com/SFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to expand their role in advanced cancers and early-stage, curative-intent settings. While immunotherapy has become a pillar of cancer treatment and is considered safe, ICIs are associated with a spectrum of unique toxicities termed immune-related adverse events (irAEs). These irAEs can affect any organ system in the body, including the heart and cardiovascular system, occur at any point during or after treatment, and vary in presentation from mild to severe, and sometimes life threatening. Cardiac pathology attributed to irAEs include myocarditis, cardiomyopathy, pericardial disease, arrhythmias and conduction disease, impaired ventricular function with heart failure, and vasculitis. Autoimmune myocarditis is the most common and best characterized cardiac irAE to date. This activity, based on a PeerView Live Clinical Consults cardio-oncology symposium, provides essential guidance for prompt identification and initiation of treatment of irAEs. In the current era of cancer immunotherapy, healthcare professionals must develop a high level of vigilance and be able to correctly and rapidly manage and monitor patients with cancer exhibiting symptoms of possible cardiac irAEs to ensure the best possible outcomes. The expert faculty presents management algorithms, real-world case scenarios, and practical challenges related to multidisciplinary coordination of care to improve collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Review the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse events (irAEs) during or after treatment with cancer immunotherapies; Apply algorithms, practical tools, and available therapies based on the latest clinical evidence and recommendations for baseline risk assessment, identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs; and Utilize effective shared decision-making and team-based approaches to facilitate multidisciplinary and interprofessional collaboration and improve clinician-patient communication and outcomes for patients at risk of or experiencing cardiac irAEs

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE? Dec 19, 2022

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Maureen A. McMahon, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the Experts Dec 19, 2022

Go online to PeerView.com/TSR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an expert panel examines the latest evidence for currently approved targeted agents in systemic lupus erythematosus (SLE) and lupus nephritis (LN) and offers personal anecdotes and reflections to illustrate how scientific findings can inform everyday clinical practices and guide individualized approaches to care. Additionally, the panel discusses the need for culturally competent care to ameliorate healthcare disparities offering evidence-based tools and tactics to overcome barriers and improve access to care and health information needs for patients in marginalized populations. Upon completion of this activity, participants should be better able to: Employ best practices related to the diagnosis and assessment of SLE and LN; Describe the pathophysiology of SLE and LN, recognizing targets for therapeutic intervention; Outline the mechanism of action, efficacy, and safety of current targeted therapies for SLE and LN; Select appropriate pharmacologic therapy for individual patients with SLE and LN to ensure long-term survival, achieve the lowest possible disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve the management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration / Modern Therapeutics Dec 19, 2022

Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide the best care for your patients—participate in this activity to hear the latest on using collaborative strategies to optimize outcomes in HCC. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of novel and emerging systemic therapy approaches for patients with advanced/metastatic HCC; Review the latest evidence on innovative strategies, including novel locoregional modalities, combinations of locoregional and systemic therapies, and perioperative/conversion approaches, for patients with HCC across the disease continuum; Develop contemporary, personalized management plans for patients with HCC that consider the available clinical evidence, expert/guideline recommendations, clinical trial opportunities, and patient-, disease-, and treatment-specific factors; and Implement best practices for multidisciplinary collaboration and care coordination when managing patients with HCC, including team-based strategies to maximize treatment efficacy, safety, tolerability, and patient quality of life.

Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World Dec 19, 2022

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC

Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease Dec 19, 2022

Go online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), and Employ appropriate strategies to differentiate cold agglutinin disease (CAD) from other forms of autoimmune hemolytic anemia (AIHA) to provide optimal care for patients.

Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies Nov 30, 2022

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.

Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes? Nov 30, 2022

Go online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care. Upon completion of this activity, participants should be better able to: Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes; Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors; and Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT.

Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition? Nov 22, 2022

Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

Sandeep K. Gupta, MD - Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care Nov 17, 2022

Go online to PeerView.com/MKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic esophagitis (EoE) is an increasingly prevalent, chronic, T2 inflammatory disease triggered by food and/or environmental allergens. Due to underlying tissue inflammation, patients suffer diminished quality of life due to symptoms such as weight loss, difficulty swallowing, and heartburn. Patients can experience these symptoms for a long time before receiving a proper diagnosis. Once diagnosed, treatment options have historically been limited. Fortunately, therapies that treat other type 2 disorders are in development or are approved to treat EoE. At a recent live event, experts used patient cases to discuss the diagnosis, underlying causes, and the newest treatments for EoE, including biologic therapies. Watch this on-demand version now! Upon completion of this activity, participants should be better able to: Distinguish signs and symptoms of eosinophilic esophagitis (EoE) among children and adults to enable an earlier diagnosis and minimize complications due to uncontrolled disease; Recognize underlying mechanisms of EoE, including the role of key cytokines such as interleukins -4, -13, and -5 as drivers of type 2 inflammation and how this relates to emerging treatment; and Apply the latest expert recommendations and clinical evidence to the treatment of patients with EoE, particularly as novel and emerging agents become available.

R. Scott Wright, MD - Diagnosing and Treating Hyperlipidemia in Family Medicine: Exploring the Latest Clinical Evidence and the Role of Novel PCSK9-Targeting Therapies Nov 17, 2022

Go online to PeerView.com/QCN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hyperlipidemia discusses evidence-based strategies for diagnosing and individualizing treatment plans with PCSK9-targeting agents to improve patient outcomes. Upon completion of this activity, participants should be better able to: Perform a diagnostic evaluation based on current clinical guidelines for the treatment of hyperlipidemia; Assess the mechanisms of action, efficacy, and safety of PCSK9-targeting agents designed to further reduce lipid levels in patients with hyperlipidemia; Identify patients who may benefit from treatment with PCSK9-targeting therapies; and Recognize the role of multidisciplinary collaboration and patient education to optimize outcomes in patients with hyperlipidemia.

Alicia K. Morgans, MD, MPH - Creating a Roadmap for Modern Prostate Cancer Treatment: How to Use the Most Recent Evidence on Novel Therapeutic Strategies and Shared Decision-Making to Personalize Patient Care Nov 17, 2022

Go online to PeerView.com/XGS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Two experts highlight how a prostate cancer care team can use the latest clinical evidence, treatment guidelines, and consensus recommendations to improve outcomes for patients with prostate cancer and will give practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. By providing a “roadmap” to the multiple pathways of prostate cancer management, this program serves as a resource for professionals interested in the present and future applications of new science in patient care. Upon completion of this activity, participants should be better able to: Review current guideline recommendations related to germline and somatic tumor testing in patients with prostate cancer; Select patients with advanced prostate cancer who are likely to benefit from novel systemic therapies and combination strategies based on recent clinical evidence, regulatory updates, genetic/molecular status, and current practice guidelines; and Implement personalized treatment plans for patients with advanced prostate cancer that incorporate new agents and combinations, expert recommendations, shared decision- making, and multidisciplinary team-based care.

Nasser Altorki, MD - Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right Nov 17, 2022

Go online to PeerView.com/CDB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Research and clinical practice continue to build on the success achieved to date with cancer immunotherapy and to refine rational strategies to expand its benefits to more patients, including in curative-intent settings. Immunotherapy has started to radically transform the multimodal approach to treatment of resectable stage I-III NSCLC. Recently, highly positive data have emerged from the first few phase 3 trials evaluating neoadjuvant and adjuvant immunotherapies in resectable lung cancer, leading to regulatory approvals and new standards of care in these settings. What do these advances mean for thoracic surgeons, medical oncologists, pulmonologists, and other multidisciplinary specialists, and what changes in practice are needed? What challenges and unanswered questions remain? This PeerView educational activity, based on a recent live symposium, brings together top experts to discuss new, practice-changing evidence, the implications and applicability of the latest data to practice, and how to achieve better partnerships across disciplines to facilitate the incorporation of immunotherapies into new standards of care to improve outcomes and quality of life for patients with stage I-III NSCLC. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings; Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy; Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions; and Collaborate with the multidisciplinary team to integrate immunotherapy into individualized, multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.

Morie A. Gertz, MD - Don’t Miss the Rare When Diagnosing and Treating Autoimmune Hemolytic Anemia: Focus on CAD Nov 14, 2022

Go online to PeerView.com/MVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses strategies that target the classical complement pathway and individualizing treatment plans for patients living with CAD. Upon completion of this activity, participants should be better able to: Describe the consequences of inhibiting complement C1s as long-term therapy for CAD, particularly on symptoms influenced predominantly by activation of the classical complement pathway (eg, chronic hemolysis, anemia, and fatigue); and Integrate classical complement pathway–targeted therapies into individualized treatment plans for CAD based on consideration of efficacy and safety data, patient-specific characteristics, and other potential prescribing considerations.

Richard K. Bogan, MD, FCCP, FAASM - Managing Disorders of Hypersomnolence: Reducing Patient Burdens, Protecting Patient Health Nov 14, 2022

Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.

Leonard B. Bacharier, MD / Monica Kraft, MD - Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled, Moderate to Severe Asthma Nov 09, 2022

Go online to PeerView.com/ATS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. In this activity, based on a recent live virtual symposium, our experts explain the advances in understanding of the pathogenesis of asthma. Our unique “How I Think, How I Treat” educational format offers a personal look at the way these experts apply evidence-based guidelines and translate new data to diagnose, assess, and treat their patients with uncontrolled, moderate to severe asthma effectively, with a goal of preserving lung function and improving quality of life. Upon completion of this activity, participants should be better able to: Assess severity of disease in pediatric and adult patients with uncontrolled, moderate to severe asthma, including evaluation of medication adherence; Identify pediatric and adult patients with uncontrolled, moderate to severe asthma who might be eligible for treatment with biologic therapy by testing for endotype/biomarkers (eg, IgE, eosinophils, FeNO); and Develop treatment plans for patients with uncontrolled, moderate to severe asthma based on the latest clinical evidence and guidelines, as well as other factors such as disease severity, comorbidities, exacerbation risk, and patient/caregiver preferences and goals.

Milind Desai, MD, MBA - Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy? Nov 08, 2022

Go online to PeerView.com/KST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM; Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner; Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM; and Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management.

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO - Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations Nov 08, 2022

Go online to PeerView.com/RJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The term "EGFR-positive lung cancer” is no longer adequate or specific enough to characterize this complex molecular subtype of lung cancer. Increased granularity is needed both in biomarker testing and targeted treatment selection for patients with different types of EGFR mutations. A growing number of new agents and combinations have become available for patients with common (eg, exon 19 deletion, exon 21 L858R) and uncommon (eg, exon 20 insertions) EGFR mutations, and more are on the horizon, requiring a precision approach. Watch PeerView’s latest educational video, based on a recent live symposium, and learn to better navigate biomarker-driven, individualized therapy for patients with EGFR-mutated NSCLC. Experts analyze the expanding evidence base and provide actionable, case-based guidance for improving testing, interpretation of results, and therapeutic decision-making for patients with NSCLC across a variety of EGFR mutations. Upon completion of this activity, participants should be better able to: Review the different types of EGFR mutations and their role as therapeutic targets in NSCLC, including in earlier disease stages; Collaborate with the multidisciplinary team to promote widespread biomarker testing in patients with NSCLC, select appropriate tests to detect common and less common EGFR mutations, and ensure accurate interpretation of results to guide targeted therapy selection; Apply current evidence and guidelines to individualize targeted therapy for patients with EGFR-mutated NSCLC based on EGFR mutation type and patient needs, values, and preferences; and Communicate with the multidisciplinary team and with patients to promote rapid detection and management of treatment-related adverse events in patients receiving EGFR-targeted therapies for NSCLC.

Mark W. Stolar, MD - A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes Nov 02, 2022

Go online to PeerView.com/FZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Timely screenings and referrals to eye care specialists for diabetic retinopathy (DR) and diabetic macular edema (DME) can make a real difference between good vision and blindness in patients with diabetes. But exactly when should patients with diabetes be screened for DR/DME in the primary care setting and which signs and symptoms should trigger a referral to specialty care? In this activity, based on a recent live virtual symposium, leading experts review guideline recommendations for DR/DME screening and referral in the primary care setting and present realistic patient cases to explore best practices and improve vision outcomes for patients with diabetes. Upon completion of this activity, participants should be better able to: Describe the roles of primary care professionals in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referral to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

Nicole Lamanna, MD / Deborah M. Stephens, DO - Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices Oct 28, 2022

Go online to PeerView.com/XPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Have you caught up with therapeutic changes in chronic lymphocytic leukemia (CLL) and the latest science supporting new standards of care centered on continuous or fixed-duration therapy with targeted agents (including BTK and BCL-2 inhibitors)? In this PeerView MasterClass & Case Forum recorded at the 2022 SOHO Annual Meeting, experts give insights on how to apply this evidence and select highly personalized targeted strategies (focused on covalent and noncovalent BTK and BCL-2 inhibitor agents), when managing diverse patient populations. Watch the experts tackle challenging cases and learn strategies for selecting upfront therapy and planning sequential care in relapsed/refractory CLL. Take the challenge, see how treatment has changed, and tune in today! Upon completion of this activity, participants should be better able to: Cite updated guidelines and evidence supporting the integration of targeted drug classes in CLL, including continuous therapy, fixed-duration options, and novel combinatorial regimens; Select personalized treatment with targeted agents, including fixed-duration or continuous therapy strategies, or appropriate combinational or sequential options for patients presenting with treatment-naïve or R/R CLL; Manage treatment-emergent adverse events associated with the use of targeted agents in the CLL setting, including single-agent and combination approaches

Praneetha Thulasi, MD, Jonathan L. Kaufman, MD - The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity Oct 28, 2022

Go online to PeerView.com/AHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to care for your patients with multiple myeloma (MM) who are experiencing ocular complications associated with the latest myeloma treatments? Ophthalmologists play an important in the care of myeloma, and in this PeerView MasterClass & Ophthalmology Case Forum an ophthalmologist and an oncologist highlight the importance of the ophthalmology and oncology connection in myeloma care. Tune in to get practical guidance on the challenges of accurately recognizing and characterizing ocular toxicity in MM patients receiving novel therapy and case-based guidance on collaborating within a modern MM management team, and see how addressing ocular toxicity can contribute to the delivery of highly effective treatment. Upon completion of this activity, participants should be better able to: Recognize the range of novel, therapy-associated ocular complications in the multiple myeloma treatment setting; Integrate proven techniques, including scheduled and routine eye examinations, dry eye prophylaxis, and therapeutic dose adjustment to address ocular toxicity in patients with multiple myeloma; Work collaboratively within oncology-ophthalmology teams to effectively monitor and manage treatment-emergent ocular toxicity in multiple myeloma patients

Scott T. Tagawa, MD, MS, FACP - Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates Oct 28, 2022

Go online to PeerView.com/VRE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey. These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants should be better able to: Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations; Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care; Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

Prof. Arjan Bredenoord - The Latest on New Options for Eosinophilic Esophagitis: Considering Targeted Biologic Therapy Oct 28, 2022

Go online to PeerView.com/RFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of eosinophilic esophagitis (EoE)? Hear what was presented at the 30th United European Gastroenterology Week (UEG Week 2022) from Professor Arjan Bredenoord as he shares the latest evidence on novel biologic therapies for EoE and provides practical guidance on their safe and effective integration into clinical practice. Upon completion of this activity, participants should be better able to: Summarize recent clinical research data and treatment guidelines concerning the management of eosinophilic esophagitis (EoE); Integrate the latest clinical evidence concerning novel and emerging targeted therapies into treatment plans for the management of patients with EoE

Sagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies Oct 28, 2022

Go online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit! Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease; Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others; Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer Oct 28, 2022

Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the right patients who are most likely to benefit from these therapies and determine where within the NSCLC treatment arsenal these therapies fit the best. Watch PeerView’s latest educational video, based on a recent live symposium, which combines high-level seminars highlighting the latest evidence on HER2-, HER3-, and TROP2-targeting ADCs in NSCLC with a practicum dedicated to providing useful guidance on the implications and applications of the science to modern oncology practice to improve outcomes in patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the frequency, role, and targetable potential of HER2, HER3, TROP2, and other alterations in NSCLC; Compare the characteristics, efficacy/safety, and ongoing investigations of emerging ADCs targeting HER2, HER3, TROP2, and other alterations in NSCLC; Apply the latest evidence and guidelines on patient assessment in NSCLC, including biomarker testing as indicated, to identify patients for targeted therapies, including emerging ADCs targeting HER2, HER3, TROP2, and other alterations in the context of a clinical trial; Utilize best practices for identifying and managing treatment-related adverse events in patients receiving targeted therapies for NSCLC to promote optimal adherence, outcomes, and quality of life

Brendon M. Stiles, MD - Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings Oct 28, 2022

Go online to PeerView.com/WRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Approximately 40% of patients with early-stage lung cancer experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Management of patients with NSCLC should be individualized based on a number of factors, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have prompted strong interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. Early findings from studies in the neoadjuvant setting are beginning to emerge now as well, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. As part of the multidisciplinary team, thoracic surgeons play an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational video, based on a recent live symposium, provides an essential overview of the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings, as well as practical advice for optimal integration of targeted therapies in practice or as part of a clinical trial. Multidisciplinary discussions on the new practice-changing data highlight important implications for the surgeon–oncologist partnership, utilizing EGFR-targeted therapy as part of multimodal management of patients with resectable NSCLC with the goal of improving outcomes and quality of life. Upon completion of this activity, participants should be better able to: Review the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and importance of identifying patients who might benefit from these therapies in perioperative settings; Apply the latest evidence and guidelines to identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches; Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Professor Jacob P. Thyssen - Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World Oct 28, 2022

Go online to PeerView.com/RBZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis is a chronically relapsing skin disease that often begins in early childhood and can persist into adulthood, having a detrimental effect on the lives of patients and their families throughout the lifespan. In this activity, based on a recent live web broadcast, our global experts provide both pediatric and adult dermatologists, allergy/immunology specialists, and other specialty advanced practice providers around the world greater insight into the assessment of disease severity, the use of targeted biologic therapy, and the importance of patient engagement and shared decision-making in the management of atopic dermatitis. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD); Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines; Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy; Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care

Taofeek K. Owonikoko, MD, PhD - Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions Oct 28, 2022

Go online to PeerView.com/XXU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently validated and emerging therapies are providing new hope for patients with small cell lung cancer (SCLC). In patients with extensive-stage or metastatic disease, regulatory approvals of chemo-immunotherapy combinations, the transcription inhibitor lurbinectedin, and the myeloprotective agent trilaciclib have led to new guideline-recommended standards of care. Further progress is expected as ongoing clinical trials are evaluating existing therapies in different settings, including in earlier stages of disease and in various combinations, as well as promising novel therapies and rational combinations employing different agent classes and mechanisms of action. Bringing these treatment advances to the clinic comes with unique challenges, from sifting through data to ensure that patients benefit from these treatment advances and determining which patients are eligible for clinical trial enrollment to collaborating with the multidisciplinary team to manage unique adverse events associated with novel treatments and counseling patients. In this PeerView Candid Conversations & Clinical Consults program, leading experts will provide oncology specialists and multidisciplinary professionals who treat patients with lung cancer with the information they need to navigate the evidence on current and emerging therapies for SCLC. With illustrative cases serving as the cornerstone of the discussion, this activity will go beyond the basics of treatment and provide an intimate look at how top lung cancer specialists bring therapeutic advances into their own practices and what they think the future will bring. Learn about new data, guideline recommendations, and strategies to improve multidisciplinary collaboration and care; increase shared decision-making; and promote health equity in SCLC clinical care and research. Upon completion of this activity, participants should be better able to: Cite the latest evidence on available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other strategies, as well as emerging prospects in biomarker testing and subtyping that may help inform selection of patients for different therapies; Incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or clinical trials based on the latest evidence, guidelines, and patient needs, values, and preferences; Utilize best practices for diagnosing and managing treatment-related toxicity in patients with SCLC Implement multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC

Sagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA Antibodies Oct 28, 2022

Go online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't miss this opportunity to learn why these customizable and convenient agents are part of the revolution in care for MM. Upon completion of this activity, participants should be better able to: State the rationale for and current evidence supporting the use of BCMA-targeting options in RRMM, including triple-class–refractory disease; Create sequential, evidence-based treatment plans that integrate novel antibody options for management of patients with RRMM; Utilize proven tools and cross-disciplinary teamwork to manage the unique safety considerations associated with BCMA-directed antibodies, including ocular toxicity, CRS, and neurotoxicity, among others

Sara M. Tolaney, MD, MPH - Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer Oct 20, 2022

Go online to PeerView.com/VMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events. Upon completion of this activity, participants should be better able to: Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer; Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration; Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs); Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH Oct 20, 2022

Go online to PeerView.com/ACR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses how to utilize the American Gastroenterological Association’s Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Upon completion of this activity, participants should be better able to: List the disease pathways and mechanisms that define NASH as a metabolic disease; Identify the pathophysiology and role of GLP-1 as a therapeutic target in NASH; Differentially diagnose NASH in a timely manner; Integrate current and emerging agents into early management plans for patients with NASH based on the AGA NASH Clinical Care Pathway

Guillermo Garcia-Manero, MD; Gail J. Roboz, MD - The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes Oct 20, 2022

Go online to PeerView.com/EEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the “innovation moment” in myelodysplastic syndromes (MDS)? In this “Clinical Consults” program, two leading experts use case-based instruction to illuminate modern, personalized treatment for patients with MDS, including individuals presenting with lower- or higher-risk disease. Throughout, “mini lectures” support the panelists’ case-based decisions. Learn about the evidence supporting optimized risk assessment, the use of mutational analyses to augment baseline findings, and the integration of novel therapeutics into existing treatment plans. Don't delay, seize the “innovation moment” for your patients with MDS today! Upon completion of this activity, participants should be better able to: Cite patient- and disease-related features, including age, molecular/cytogenetic features, and risk assessment, that influence prognosis and guide treatment decisions for MDS; Describe current efficacy and safety evidence related to approved and emerging treatments for newly diagnosed or relapsed/refractory and low-, intermediate-, and high-risk MDS; Develop risk-adapted, personalized treatment plans that incorporate novel therapeutics for patients with MDS; Manage the unique spectrum of adverse events associated with novel and emerging therapies for MDS

Anju T. Peters, MD, MS - Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy Oct 20, 2022

Go online to PeerView.com/TJV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP. In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Professor Aleix Prat, MD, PhD - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients Oct 20, 2022

Go online to PeerView.com/FGB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. HER2-targeting therapies have led to remarkable improvements in patients with HER2-positive early and advanced breast cancer. Recently, novel antibody–drug conjugates (ADCs) and other HER2-targeting therapies have also demonstrated impressive activity in patients with HER2-low breast cancer, who account for approximately 40%-50% of patients with breast cancer and are a population with a high unmet medical need. The concepts of how to best define and test for HER2-low breast cancer are evolving, but the modern HER2-targeting agents offer new hope for dramatically improved outcomes in patients who currently have limited options. This PeerView educational video, based on a recent live symposium, explores the biology and foundational concepts of HER2-low breast cancer, highlights the rationale for and data supporting the use of HER2-targeted therapies in HER2-low breast cancer, assesses emerging approaches for identifying patients with HER2-low breast cancer who could benefit from HER2-targeted therapies, and clarifies how to best incorporate these therapies into practice in real-world settings. Clinical case scenarios are also used to provide useful guidance for testing and treatment of patients with HER2-low breast cancer. Upon completion of this activity, participants should be better able to: Explain the biologic rationale and clinical evidence on the growing role of HER2-targeting therapies in the treatment of patients with HER2-low breast cancer; Apply standard and emerging testing approaches to identify patients with HER2-low breast cancer to determine their eligibility for novel HER2-targeted therapies; Integrate individualized management plans that incorporate a collaborative and coordinated multidisciplinary team-based approach to care in accordance with the latest treatment guidelines and recommendations for patients with lower spectrum HER2-expressing breast cancer in the context of clinical practice or clinical trials

Javier Cortes, MD, PhD - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies Oct 19, 2022

Go online to PeerView.com/DFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Breast cancer is a heterogeneous disease comprising different subtypes, with estrogen receptor positive (ER+) being the most common subtype. Endocrine therapy (ET) is the primary treatment in ER+ breast cancer, which includes different strategies that directly or indirectly modify estrogen production. CDK4 and 6 inhibition as well as PI3K inhibition have improved outcomes in these patients, but most still develop endocrine resistance. ESR1 gene mutations, somatic alterations, microenvironmental factors, and epigenetic changes have all been implicated as underlying mechanisms promoting resistance. Novel ER-targeting agents such as oral selective estrogen receptor degraders (SERDs) are showing therapeutic promise in the face of ET resistance. In addition, other agents are being evaluated in ER+ disease, including selective estrogen receptor modifiers (SERMs), SERM/SERD hybrids, selective estrogen receptor covalent antagonists (SERCAs), proteolysis targeting chimeras (PROTACs), and others.This PeerView educational activity, based on a recent live symposium, highlights and analyzes the latest evidence and advances in the treatment of ER+/HER2- breast cancer, focusing on the expanding evidence base supporting the use of novel ER-targeted agents such as oral SERDs as a new standard of care in pretreated ER+/HER2- breast cancer. Practical guidance is also provided on how to apply the latest evidence to practice, optimize the use of these agents, and individualize treatment plans that take into account key data, patient- and tumor-related factors, and the specific needs and preferences of each patient. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including novel oral SERDs and other ER-targeting therapies, and their evolving role in clinical practice; Develop individualized treatment plans for patients with previously treated ER+/HER2- breast cancer that take into account the latest treatment options and all the relevant treatment-, tumor-, and patient-related factors; Integrate a team-based, collaborative, coordinated, and patient-centered approach to select appropriate candidates for SERDs and other new therapies for ER+/HER2- breast cancer, provide essential patient education, and ensure optimal delivery of therapy

Norman E. Lepor, MD, FACC, FAHA, FSCAI - Envisioning the Future of Hyperlipidemia Management: How Can We Leverage PCSK9-Targeting Therapies to Prevent Primary and Secondary Cardiovascular Events? Oct 07, 2022

Go online to PeerView.com/TVJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hyperlipidemia management examines the evidence for PCSK9-targeting therapies to prevent primary and secondary cardiovascular (CV) events. Upon completion of this activity, participants should be better able to: Summarize current clinical evidence and guideline recommendations for the treatment of hyperlipidemia, both for primary and secondary prevention of CV events; Recognize novel mechanisms of action and recent clinical evidence on approved and emerging investigational lipid-lowering therapies that target PCSK9; and Develop treatment protocols using appropriate lipid-lowering therapy including available and emerging agents, alone or in combination, for providing long-term LDL-C reduction and improving adherence.

Jivianne T. Lee, MD, FACS - Room to Breathe: Leveraging Biologic Agents and Multidisciplinary Care to Optimize Management in Chronic Rhinosinusitis With Nasal Polyps Oct 07, 2022

Go online to PeerView.com/ZFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this interactive activity, an expert in chronic rhinosinusitis with nasal polyps discusses how to identify and develop treatment plans for patients with the disease. With a focus on multidisciplinary care and treatment guidelines, the activity will test learners’ knowledge about the latest biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with severe, inadequately controlled CRSwNP to determine eligibility for targeted biologic therapy; Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders; and Develop treatment plans for patients with CRSwNP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

Steven E. Carsons, MD - Expert Perspectives on Novel Targeted Therapies for Sjögren’s Disease: Hope Is on the Horizon Oct 04, 2022

Go online to PeerView.com/HPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss the pathology of Sjögren's disease and potential treatment targets, as well as the clinical criteria and biomarkers used to diagnose the disease and aid in patient classification. Upon completion of this activity, participants should be better able to: Recognize the burden of disease, impact on quality of life, and unmet needs experienced by patients with Sjögren's disease; Describe the pathology of Sjögren's disease and potential treatment targets; Apply clinical criteria, guidelines, and biomarkers to diagnose Sjögren's disease and aid in patient classification; and Identify patients who may derive benefit from novel therapeutic options for Sjögren's disease using clinical trial data and shared decision-making.

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Nirav Shah, MD, MS - Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease Oct 04, 2022

Go online to PeerView.com/FHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready for new options and more sequential treatment choices in mantle cell lymphoma (MCL)? This activity, led by two MCL experts, will help you prepare through a foundational MasterClass on the evidence supporting covalent—and now noncovalent—BTK inhibitor options for the sequential management of MCL. This overview of key research links to Case Forum sessions that demonstrate how novel and emerging BTK inhibitors can be effectively integrated into team-based clinical practice, particularly in challenging R/R MCL settings. Watch the experts now and stay ahead of the curve! Upon completion of this activity, participants should be better able to: Describe the barriers to optimal MCL care and the practice-changing evidence supporting the use of novel and emerging BTKi strategies in R/R disease settings; Select appropriate management options with novel and emerging BTKi for patients with R/R MCL, including in settings of BTKi-naïve, -intolerant, or -resistant disease; and Develop coordinated, team-based approaches to manage practical aspects of MCL care when using BTKi strategies, such as monitoring, patient/caregiver education, adherence, and treatment-emergent AEs.

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF - An Exploration of Advances in the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation in a Unique Era of Patient Care: Incorporating an Individualized Approach to Help Your Patients Find Relief Sep 27, 2022

Go online to PeerView.com/CYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Brooks D. Cash shares expert guideline-based strategies to confirm a diagnosis of IBS-D, IBS-C, or CIC, highlighting key differential diagnoses to rule out and alarm features that warrant further investigation. You will be able to translate the latest clinical findings related to current over-the-counter and prescription treatments for IBS-C, IBS-D, and CIC, as well as gain insight into the clinical use of newer/novel treatment options. Dr. Cash also shares effective communication strategies you can use with your patients to increase their participation in their care and maximize their treatment satisfaction. Upon completion of this activity, participants should be better able to: Integrate appropriate, validated testing measures to make definitive, timely diagnoses of IBS/CIC; Treat IBS/CIC in accordance with current evidence and guidelines, recognizing the appropriate use of new and emerging therapeutic agents; and Implement strategies to establish effective communication and help patients with IBS/CIC increase participation in their care.

Sonia Glennie, ARNP, MSN, OCN, AGPCNP-BC - Moving Beyond Conventional Care for DLBCL: Oncology Nurse Leadership for the Effective and Safe Use of Innovative Antibody and Cellular Therapies Sep 22, 2022

Go online to PeerView.com/ZUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Nurses play an essential role in caring for patients with diffuse large b-cell lymphoma (DLBCL); learn more about the core elements of nursing practice in this PeerView video activity, featuring two leading oncology nurses who will focus on novel antibody and CAR-T cell therapies for the management of R/R DLBCL. Using a case-based format, the panelists will detail how antibodies and CAR-T therapy are now a part of the treatment toolkit and provide guidance on important considerations including: therapeutic sequencing, safety concerns, and counseling patients on appropriate dosing, treatment schedules, and premedication recommendations. Upon completion of this activity, participants should be better able to: Cite current clinical evidence supporting the integration of novel antibody and CAR-T cell therapies for the management of diffuse large B-cell lymphoma (DLBCL); Educate patients on safety, dosing, and treatment expectations associated with novel CD19, CD79, and CD3/CD20 targeting antibodies in the DLBCL setting; Counsel patients on the therapeutic role of cellular therapy in DLBCL, efficacy expectations, unique pre-therapy requirements, and adverse events such as CRS and neurotoxicity; and Manage practical considerations with novel antibodies and CAR-T therapy in DLBCL, including coordination of clinical visit or referral to specialized care, dosing considerations, and management of unique adverse events.

David Staskin, MD - Controlling the Urgency Emergency, Restoring QOL: Safe and Effective Management of Overactive Bladder Sep 19, 2022

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Alexander Drilon, MD - Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC Sep 19, 2022

Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences.

Sarah S. Chisolm, MD - Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care? Sep 06, 2022

Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of prurigo nodularis (PN) impact patient quality of life; Explain how type 2 inflammation may play a role in the pathophysiology of PN; Describe current and emerging treatment options for PN in the context of mechanism of action, efficacy, and safety; and Develop individualized treatment plans for PN using currently available therapies and appropriately incorporating novel agents as they become available.

R. Sharon Chinthrajah, MD - IgE-Mediated Food Allergies: Improving Patient Quality of Life Through a Multidisciplinary Approach as a New Era of Treatment Dawns Sep 06, 2022

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know? Sep 02, 2022

Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis; Incorporate evidence-based and guideline-directed treatment for pediatric and adult patients with moderate to severe asthma into customized management plans; and Use techniques to educate and communicate with patients and caregivers to engage them in care and improve adherence to individualized treatment plans.

Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life Sep 02, 2022

Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations to the diagnosis and treatment of patients with bronchiectasis, with a goal of identifying and treating underlying causes; Describe the underlying mechanisms believed to contribute to inflammation in non–cystic fibrosis bronchiectasis and their correlation to emerging treatments; Assess recent clinical trial data concerning efficacy and safety of novel and emerging treatment options for non–cystic fibrosis bronchiectasis; and Develop strategies for preventing and treating exacerbations (eg, airway clearance, use of antibiotics, corticosteroids) in patients with non–cystic fibrosis bronchiectasis based on the latest expert recommendations using a personalized approach.

Anjali Tiku Owens, MD - Going Beneath the Surface of Hypertrophic Cardiomyopathy: Understanding the Pathophysiology and Deploying New Strategies for Timely Diagnosis and Targeted Treatment Sep 01, 2022

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Robert Sidbury, MD, MPH - Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis? Sep 01, 2022

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care Aug 29, 2022

Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.

Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment Aug 29, 2022

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care Aug 29, 2022

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.

Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment Aug 25, 2022

Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action Aug 25, 2022

Go online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational and counseling strategies, patient monitoring, and adverse event management, that can be used to modernize care and facilitate the integration of effective, innovative therapies into the management of newly diagnosed myeloma, the early relapse setting, or heavily pretreated disease are described. Upon completion of this activity, participants should be better able to: Summarize updated evidence and current guidelines supporting treatment roles of novel therapeutics in newly diagnosed and relapsed MM care, including novel monoclonal antibodies, antibody–drug conjugates, targeted agents, and CAR-T therapy; Manage the unique spectrum of adverse events associated with novel therapeutics used to treat MM, including events such as infection, infusion reactions, ocular toxicity, GI events, CRS, or neurotoxicity; Counsel patients about efficacy and safety expectations and potential toxicities associated with novel therapies across the MM spectrum, including in patients receiving antibody-based regimens, targeted agents, or cellular therapy.

Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy Aug 25, 2022

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a collaborative care model; and Incorporate emerging therapies for managing patients with HCM based on their efficacy, safety, and ability to address the unmet needs of patients and the pathophysiology of HCM.

Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options Aug 11, 2022

Go online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patient advocate explore these themes through a case-based discussion of novel antibody platforms in a range of MM treatment settings. Learners can expect insights on the safety and efficacy evidence supporting the use of antibody-based therapies in newly diagnosed and relapsed MM, along with practical guidance for safe delivery of care, and strategies for engaging with patients when developing treatment plans that include antibody components. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surrounding the use of novel antibody platforms in multiple myeloma (MM); Integrate established and emerging antibody options, including monoclonal and bispecific antibodies, into treatment plans for patients with MM based on guideline recommendations and the latest clinical data; Address practical aspects of antibody therapy in MM, including unique safety considerations and effective sequential treatment; and Counsel patients with MM on dosing, safety, drug delivery, and therapeutic expectations with novel antibodies when engaging in shared decision-making discussions.

Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care Aug 11, 2022

Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents Aug 11, 2022

Go online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern HER2-directed therapeutics. In this activity, experts in HER-positive gastric cancer discuss the latest clinical evidence that supports the rapid integration of HER2-directed therapies across GI cancer settings. This “Seminars and Practicum” activity pairs compelling case discussion with the science that illustrates how to use innovative HER2 therapies to meaningfully improve patient outcomes—and the implication of this management model for EU and US practice. Don’t miss this exciting, informative learning opportunity! Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended HER2 testing into the routine management of patients with gastric, colorectal, and other GI tract cancers; Assess key safety and efficacy evidence on recently approved and emerging HER2-targeted therapies for different populations of patients with GI cancers; Develop individualized management plans for patients with HER2-positive GI cancers that leverage biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-, disease- and treatment-specific factors; and Employ appropriate strategies and best practices to monitor for, mitigate, and manage AEs related to novel therapies for HER2-positive GI cancers.

David Cornblath, MD - Optimizing Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy: Honing Diagnostic Accuracy, Personalizing Treatment Plans Aug 10, 2022

Go online to PeerView.com/FJH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated educational activity, an expert in chronic inflammatory demyelinating polyneuropathy (CIDP) discusses the diagnosis, assessment, treatment, and monitoring of the disease. A patient also shares her experiences living with and treating her CIDP. Upon completion of this activity, participants should be better able to: Apply guideline-directed criteria to diagnose chronic inflammatory demyelinating polyneuropathy (CIDP), including correct interpretation of electrodiagnostic findings; Incorporate evidence surrounding efficacy, safety, and tolerability of recommended pharmacotherapies (eg, corticosteroids, IVIg, SCIg, and plasma exchange) and shared decision-making into CIDP treatment planning; and Employ validated assessment tools to monitor treatment response and guide clinical decision-making.

Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes Aug 10, 2022

Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varying degrees of urgency for referral, offering a glimpse into how decisions made by primary diabetes care professionals can speed access to the appropriate eye care professional to directly benefit and improve outcomes for patients with, or at risk for, DR/DME. Upon completion of this activity, participants should be better able to: Describe the roles of diabetes specialists in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referrals to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

Prof. Carmelo Rizzari - The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients Aug 10, 2022

Go online to PeerView.com/JFN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimized use of asparaginase is a cornerstone of successful administration of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) and has implications for patient outcomes across populations—are you prepared for the emergence of novel asparaginase formulations and the use of strategies that can help avoid treatment discontinuation? This MasterClass & Case Forum video presents an opportunity to understand and surmount the challenges associated with delivering effective ALL care with the asparaginase component of modern therapy. In this activity, an expert panel addresses topics ranging from current guidance on first- and second-line asparaginase options, monitoring and management of barriers such as asparaginase hypersensitivity, and therapeutic planning using available tools to maintain asparaginase exposure. Upon completion of this activity, participants should be better able to: Summarize comprehensive management recommendations for pediatric, AYA, and adult patients with ALL, including chemotherapy and asparaginase protocols, immunotherapy, and tyrosine kinase inhibitors; Cite the clinical impact of E coli asparaginase hypersensitivity and asparaginase discontinuation in ALL, including in pediatric, AYA, and adult populations; Develop evidence-based treatment plans for asparaginase sequencing with E coli and Erwinia asparaginase, including recombinant formulations; and Manage E coli asparaginase hypersensitivity, including monitoring and strategies for switching to Erwinia asparaginase options.

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL Aug 09, 2022

Go online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence on the “upgraded” sequential use of BTK inhibitors and other therapeutic innovations in pretreated B-cell cancer settings. Throughout, the experts will provide case-based insights on the principles of BTK inhibitor selection and sequencing in the setting of disease progression, therapeutic intolerance, and other challenging pretreated populations. Upon completion of this activity, participants should be better able to: Cite barriers to effective sequential therapy with BTK inhibitors, the mechanistic and selectivity differences between covalent and non-covalent agents, and current efficacy and safety evidence supporting individualized BTK inhibitor therapy in relapsed/refractory (R/R) B-cell cancer settings; Develop safe, individualized, and evidence-based sequential therapy plans that incorporate the use of BTK inhibitors for patients with R/R CLL/SLL who have progressed on prior therapy; Recommend appropriate BTK inhibitor therapy for patients with R/R MCL or other B-cell malignancies that is informed by the principles of sequential care, strategies to maximize safety, and the option of clinical trial enrollment.

Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches? Aug 09, 2022

Go online to PeerView.com/NTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heterogeneity, and limited response to chemotherapy and targeted treatments. With clinical trials validating the efficacy of immune checkpoint inhibition across multiple lines of therapy and regardless of PD-L1 expression, nivolumab and pembrolizumab have become standards of care in the frontline setting as part of various combinations, and nivolumab monotherapy has been approved in patients with ESCC after previous chemotherapy. Recently, nivolumab plus ipilimumab became the first chemotherapy-free combination to gain approval for frontline use in patients with ESCC. In light of these treatment advances, do you know how to select among the different immunotherapy options and determine the best therapeutic approach for each of your patients with advanced gastroesophageal cancers? Hear from the experts on which biomarkers and other factors are/are not helpful in guiding clinical decisions, and how you can bring your patients the latest cutting-edge therapies backed by robust evidence. Also, learn from illustrative cases discussed by the faculty on how to apply the current data to practice. Upon completion of this activity, participants should be better able to: Identify patients with advanced gastroesophageal cancers (ie, gastric, GEJ, or esophageal cancer) who may benefit from recently approved immunotherapy options based on efficacy and safety evidence; Incorporate recently approved immunotherapy options into treatment plans for eligible patients with advanced gastroesophageal cancers across multiple lines of therapy; and Apply a team approach to optimize the use of immunotherapy, including strategies to promptly recognize and manage immune-related adverse event, in patients with advanced gastroesophageal cancers.

Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy Aug 09, 2022

Go online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in MM while addressing safety and efficacy evidence supporting the use of antibodies and cellular therapy. Upon completion of this activity, participants should be better able to: Summarize current evidence surrounding novel and emerging immunotherapeutics, including antibody-based and CAR-T options, for the treatment of multiple myeloma (MM); Integrate novel antibody and cellular therapies into team management plans for patients with newly diagnosed or relapsed MM; and Develop team-based management plans for addressing practical dosing/schedule, safety, care coordination, and patient counseling considerations associated with the use of antibody- and cell therapy-based options in the MM setting.

Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes Aug 05, 2022

Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and can have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity, based on a recent PeerView Live event held during the 2022 ASCO Annual Meeting, focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials will also be highlighted to continue to push for progress in better understanding the biology and expanding the treatment options for SCLC. Upon completion of this activity, participants should be better able to: Describe available and emerging therapeutics in SCLC, including immunotherapy, transcription inhibitors, myeloprotective therapies, and other treatment strategies, as well as emerging prospects in biomarker testing and subtyping that may help guide patient selection for different therapies; Apply the latest evidence and guidelines to incorporate new and emerging therapies into individualized treatment plans for eligible patients with SCLC in clinical practice or through clinical trial enrollment; Implement best practices for diagnosing and managing treatment-related toxicity in patients with SCLC; and Integrate multidisciplinary strategies and shared decision-making to ensure early diagnosis, individualized treatment, optimal management, and equitable care of patients with SCLC.

Hussein A. Tawbi, MD, PhD - New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease Aug 05, 2022

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Michael B. Atkins, MD - Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease Aug 05, 2022

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma; Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma; and Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Bruce Cree, MD, PhD, MAS - Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy Aug 05, 2022

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options.

Leonard H. Calabrese, DO - Recognition and Management of Axial Spondyloarthritis: Best Practices for Family Medicine Physicians Aug 05, 2022

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Joan T. Merrill, MD - New Directions in Kinase Inhibition in Systemic Lupus Erythematosus: Emerging Evidence From Copenhagen Aug 02, 2022

Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rationale and recent safety and efficacy data supporting a role for targeting TYK2 and BTK as potential therapeutic approaches in SLE; and Identify SLE patients who might benefit from emerging TYK2 and BTK inhibition strategies through clinical trial enrollment and recognizing potential implications for a future treatment paradigm.

Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care Aug 02, 2022

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know Aug 02, 2022

Go online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice. Upon completion of this activity, participants should be better able to: Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities; Describe advances in understanding of AD and AA pathophysiology that have led to the development of therapies with specific molecular targets; Assess new and emerging treatments for AD and AA in terms of their mechanisms of action, efficacy and safety profiles, nuances of administration and use, and other factors relevant to the benefit:risk profile; and Employ a holistic and team-based healthcare approach to the management of AD and AA that addresses both the physical and psychological comorbidities of disease.

Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management Jul 25, 2022

Go online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational activity recorded at the annual European hematology meeting in Vienna; throughout experts will explore the evidence-based use of BTK inhibitors in these different CLL settings. Tune in to see case-based guidance on modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and treatment settings in the context of EU and US practice. Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum Jul 22, 2022

Go online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has led to regulatory approval of the FGFR-targeted therapy erdafitinib for FGFR mutation-positive bladder tumors, and antibody–drug conjugates (ADCs). Additional advances have occurred in the localized disease setting such as novel bladder-sparing and perioperative approaches, as well as the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. Further, important combination approaches expand the therapeutic capacity available to patients with bladder cancer. This CME-certified activity will highlight strategies for optimal care for managing patients with bladder cancer in light of current evidence and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Identify patients with early-stage bladder cancer who could potentially benefit from the use of novel therapeutic strategies in the adjuvant and neoadjuvant settings (ie, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials; Integrate therapeutic strategies into management protocols for eligible patients with metastatic bladder cancer based on regulatory status and treatment roles of emerging therapeutic classes (ie, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates), including in the context of clinical trials; Develop appropriate strategies to mitigate and manage the unique adverse events associated with the variety of novel and emerging therapeutic classes for the management of bladder cancer.

Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice Jul 22, 2022

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on multi-faceted strategies for ALL management based on modern chemotherapy protocols, antibody-based approaches, cellular therapy, and TKIs; Cite evidence supporting the use of novel asparaginase compounds for ALL in the context of asparaginase toxicity/hypersensitivity, including in pediatric, AYA, and adult populations; and Apply new science to the team-based management of ALL, including when managing asparaginase hypersensitivity or toxicity, developing TKI-based protocols in Ph-positive disease, or when utilizing novel immunotherapy-based approaches in patient care.

Shmuel Shoham, MD - Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge Jul 21, 2022

Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (mAbs); Use strategies to overcome barriers to COVID-19 pre-exposure prophylaxis access for post-transplant patients; and Incorporate evidence-based recommendations and guidelines, mAb qualities and clinical profiles, and shared decision-making into strategies to customize mAb pre-exposure prophylaxis at point of care for post-transplant patients needing protection against COVID-19.

Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches Jul 21, 2022

Go online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on both disease stage and a variety of patient- and treatment-specific factors. Participate in this PeerView activity for an in-depth examination of how interventional radiologists can collaborate with the HCC management team to offer the best possible care for their patients! Upon completion of this activity, participants should be better able to: Evaluate the current and emerging therapeutic roles of and key clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immune checkpoint inhibitors, and combinations, for patients with intermediate- to advanced-stage HCC; Recommend clinical trials assessing innovative strategies, including tumor treating fields, Y-90 glass and resin microspheres, and combinations of locoregional and systemic therapies, to patients with HCC across the disease spectrum; and In collaboration with multidisciplinary colleagues, develop evidence-based management plans that incorporate novel therapeutic approaches, patient-specific factors such as underlying liver disease severity and biomarker status, and expert recommendations on timely transitions from locoregional to systemic therapy for patients with intermediate- and advanced-stage HCC.

Karl D. Lewis, MD - Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment Jul 21, 2022

Go online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event held at the 2022 American Society of Clinical Oncology Annual Meeting, our expert panel links the evidence supporting the use of immunotherapy in locally advanced and metastatic BCC with case-based teaching designed to mimic the collaborative aspects of real-world, multidisciplinary tumor boards, ultimately illustrating how checkpoint inhibitors can be integrated into the care of patients with BCC. Leverage the power of immunotherapy to improve clinical outcomes for your patients with advanced BCC! Upon completion of this activity, participants should be better able to: Cite the rationale, therapeutic role, and current evidence and guidelines supporting the use of immune checkpoint inhibitors (ICIs) in the management of advanced BCC; Integrate novel immunotherapy options into the management of appropriate patients with advanced BCC in consultation with the wider management team; and Employ proactive, team-based approaches to recognize, mitigate, and manage potential immune-related adverse events in patients receiving ICI therapy for advanced BCC.

Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes Jul 20, 2022

Go online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instruction on the use of next-generation triplets and quadruplets, maintenance strategies, and effective therapeutics in early relapse and treatment-refractory disease. Link cutting-edge evidence in MM to clinical decisions in your own practice—watch today! Upon completion of this activity, participants should be better able to: Cite current practice recommendations and clinical evidence surrounding the efficacy of novel proteasome inhibitor and IMiD options, novel antibody platforms, targeted agents, and cellular therapy across MM treatment settings; Select personalized, evidence-based regimens with novel components for the management of patients with newly diagnosed MM according to baseline comorbidities, functional status, and patient preferences, among other factors; Select evidence-based treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options into patient care; and Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome.

Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care Jul 20, 2022

Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.

Aditya Bardia, MD, MPH - Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease Jul 20, 2022

Go online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. CDK4 and 6 inhibitors and endocrine therapy have significantly improved outcomes in ER+/HER2- advanced breast cancer, and recently, the first CDK4 and 6 inhibitor was approved in combination with endocrine therapy in the adjuvant setting for patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20%. However, pretreated ER+/HER2- breast cancer remains a challenging area with limited treatment options. A number of novel ER-targeting therapies are being investigated in this setting and are showing great promise, including oral selective estrogen receptor degraders (SERDs), selective estrogen receptor modifiers (SERMs), SERD/SERM hybrids, selective estrogen receptor covalent antagonists (SERCAs), and proteolysis-targeting chimeras (PROTACs). This activity, based on a PeerView Live Seminars & Practicum educational web broadcast held in conjunction with the 2022 ASCO Annual Meeting, provides the multidisciplinary breast cancer care team with the latest research and evidence on current and emerging targeted and endocrine therapy options and the implications of these therapeutic advances for practice to ensure that more patients benefit and have improved outcomes. The patient perspective is highlighted as well, and advice for overcoming persistent disparities in breast cancer clinical care are shared. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanisms of action, and latest efficacy and safety data of approved and emerging treatment options for patients with ER+/HER2- breast cancer, including CDK4 and 6 inhibitors, SERDs, and SERCAs, and their evolving role in clinical practice; Develop personalized treatment plans for patients with ER+/HER2- breast cancer that take into account recent approvals and safety and efficacy findings from emerging therapies in the context of clinical practice or clinical trials, particularly in areas of high unmet need; and Integrate a team-based, collaborative, and coordinated approach to care, educate patients about new and emerging treatment options for which they may be eligible, and engage patients in shared decision-making to ensure that their unique needs and preferences are taken into account when making treatment decisions.

David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease Jul 20, 2022

Go online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic setting, ICIs are transitioning to earlier disease settings as part of perioperative neoadjuvant and/or adjuvant treatment strategies, which will likely result in reduced recurrence rates and more patients achieving cure. The number of available ICIs is expected to grow, as many new agents and combinations are in the final stages of testing, and novel checkpoints such as TIGIT and LAG-3 are showing promise in clinical trials. Consequently, predictive biomarker testing to refine treatment selection is paramount, and there is increasing focus on new surrogate endpoints to assess ICI efficacy, especially in early-stage settings where pathologic complete response, major pathologic response, and disease-free survival are helping to move the field forward faster. However, these exceptional advances are not without challenges. Not all patients with lung cancer benefit from ICIs, while others who could benefit do not have access to these therapies due to persistent disparities in biomarker testing, clinical care, and research. Determining the best immunotherapy option for each individual patient at the right time and in alignment with the particular needs and preferences of each patient is not simple and requires multidisciplinary collaboration and patient-centric shared decision-making. In addition, astute vigilance is required to mitigate potential immune-related adverse events (irAEs) to keep more patients benefiting from these therapies. This activity, based on a PeerView Live Seminars & Practicum educational event held at the 2022 ASCO Annual Meeting, provides guidance for navigating the evidence supporting the use of current and emerging immunotherapies throughout the NSCLC disease continuum and translating evidence to practice with the goal of improving patient outcomes in both advanced/metastatic and early-stage settings. Produced in partnership with LUNGevity Foundation, patient perspectives are also emphasized to improve team-based collaboration, patient engagement, shared decision-making, and health equity in clinical care and research. Upon completion of this activity, participants should be better able to: Describe the latest evidence supporting the use of current and emerging immune checkpoint inhibitors (ICIs) and combinations in locally advanced or metastatic and early-stage non–small cell lung cancer (NSCLC); Select the most appropriate ICI-based treatment for eligible patients with locally advanced/metastatic and early-stage NSCLC, considering the disease presentation, tumor characteristics, biomarker results, patient needs and preferences, current evidence and guidelines, multidisciplinary perspectives, and other relevant factors; Implement multidisciplinary and patient-centric approaches to ensure optimal and equitable use of immunotherapies in the care of all eligible patients with NSCLC; and Apply current guidelines and best practices for monitoring and management of immune-related adverse events (irAEs) in patients with NSCLC who are receiving or have received immunotherapy.

Robert I. Haddad, MD - The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care Jul 20, 2022

Go online to PeerView.com/HVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What is your sense of the “next steps” with practice-changing immunotherapy options for head and neck cancer (HNC)? Future advances will likely be driven by longer-term evidence in recurrent/metastatic disease, the use of immunotherapy in conjunction with surgery and radiotherapy, the potential of novel combinatorial regimens, and the emergence of newer PD-1–targeting therapies or innovative immune-based treatments. In this “Clinical Consult” activity, based on a live symposium held at the 2022 ASCO Annual Meeting and developed in collaboration with the Head and Neck Cancer Alliance (HNCA), a panel of experts will use case-based conversations to illustrate the present and future of immunotherapy across lines of care in HNC and provide guidance on the next wave of innovation emerging from clinical trials. Upon completion of this activity, participants should be better able to: Summarize updated clinical evidence and guideline recommendations regarding the use of checkpoint inhibitors and other immunotherapy options to treat the spectrum of head and neck cancer; Incorporate checkpoint inhibitors into treatment plans for resectable, locally advanced, and recurrent/metastatic head and neck cancer based on current evidence, guideline recommendations, patient preferences, and availability of clinical trials; and Develop a management plan for immune-related adverse events associated with checkpoint inhibitors used as monotherapy or in conjunction with other modalities.

Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care Jul 19, 2022

Go online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC as well. Designed to bridge the gap between theory and practice, this CME/MOC-certified educational activity, in partnership with KCCure, features expert guidance on how oncologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Upon completion of this activity, participants should be better able to: Assess the therapeutic roles of and key efficacy and safety evidence on novel and emerging systemic therapy strategies for patients with localized or advanced/metastatic RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, guideline recommendations, and patient-, disease- and treatment-specific factors; Integrate evidence-based strategies and best practices to recognize, mitigate and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC.

David Alain Wohl, MD - Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities Jul 19, 2022

Go online to PeerView.com/BED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women. Upon completion of this activity, participants should be better able to: Incorporate clinical data on pre-exposure prophylaxis (PrEP) for HIV into culturally competent educational and counseling strategies to improve the uptake of PrEP in vulnerable populations, including Black women, Black/Latinx same-gender loving men, and transgender men and women; Facilitate access to PrEP among Black women, Black/Latinx same-gender loving men, and transgender men and women; and Use PrEP as part of a broader strategy to reduce disparities in HIV incidence in Black women, Black/Latinx same-gender loving men, and transgender men and women.

Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care Jul 12, 2022

Go online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TKI therapy, and newer treatment modalities. Throughout, our experts will provide “Tumor Board”-style illustrations of how to address the needs of a given patient, implement appropriate therapeutic sequencing, and embrace the increasingly important role of multidisciplinary care across the disease continuum. Upon completion of this activity, participants should be better able to: Assess the efficacy/safety profiles and clinical roles of new and novel systemic therapy options and combinations for patients with advanced HCC, Implement a tailored approach to treatment selection and sequencing for patients with HCC, taking into consideration recent clinical evidence, expert and guideline recommendations, and patient-, disease-, and treatment-specific factors, Consider ongoing clinical trials assessing innovative strategies, including tumor treating fields, combinations of locoregional therapies with systemic therapies and adjuvant immunotherapies, as treatment options for patients with HCC across different disease and treatment settings, Integrate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety, tolerability, and patient QOL, for the optimal assessment and management of patients with HCC across the disease continuum.

David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies Jul 11, 2022

Go online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest clinical data on emerging treatments that target the underlying pathology of AD.

Lisa H. Lancaster, MD - The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management Jul 11, 2022

Go online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulmonary function tests, and high-resolution computed tomography. Until recently, therapy for SSc-ILD has been limited to supportive care and immunosuppressants. Fortunately, antifibrotic agents approved for idiopathic pulmonary fibrosis (IPF) have either received approval, or are in development, for SSc-ILD. Because SSc-ILD affects multiple organ systems and has many comorbidities, interprofessional management is essential from diagnosis throughout the disease course. In this expert-led activity, you will be able to self-assess your baseline levels of understanding, skill, and confidence, resulting in a tailored educational experience focused on the areas where you need it most. Upon completion of this activity, participants should be better able to: Diagnose SSc-ILD promptly and conduct comprehensive interprofessional assessments using clinical signs and symptoms, and guideline-directed testing, Use recent trial data and guidelines to guide the use of existing and emerging agents to treat SSc-ILD in an interprofessional care team, Leverage the interprofessional care team to manage the risk factors and comorbidities of SSc-ILD.

Reynold A. Panettieri, Jr., MD - The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins Jul 11, 2022

Go online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, and their use is not restricted by phenotype/endotype or biomarkers. In this activity, based on a recent live web broadcast, our experts will review the latest clinical data, including key insights from medical congresses up to and including ATS 2022, with respect to novel and emerging therapies and other factors that impact the selection of treatment for patients with severe asthma who continue to have uncontrolled disease despite treatment. You will achieve greater insight into the most up-to-date evidence on the pathophysiology of severe asthma, particularly with regard to the role of epithelial alarmins in the development of severe asthma. Upon completion of this activity, participants should be better able to: Discuss the rationale for the use of therapeutic options that target epithelial alarmins, including TSLP, IL-33, and IL-25, for the treatment of severe asthma, Employ the latest pathophysiologic insights into the role of epithelial alarmins to the treatment of patients with severe asthma, Develop treatment plans for patients with severe asthma, particularly those whose disease remains uncontrolled despite treatment, based on the latest clinical evidence with regard to novel and emerging therapies.

Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting Jul 08, 2022

Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.

Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity Jul 08, 2022

Go online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number of limitations associated with the current immunotherapies, patient outcomes are still suboptimal, and new options are needed to maximize the potential of cancer immunotherapy as the fourth treatment pillar in oncology. New rational combinations leveraging synergies between old and new checkpoints have emerged, with inhibitory targeting of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine–based inhibitory motif domains (TIGIT) along with the PD-L1/PD-1 pathway as one potential strategy under extensive investigation across different cancers. To realize the potential of anti-TIGIT checkpoint inhibition, build upon previous advances in cancer immunotherapy, expand into more tumor types and earlier stages of disease, and provide new treatment options in areas of high unmet need to more patients with cancer, it is essential for those involved in the care of patients with solid tumors to become familiar with this novel therapeutic approach and develop competence related to its clinical integration, enabling rapid translation from discovery to the clinic. This educational activity features an expert discussion of the rationale and mechanism of action of agents targeting TIGIT, enhanced with engaging three-dimensional explanations, and provides practical guidance to identify patients most likely to be the best candidates for novel ICI-based treatment approaches. Upon completion of this activity, participants should be better able to: Describe the rationale for use, mechanisms of action, and preclinical and clinical evidence supporting the use of novel ICIs, such as antibodies targeting TIGIT, and synergistic ICI-based combinations showing promise in overcoming the limitations of current immunotherapies and expanding the benefits to more patients with solid tumors, Identify patients who are most likely to be the best candidates for novel ICI-based treatment approaches, including dual-targeted inhibition of TIGIT and anti–PD-L1/PD-1, based on clinical evidence, biomarker status, comorbidities, patient preferences for chemotherapy-free treatment options, and other relevant factors, working collaboratively as a healthcare team.

John N. Allan, MD - Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy Jul 06, 2022

Go online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern CLL management, the practice-changing evidence that validated targeted therapy platforms, and the science that is redefining the roles of hematopoietic stem cell transplantation and cellular therapy, including in challenging pretreated CLL settings. Upon completion of this activity, participants should be better able to: Cite current guidelines and evidence on the treatment roles of hematopoietic stem cell transplantation; BTK, PI3K, and BCL-2 inhibitors; monoclonal antibodies; and CAR-T cell therapy in the CLL setting, Discuss evidence surrounding the efficacy and safety of novel therapeutics across the spectrum of CLL, including in higher-risk disease settings or in patients relapsing after multiple prior treatments, Recommend regimens with novel components for patients presenting with treatment-naïve, high-risk, or relapsed/refractory CLL.

James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT Jul 06, 2022

Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.

Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma Jul 04, 2022

Go online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’s lymphoma. These advances, driven by the use of CD19-directed cell therapy constructs, have spurred numerous ongoing investigations of existing CAR-T therapies in additional CD19-expressing leukemias and lymphomas (eg, chronic lymphocytic leukemia, small lymphocytic lymphoma). Unfortunately, many hematology-oncology and bone marrow transplant BMT professionals have not adapted their practice to reflect the reality of cellular therapy in 2022—from the availability of new constructs with recent regulatory approvals to the management of practical considerations, such as referrals to specialized centers, appropriate follow-up, and toxicity management. This video-based activity from PeerView will deliver expert guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in a variety of settings. The panelists will draw on personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, including enrollment of eligible patients in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Identify patients with leukemia or lymphoma who are eligible for and may benefit from CAR-T therapy based on current indications, clinical evidence, guideline recommendations, and clinical trial opportunities, Implement best practices for integrating CAR-T therapy into the care of patients with leukemia or lymphoma, including referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care, Utilize appropriate AE management strategies for patients with relapsed/refractory leukemia or lymphoma who are experiencing toxicity while receiving CAR-T therapy, including cytokine release syndrome or neurotoxicity.

Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols Jul 04, 2022

Go online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell co-stimulation blocking agent abatacept, as well as additional novel strategies being tested in a range of acute and chronic GVHD settings. In this activity from the 2022 Tandem meetings, our expert panelists distill the current evidence on novel therapeutics in the prevention and treatment of GVHD; throughout, they illustrate how and when to integrate novel therapeutics into care, provide guidance on how to prepare for emerging strategies, and offer practical takeaways on the changing nature of GVHD management. Upon completion of this activity, participants should be better able to: Discuss current evidence supporting the use of novel therapeutics as prophylactic or treatment options for acute or chronic graft-versus-host disease (GVHD) in the post-transplant setting, including JAK and BTK inhibitors, T-cell blocking agents, α1-antitrypsin, and ROCK inhibitors, among others, Develop management plans informed by evidence and practice guidelines that incorporate novel therapeutics into the management of acute GVHD, Integrate novel and emerging therapies into management plans for the management of chronic GVHD, including novel combinatorial strategies and/or options for second-line management.

Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors Jul 04, 2022

Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a recent live web broadcast, will provide essential updates and practical guidance regarding biomarker testing and individualized treatment of patients with HER2-altered cancers, and novel targets such as HER3 and TROP2 will be explored as well. Upon completion of this activity, participants should be better able to: Identify patients with solid tumors with HER2, HER3, and TROP2 alterations using established and emerging testing approaches, Incorporate therapies directed at HER2, HER3, and TROP2 into the treatment of patients with tumors with targetable alterations based on the characteristics, mechanisms of action, and latest clinical evidence on approved and emerging therapies, Develop individualized management plans that leverage predictive testing, the most recent clinical findings, and multidisciplinary team-based care in accordance with the latest treatment guidelines and recommendations for patients with solid tumors with HER2, HER3, and TROP2 alterations, either in the context of clinical practice or clinical trials.

Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum Jun 24, 2022

Go online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several questions about incorporating these new agents, which include bladder-sparing options, immune checkpoint inhibitors, targeted therapies (FGFR inhibitors), and antibody-drug conjugates, into clinical practice. For instance, will the presence of immune-related adverse events (irAEs) in some patients linger after the end of therapy and limit the possible subsequent use of ADCs or FGFR inhibitors? To answer these questions, experts in bladder cancer highlight strategies for optimal care of patients in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this activity, participants should be better able to: Summarize the current roles, mechanisms of action, and key evidence pertaining to novel systemic therapies for patients with localized or metastatic bladder cancer, such as immunotherapies, small molecule targeted therapies, and antibody-drug conjugates, among others, Plan personalized treatment algorithms for patients with localized or metastatic urothelial cancer that incorporate novel and emerging therapies, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Implement evidence-based strategies and expert recommendations to prevent, mitigate and/or manage treatment-related adverse events that may occur among patients receiving novel systemic therapies for bladder cancer.

Kimberly A. Brown, MD, FAASLD, FAST, AGAF - Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes Jun 16, 2022

Go online to PeerView.com/XNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Summarize the prevalence, pathophysiology, and consequences of decompensated cirrhosis and portal hypertension (eg, refractory ascites and EVH), Evaluate the latest evidence for current and emerging approaches to managing patients with refractory ascites and EVH.

Nasser Altorki, MD - How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC Jun 14, 2022

Go online to PeerView.com/GWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. Remarkable data have emerged from several immunotherapy trials in perioperative settings and FDA has granted new regulatory approvals for both neoadjuvant and adjuvant immunotherapy regimens, effectively establishing new standards of care in early-stage NSCLC. Still, many questions remain on how to transition these exciting advances to practice and improved patient outcomes in real-world setting. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView educational activity based on a recent live event. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC. Watch intriguing debates framed by real cases and discussion points selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this activity, participants should be better able to: Discuss the mechanistic and biologic rationale for using immunotherapy as a component of multimodal therapy in early-stage lung cancer and key clinical trials evaluating immunotherapies in these settings, Summarize the latest findings on surrogate endpoints, such as pathologic response criteria, to assess treatment response and evaluate the prognosis of patients with resectable lung cancer who are receiving immunotherapy, Identify patients with resectable NSCLC who are eligible for perioperative immunotherapy, considering the benefits/limitations and surgical implications based on an understanding of the latest evidence and persisting misperceptions, Integrate best practices for multidisciplinary communication and collaboration to enhance appropriate incorporation of immunotherapies into multimodal treatment plans for eligible patients with stage I-III resectable NSCLC.

Ashish M. Kamat, MD, MBBS - Multidisciplinary Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer: Clinical Consults and Cases From the Community Jun 14, 2022

Go online to PeerView.com/VSV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent transformation of the bladder cancer therapeutic landscape includes the PD-1/PD-L1–targeting immune checkpoint inhibitors for advanced/metastatic bladder cancer, erdafitinib for FGFR mutation–positive bladder tumors, and the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan in the post–immune checkpoint inhibitor setting. Utilizing these agents in localized disease settings has led to the emergence of novel bladder-sparing and perioperative approaches, including the first regulatory approval of adjuvant immunotherapy in high-risk muscle-invasive bladder cancer. In light of these developments, the challenge for urology professionals is how to best blend the diverse clinical evidence for these agents with the realities of real-world cancer care. This PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, will guide learners through the modern realities of managing bladder cancer across disease and treatment settings. Realistic and diverse patient cases will be directly linked to mini lectures in which bladder cancer experts will interpret clinically meaningful evidence on current and emerging therapeutic options and offer guidance on the clinical integration of these therapies into personalized management plans. Prepare to apply practical lessons stemming from the evidence related to novel systemic therapies, their applications in metastatic bladder cancer, and their emerging uses in locally advanced, resectable, or non–muscle-invasive disease. Upon completion of this activity, participants should be better able to: Implement guideline-concordant genetic and molecular assessment as part of the routine management of patients with bladder cancer while considering the current therapeutic roles and mechanistic rationales of novel systemic therapies across bladder cancer settings and patient populations (eg, localized or metastatic), Select patients with early-stage bladder cancer who are eligible for recently approved and emerging therapeutic strategies in the adjuvant and neoadjuvant settings (eg, NMIBC and MIBC) based on recent approvals, clinical evidence, and ongoing trials, Develop personalized, evidence-based treatment plans for patients with advanced/metastatic bladder cancer that incorporate new agents and combinations (including in the context of a clinical trial), expert recommendations, genetic/molecular status, and principles of shared decision-making and multidisciplinary collaboration, Employ strategies to facilitate early recognition, reporting, and appropriate management of toxicities associated with newer systemic therapy options for bladder cancer in collaboration with the broader care team, patients, and caregivers.

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Fine-Tuning the JAK/STAT Pathway in Psoriasis: Safely Targeting the Underlying Mechanisms of Disease With TYK2 Inhibition Jun 14, 2022

Go online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlation to emerging therapies for the treatment of moderate to severe psoriasis, Summarize recent efficacy and safety data for current and emerging therapies for the treatment of moderate to severe psoriasis, Recommend treatment for patients with moderate to severe psoriasis according to the latest guidelines and clinical evidence, particularly as emerging therapies become available.

Amy Goodrich, CRNP - Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients Jun 14, 2022

Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView’s expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.

Prof. Solange Peters, MD, PhD - Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers May 30, 2022

Go online to PeerView.com/HCZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immune checkpoint inhibitors (ICIs) changed the standards of care in the treatment of advanced solid tumors and are now rapidly transitioning into early-stage, curative-intent settings. New regulatory approvals have been recently granted for several ICIs as neoadjuvant and adjuvant treatments for different cancers, and many more studies are under way. This shift is truly needed, as outcomes had plateaued in resectable cancers. To overcome the challenges of conducting ICI clinical trials in early-stage cancers and facilitate more rapid progress, the need for new surrogate measures of efficacy has been widely recognized. Pathologic response assessment of resection specimens after neoadjuvant therapy has emerged as one such new tool, and there is accumulating evidence supporting its relevance and advantages. However, some unanswered questions remain, and there has been a lack of clarity on how to define, score, and interpret pathologic response, although efforts are ongoing to refine and standardize these measurements. This PeerView educational activity, based on a recent live symposium, provides cutting-edge updates on novel surrogate measures of efficacy of immunotherapies in resectable cancers and practical guidance for using these new tools in clinical trials and practice, with an emphasis on pathologic response assessment after neoadjuvant immunotherapy. Upon completion of this activity, participants should be better able to: Discuss the definition of pathologic response and the biologic and historic rationale, clinical evidence, benefits, and limitations of its use as an early surrogate endpoint of response to neoadjuvant immunotherapy in various solid tumors, Implement different scoring systems available for assessing pathologic response, accounting for practical considerations and complexities, including their accuracy, standardization, reproducibility, and other nuances, to guide treatment decisions in the context of a clinical trial or clinical practice across tumor types, Integrate appropriate strategies for interdisciplinary collaboration and coordination among all members of the healthcare team to effectively leverage pathologic response assessment after neoadjuvant immunotherapy as a surrogate marker in clinical trials and to direct clinical decision-making in practice.

Linda Ahn, MSN, ANP-BC, AOCNP - Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies May 30, 2022

Go online to PeerView.com/PFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) represent a unique class of anticancer therapies showing promise in a broad range of solid tumors. ADCs targeting HER2 and TROP2 have already garnered regulatory approvals in some cancer types, with more trials under way, and therapies against other new targets, including HER3, are being explored as well. This PeerView educational activity based on a recent live symposium focuses on the implications of recent advances with ADCs and provides guidance for oncology nurses and other key members of the cancer care team on their clinical integration in a new era of targeted therapy across solid tumors. Upon completion of this activity, participants should be better able to: Describe the properties, mechanisms of action, latest clinical evidence, and current and potential clinical roles of validated and emerging HER2-, HER3-, and TROP2-targeted antibody-drug conjugates (ADCs) in different solid tumors, Employ evidence-based and team-based strategies to mitigate and manage treatment-related adverse events in patients with cancer receiving HER2-, HER3-, and TROP2-targeted ADC therapy, Provide appropriate education, guidance, and counseling to patients with solid tumors on the role, optimal use, and therapeutic and safety considerations of approved and emerging HER2-, HER3-, and TROP2-targeted ADCs within the context of clinical practice or through clinical participation.

Liana G. Apostolova, MS, MD, FAAN - Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease? May 27, 2022

Go online to PeerView.com/JYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disorder affecting 10% of people over age 65 and increasing in global prevalence. Recent advances in disease-modifying therapies have opened the door to the possibility of treatment approaches that can slow or prevent disease progression and improve patient outcomes. Now, with several anti–amyloid beta (Aβ) monoclonal antibodies in late-stage development, there is hope for families, clinicians, and researchers. The greatest likelihood of treatment success lies in timely diagnosis and early intervention. In this activity, based on a live symposium held at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases in Barcelona, Spain, an international panel of experts will discuss the importance of early recognition and diagnosis of AD and present the latest evidence on validated and emerging biomarkers that can aid in the early diagnosis of AD. They will also explore the mechanisms of action, efficacy, and safety data for promising disease-modifying therapies in development for the treatment of AD. Using patient case examples to frame the discussion, the expert faculty panel will provide practical guidance on how clinicians can effectively and safely integrate new diagnostic tools and disease-modifying therapies into clinical practice. Upon completion of this activity, participants should be better able to: Describe the rationale for identifying patients at risk for Alzheimer’s disease (AD) early in the disease course, Utilize validated neuroimaging techniques and molecular biomarkers to make early and accurate neuropathological diagnoses of AD, Select appropriate AD patients who may benefit from novel disease-modifying therapies based on an understanding of their respective mechanisms of action, efficacy, and safety profiles.

Brett King, MD, PhD - Addressing Healthcare Disparities and Optimizing Patient Outcomes in Atopic Dermatitis and Alopecia Areata: Expert Insight on How to Improve Access and Quality of Care May 26, 2022

Go online to PeerView.com/TJZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss strategies to optimize patient outcomes in atopic dermatitis and alopecia areata. Upon completion of this activity, participants should be better able to: Appropriately diagnose atopic dermatitis (AD) and alopecia areata (AA) and assess severity to determine the best treatment strategy in individual patients, recognizing wide variation in clinical presentation among different ethnicities, Describe current and emerging treatments for AD and AA in the context of mechanism of action, efficacy and safety profile, dosage and administration, and other factors relevant to clinical use, Utilize available resources to identify and overcome racial and ethnic health disparities in the management of AD and AA and ultimately improve health outcomes in under-represented populations.

Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes May 26, 2022

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Sarina Elmariah, MD, PhD, MPH - Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options May 25, 2022

Go online to PeerView.com/DTN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely pruritic, hyperkeratotic nodules symmetrically distributed on the trunk and extremities. PN is defined by intense pruritus lasting ≥6 weeks, history of repeated scratching, and subsequent development of pruritic, elevated, firm, and nodular skin lesions, in a vicious itch–scratch cycle. The intense itch associated with PN leads to sleep disturbances and reduced social participation and work productivity, resulting in a drastically reduced quality of life and psychosocial disturbances. Unfortunately, these issues experienced among patients with PN are further compounded by the lack of effective treatment options. In this activity, based on a recent live educational symposium, a panel of experts addresses real-world questions and dilemmas faced by providers and the PN patients for whom they care. By providing practical guidance on how to effectively integrate the latest evidence and expert recommendations into real-world clinical scenarios, this activity provides participating clinicians with the necessary tools to effectively navigate the rapidly changing landscape for PN. Additionally, patient videos are utilized throughout to convey key information regarding the burden of PN and optimal management strategies. Upon completion of this activity, participants should be better able to: Discuss the impact on quality of life and economic implications of prurigo nodularis (PN), Describe the pathophysiology of PN as it relates to clinically relevant disease mechanisms and novel therapeutic targets, Evaluate emerging treatment options for PN in the context of mechanism of action, efficacy, and safety, Treat PN in accordance with current evidence and expert recommendations, recognizing that an effective treatment approach should be based on clinical judgment and tailored to the individual needs of the patient.

Anthony Martinez, MD, AAHIVS, FAASLD - Sharing the Cure: Best Practices for Primary Care Providers to Improve HCV Prevention, Care, and Treatment May 25, 2022

Go online to PeerView.com/ABJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses best practices for improving screening and treatment of HCV infection in the primary care setting. Upon completion of this activity, participants should be better able to: Apply evidence-based guidelines for screening and evaluating patients for HCV infection in the primary care setting, Implement effective follow-up and counseling for patients upon a confirmed diagnosis of HCV infection, Differentiate currently available medications to treat HCV infection based on safety, efficacy, and recommended usage, Integrate direct-acting antiviral agents into individualized treatment plans for patients with HCV infection in accordance with current guidelines and expert recommendations, Employ a multidisciplinary team-based approach for treating HCV infection, distinguishing among patients who can be managed in the primary care setting versus those requiring linkage to specialist care.

Kurt A. Schalper, MD, PhD - Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do May 25, 2022

Go online to PeerView.com/KCV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapy in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 monoclonal antibodies is swiftly expanding from metastatic to early-stage, curative-intent settings in an increasing number of solid tumors. Furthermore, it’s on the cusp of further explosive growth as other novel agents, including inhibitors of new checkpoints such as LAG-3 and TIGIT, are starting to emerge. Pathologists and oncologists play a crucial role in identifying patients who would benefit the most from the broadening arsenal of immunotherapies and assessing response to these therapies. While there are substantial gaps in biomarker testing, pathologic response assessment, and the use of immunotherapies in current practice, things will only become more complicated. This PeerView Live educational activity, based on a recent symposium, will help you refine your current best practices and prepare you for what’s to come next. Top experts convene to provide a visual exploration of the most important recent advances in immuno-oncology, conduct demonstrations of representative and challenging real-world cases, and walk you through practical exercises on operationalizing biomarker testing and pathologic response assessment in different laboratory and clinical settings. Upon completion of this activity, participants should be better able to: Discuss the rationale, recommendations, and practical considerations related to cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings, Use appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings, Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making regarding cancer immunotherapies across different tumors and treatment settings.

Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC May 23, 2022

Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.

Joe R. Anderson, PharmD, PhC - Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care May 23, 2022

Go online to PeerView.com/KMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes. Upon completion of this activity, participants should be better able to: Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment, Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate, Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke, Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy.

Joseph Diaz, MD- Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life May 23, 2022

Go online to PeerView.com/HWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of 2 to 5 years; although active CSU significantly impairs quality of life. Second-generation H1 antihistamines (sgAHs) in standard dose are effective in less than 50% of CSU patients. Increasing the dose of sgAHs improves treatment responses; however, every third to fourth patient will still remain symptomatic. Omalizumab, an anti-IgE monoclonal antibody, may also be used for effective treatment, as well as cyclosporine. The current guideline-recommended treatment algorithm, though useful, is not perfect. The treatment of patients with CSU should be individualized and take into account the likelihood of patients to respond to therapy, based on predictors of response. By choosing treatment options tailored to a patient’s clinical or biochemical characteristics, treatments that are less likely to be effective may be avoided. In this activity, based on a live symposium held at the AAD Annual Meeting in Boston, a panel of experts will discuss the selection of adequate and relevant tests for the diagnostic workup in CSU and novel treatment options for CSU in the context of mechanism of action, efficacy, and safety. In addition, they will take a closer look at treating CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient. Upon completion of this activity, participants should be better able to: Select adequate and relevant tests for the diagnostic workup in chronic spontaneous urticaria (CSU) by obtaining a thorough medical history, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Describe novel treatment options for CSU in the context of mechanism of action, efficacy, and safety, Treat CSU in accordance with current evidence and expert recommendations, recognizing that as the era of personalized treatment emerges, the best use for newer agents will be achieved with a deeper understanding of both the phenotype and endotype of each CSU patient.

Erika Hamilton, MD - How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps May 23, 2022

Go online to PeerView.com/WFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the last two decades, there have been very limited advancements in the treatment of HR+, HER2- early breast cancer, and a particularly marked unmet need has existed for patients at the highest risk of recurrence. Fortunately, there is new hope of improved outcomes for these patients following the recent FDA approval of the first CDK4 and 6 inhibitor for the adjuvant treatment of patients with HR+, HER2-, node+ early breast cancer at high risk of recurrence and a Ki-67 score ≥20%. Shortly thereafter, guideline updates were released that recommended adjuvant CDK4 and 6 inhibitor therapy combined with endocrine therapy to a broader population of patients at high risk of recurrence. The emergence of this new therapeutic option along with varied indications and recommendations has resulted in much uncertainty about which patients should and should not receive adjuvant CDK4 and 6 inhibitor therapy, and how to best integrate it into clinical practice to meaningfully impact outcomes in this challenging patient population. In this educational activity, two leading experts deliver pertinent updates and use patient cases to provide practical guidance for the multidisciplinary team on how to navigate the changing standards of care in HR+, HER2- early breast cancer. Learn how to identify the most appropriate patients who can achieve the highest absolute benefit from adjuvant CDK4 and 6 inhibition, and ensure that those with a particularly poor prognosis are not excluded from this therapy. Additionally, receive guidance on how to recognize and manage treatment-related adverse events so that patients continue to adhere to CDK4 and 6 inhibitor therapy and derive maximum benefit from it in the adjuvant setting. Upon completion of this activity, participants should be better able to: Discuss the evidence, tools, and strategies for risk assessment and stratification in HR+, HER2- early breast cancer to guide treatment selection, including identification of candidates for adjuvant CDK4 and 6 inhibitor therapy, Integrate the latest safety and efficacy data on adjuvant CDK4 and 6 inhibitor therapy into clinical decisions for patients with high-risk, HR+, HER2- early breast cancer, Incorporate modern risk assessment approaches, supporting evidence, regulatory and guideline recommendations, adverse event prevention/management strategies, and shared decision-making into the establishment of individualized treatment plans for patients with HR+, HER2- early breast cancer to improve outcomes in this patient population, including reducing the risk of recurrence in patients with poor prognosis.

Professor Andrew Menzies-Gow - Tackling the Challenge of Treating Severe Asthma: Taking Aim at the Airway Epithelium May 23, 2022

Go online to PeerView.com/MRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in asthma discusses the role of the airway epithelium in severe asthma treatment. Upon completion of this activity, participants should be better able to: Apply the latest pathophysiologic insights into the role of epithelial alarmins in the development of inflammation and structural changes in the airways to the treatment of patients with severe asthma, Discuss the clinical implications of biologic treatment that is not limited by phenotype or biomarker for patients with severe asthma whose disease remains uncontrolled despite standard treatment, Identify patients with severe asthma who may be eligible for treatment with novel biologic therapies that target epithelial alarmins.

Henry M. Kuerer, MD, PhD, FACS - Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer May 19, 2022

Go online to PeerView.com/VHX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Poly (ADP-ribose) polymerase (PARP) inhibition is now the standard of care for metastatic breast cancer harboring a germline BRCA1 or BRCA2 mutation, and studies continue to investigate PARP inhibitors as monotherapies or in rational combinations. Most recently, exciting results have revealed a potential role for PARP inhibitor therapy in earlier disease settings where there is a possibility for cure, heralding a new era of targeted therapy for patients with breast cancer. In order to maximize the benefits of these advances, it is crucial for the multidisciplinary breast cancer care team to keep current with the latest data and expert recommendations to effectively integrate PARP inhibitor therapy into clinical practice, as well as genetic counseling and biomarker testing to refine individualized therapy selection. This PeerView educational activity, based on a recent live event, provides essential information on the biologic rationale for targeting PARP, the latest data and their practical implications, guidance for optimizing biomarker testing, and strategies for improving multidisciplinary collaboration so that patients with breast cancer can make the most of the recent advances with PARP inhibitor therapy. Upon completion of this activity, participants should be better able to: Describe DNA damage response (DDR) pathways and the rationale for therapeutic targeting of DDR with PARP inhibitors in early and advanced breast cancer, Identify patients with breast cancer who might benefit from treatment with PARP inhibitors based on current evidence and best practices for biomarker testing, Integrate PARP inhibitors into evidence-based, individualized treatment plans for eligible patients with early and advanced breast cancer considering latest efficacy and safety data in the context of clinical practice or clinical trials, Manage treatment-related adverse events in patients receiving PARP inhibitors for breast cancer treatment.

Jacob Sands, MD - Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice May 19, 2022

Go online to PeerView.com/PYK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and many ongoing trials and innovative approaches are anticipated to further escalate progress in this challenging subtype of lung cancer. These developments have also provided new hope to patients with SCLC, which makes it important to ensure that all patients have access to these therapies and have the opportunity to benefit from them, as well as being encouraged to consider clinical trial participation. This activity focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases to illustrate how to integrate the new therapeutic options into clinical practice. Investigational therapies and key ongoing trials are also highlighted to continue to better understand the biology of SCLC and the expanding the treatment options. Upon completion of this activity, participants should be better able to: Apply the latest efficacy and safety data on novel systemic therapeutic options for SCLC taking into consideration their characteristics, mechanism of action, most recent treatment guidelines, clinical activity, and adverse event profile, Integrate the latest therapies into preferred prescribing protocols and formularies accounting for prior treatment history, duration of chemotherapy-free interval, disease presentation, sites of recurrence, comorbidities, and other treatment- and patient-specific features for patients with SCLC, particularly in the second-line setting, Implement individualized treatment plans for patients with SCLC that leverage team-based approaches to shared decision-making, patient education and counseling, and adverse event management and monitoring.

Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology May 19, 2022

Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

Nina Shah, MD - Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing May 19, 2022

Go online to PeerView.com/MZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent advances in multiple myeloma (MM) management present a rare opportunity for clinicians, who now have a variety of options to choose from when optimizing patient care. From this starting point, hematology-oncology professionals (including those practicing in community settings) and oncology nurses can leverage the potency of novel therapeutics, including platforms based on CD38 antibodies and novel BCMA-directed therapies, across the spectrum of disease. In this unique program, an interprofessional panel, featuring an academic and community hematologist-oncologist and a nurse professional, will use a series of case-based conversations to demonstrate exactly how to support the MM patient's therapeutic odyssey with innovative therapeutics—and deliver high-quality, collaborative patient care. Upon completion of this activity, participants should be better able to: Apply current evidence and guidelines for the personalized selection of upfront therapy with novel triplets, quadruplets, and maintenance options for patients with newly diagnosed multiple myeloma (MM), including those with transplant-eligible or -ineligible disease, Plan for appropriate sequential treatment options in patients with MM relapsing after 1-3 prior lines of therapy or for those with more heavily pretreated disease, Provide team-based counseling for patients with MM about relevant prognostic factors, high-risk features, sequential management plans, treatment administration and delivery, and drug safety considerations, Develop team-based management strategies for adverse events associated with the use of modern MM treatment regimens, including those containing novel antibody, proteasome inhibitor, and targeted components.

Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer May 16, 2022

Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Implement appropriate strategies for biomarker testing and integration of novel immunotherapy options into personalized management plans for patients with recurrent or advanced endometrial cancer, in alignment with the latest clinical evidence, approved indications, and guideline recommendations, Employ proactive, collaborative strategies to mitigate and manage immune-related adverse events in patients receiving immune-based therapies for recurrent and advanced endometrial cancers, Apply multidisciplinary, interprofessional, and patient-centric practices and tools that can realistically serve to mitigate disparities in healthcare service delivery and cancer-related outcomes for patients with endometrial cancer.

Elizabeth Eaman, MD - Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations May 16, 2022

Go online to PeerView.com/YDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It is estimated that there are about 1 million adults in the United States who identify as transgender, and this number may be higher depending on the surveys used, the questions asked, and the diversity of subcultures within the transgender community. Although being transgender is not in itself a medical condition, transgender individuals have unique healthcare needs and face barriers to screening and preventive care, particularly with cancer screening. Consequently, these patients may receive lower quality medical care than the general population as a result of stigma, discrimination, and providers’ lack of knowledge about gender identity. Additionally, transgender patients may only seek medical care as part of gender affirmation and avoid primary care health concerns, including screenings. This activity, based on a recent live web broadcast, will focus on improving cancer prevention and early detection strategies in the transgender community, as well as enhancing the knowledge and competence of interdisciplinary and interprofessional healthcare providers to appropriately deliver culturally competent care. An interdisciplinary panel of recognized clinical experts will offer learners tactics to improve disease prevention in transgender patients, while the patient advocate will provide the transgender patient perspective throughout the program. Upon completion of this activity, participants should be better able to: Recognize that transgender individuals may be disproportionately at increased risk for contracting HIV and those living with HIV have an increased risk of several types of cancers, Properly screen for and identify cancer in a timely manner to prevent advanced disease in the transgender community, Develop individualized preventive care plans for transgender patients consistent with the patient's current anatomical structure, Provide affirming, inclusive, and culturally humble care to transgender patients to facilitate adherence to clinical recommendations and engagement in care.

Anjay Rastogi, MD - Making the Case for Preventing and Managing Nephropathy in Patients With Fabry Disease May 13, 2022

Go online to PeerView.com/GPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses the prevention and management of nephropathy in patients with Fabry disease. Upon completion of this activity, participants should be better able to: Employ evidence-based tools and strategies to identify patients with FD and prevent nephropathy in a timely manner, Assess safety and efficacy of current and emerging treatments for patients with FD, Apply individualized treatment for patients with FD with an emphasis on preventing nephropathy.

Michael E. Wechsler, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients With Uncontrolled, Moderate to Severe Asthma: Comparing Approaches With Experts Around the World May 13, 2022

Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to evidence-based practice guidelines, Identify patients that would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis, Select treatment for pediatric and adult patients with uncontrolled, moderate to severe asthma according to current evidence and guidelines, Use techniques to educate and communicate more effectively with patients and caregivers to better engage them in their care, and improve adherence to individualized treatment plans.

Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity May 06, 2022

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting May 05, 2022

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on a comprehensive understanding of how, in whom, and when they should be used, Adapt primary care workflows to improve the follow-up of abnormal cancer screening results and subspecialty referrals for further diagnostic assessment, Implement processes to improve patient uptake of established and novel cancer screening services, including through patient education and shared decision-making.

Milind Desai, MD, MBA - New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy: Analysis From Washington, DC May 05, 2022

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Tanios Bekaii-Saab, MD - Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer May 04, 2022

Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in mCRC, Integrate interprofessional team-based approaches to improve patient adherence and education on prevention and management strategies for adverse events associated with third-line TKI-based therapies for mCRC.

Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum May 04, 2022

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment and in combination with other modalities, into individualized treatment plans. Hear the latest on diagnostic testing for relevant biomarkers, recommendations for collaborative AE management, opportunities for clinical trial enrollment, and strategies for patient/caregiver education to help patients become well-informed participants in their own care. Upon completion of this activity, participants should be better able to: Integrate germline and tumor genetic testing into the workup of patients with advanced ovarian cancer to inform therapeutic decision-making, Incorporate PARP inhibitors and other novel treatments into the management of patients with advanced ovarian cancer, including within the context of clinical trials, considering the current clinical evidence, guideline recommendations, and patient needs and preferences, Develop practical strategies to recognize and manage AEs related to PARP inhibitor use and other novel approaches in patients with ovarian cancer, particularly in the long-term maintenance setting.

Anthony R. Mato, MD, MSCE - Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency Apr 29, 2022

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in patients with cancer, Develop risk-based prophylactic protocols for TLS that include adequate hydration, patient assessment, and antihyperuricemic medications based on current efficacy evidence, Integrate individualized antihyperuricemic therapy into TLS management plans for patients with cancer, including administration of appropriate treatment, appropriate dosing of antihyperuricemics, and patient counseling measures.

Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies Apr 29, 2022

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to translate the science to practice and improve patient outcomes. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting of HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Review current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Geoffrey Barnes, MD, MSc - Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention Apr 22, 2022

Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of treatment adherence.

Sumanta Kumar Pal, MD, FASCO - Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies Apr 22, 2022

Go online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with advanced disease. Our panel of experts will discuss how highly efficacious therapeutic strategies are changing outcomes in earlier lines of treatment and the potential for approved agents to be used in new settings. With illustrative patient cases guiding the discussion, this engaging activity will provide participants with the information they need to navigate important clinical decisions, including how to sequence available therapies; which systemic therapies to use in patients with metastatic, locally advanced, or high-risk localized disease; what steps should be taken to manage AEs associated with newer treatment strategies; and which patients could benefit from clinical trial enrollment. Don’t miss this opportunity to learn more about providing guideline-recommended individualized care for your patients with RCC. Upon completion of this CE activity, participants will be able to: Incorporate novel therapeutic approaches, latest clinical evidence, expert recommendations, and patient-, disease-, and treatment-specific factors in the development of contemporary, personalized management plans for patients with RCC, Recommend clinical trials evaluating novel agents and/or combination approaches as standard treatment options for eligible patients with RCC across the disease spectrum, Apply evidence-based strategies and best practices to diagnose, mitigate, and manage AEs related to novel systemic therapies, including combination regimens, for patients with RCC.

Herbert L. Bonkovsky, MD - Putting the Pieces Together: Would You Recognize Acute Hepatic Porphyria If You Saw It? Apr 22, 2022

Go online to PeerView.com/DQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in acute hepatic porphyria (AHP) reviews the diagnostic criteria for AHP and examines current treatment options. Upon completion of this activity, participants should be better able to: Apply laboratory and diagnostic assessments to confirm suspicion of AHP, Recognize disease burdens that patients with AHP frequently experience (eg, impact on overall health, quality of life, daily activities), Employ evidence-based treatment regimens that include siRNA therapy, as appropriate, to improve outcomes, minimize disease impact, and reduce the burdens of disease in patients with AHP.

Gregory W. Albers, MD / S. Claiborne “Clay” Johnston, MD, PhD - Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts? Apr 15, 2022

Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to include expanded and detailed recommendations for the use of dual antiplatelet therapy (DAPT), the combination of aspirin and clopidogrel or ticagrelor, to further reduce the risk of stroke. These guidelines also include specific recommendations for individuals with minor acute ischemic stroke (AIS) or a TIA. In this activity based on a recent satellite symposium in New Orleans, leading experts on stroke management highlight the current guideline recommendations and discuss the latest perspectives on DAPT before transitioning to patient case scenarios where each expert demonstrates how these advances can be translated into clinical practice to improve outcomes and reduce the risk of recurrent stroke, while accounting for bleeding risks, antiplatelet resistance, and patient adherence. Upon completion of this CE activity, participants will be able to: Identify individuals with AIS or TIA who are appropriate candidates for treatment with antiplatelet therapy to reduce the risk of recurrent stroke, Assess the benefits and risks of using P2Y12 inhibitors with aspirin as DAPT for the prevention of recurrent stroke, Apply DAPT with P2Y12 inhibitors in appropriate patients following symptom onset to reduce the risk of recurrent stroke, Employ patient-centered communication strategies to facilitate adherence to DAPT with P2Y12 inhibitors in appropriate patients with AIS or TIA to reduce the risk of recurrent stroke.

Julie Parsons, MD - Breakthroughs in Spinal Muscular Atrophy: Managing the Life-Changing Impact of Gene Replacement Therapy Apr 15, 2022

Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.

Henry M. Kuerer, MD, PhD, FACS / Heather L. McArthur, MD, MPH - Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches Apr 13, 2022

Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale, clinical characteristics, and current therapeutic options for triple-negative breast cancer (TNBC), including immunotherapies and targeted therapies, Apply the most up-to-date safety, efficacy, and biomarker data from clinical trials evaluating established and emerging therapies, including immunotherapies and targeted approaches, in the treatment of patients with TNBC, Integrate optimized and individualized approaches to biomarker testing, immunotherapeutic and targeted treatment selection and sequencing, adverse event monitoring and management, and team-based care into management plans for patients with TNBC.

Carla M. Nester, MD, MSA, FASN - Hope Is on the Horizon: The Clinical Potential of Emerging Disease-Modifying Therapies for Managing Complement 3 Glomerulopathy Apr 13, 2022

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Milind Javle, MD - Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine Apr 11, 2022

Go online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into the latest science on the biologic rationale for targeting prevalent genetic aberrations in biliary cancers and review key safety and efficacy data from recent pivotal clinical trials of novel strategies. Through discussions of relevant patient scenarios, our panel will offer insight on how to integrate biomarker-guided treatments into clinical practice and practical guidance on identifying patients with advanced biliary cancers who are eligible for targeted treatment. Upon completion of this CE activity, participants will be able to: Summarize the rationale for use and recent efficacy and safety data on newly available and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Identify patients with advanced biliary cancers who are eligible for treatments with available and emerging therapies targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 alterations, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Integrate the latest clinical evidence into the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics in the context of clinical practice or a clinical trial.

Cindy Neunert, MD, MSCS - Modern Management of ITP: Thinking Beyond the Conventional Therapies Apr 08, 2022

Go online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will be able to: Discuss current challenges, unmet needs, and newer developments in ITP including the importance of differential diagnosis, testing, and guideline recommendations in treatment decision-making, Analyze safety, efficacy, evidence, and mechanism of action of BTKis and other emerging agents to improve quality of life and invoke long-term, off-treatment remissions, Develop personalized treatment plans for front-line and second-line therapies based on patient- and disease-specific factors to improve patient outcomes in ITP.

Petros Grivas, MD, PhD - Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions Apr 06, 2022

Go online to PeerView.com/JKS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, developed in collaboration with the Bladder Cancer Advocacy Network, a panel of leading bladder cancer experts will pair important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity highlights strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Upon completion of this CE activity, participants will be able to: Incorporate the latest clinical evidence, describe the current therapeutic roles and mechanistic rationales of novel systemic therapies, including immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates, across bladder cancer settings and patient populations (eg, localized or metastatic), Develop personalized treatment plans for patients with localized or metastatic bladder cancer that incorporate novel agents, updated guideline recommendations, and patient-, disease-, and treatment-specific factors, Employ evidence-based, collaborative strategies to mitigate and manage treatment-related AEs in patients receiving novel systemic therapies for bladder cancer.

J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema Apr 06, 2022

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

Amit Bar-Or, MD, FRCPC / Daniel S. Reich, MD, PhD - Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now Apr 04, 2022

Go online to PeerView.com/TCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in MS discuss the rationale, evidence, and practical potential for BTK inhibitors in patient-centered MS care. Upon completion of this CE activity, participants will be able to: Describe the rationale for inhibiting Bruton’s tyrosine kinase (BTK) to treat multiple sclerosis (MS), Evaluate current evidence related to the efficacy and safety of BTK inhibitors in the treatment of MS, Identify patients who could benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.

John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs Apr 04, 2022

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Nasser Altorki, MD / Jonathan D. Spicer, MD, PhD, FRCSC - Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes? Apr 04, 2022

Go online to PeerView.com/CRA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to the early-stage setting and transforming the multimodal management of resectable stage I-III NSCLC. While remarkable data have emerged from several trials assessing ICIs and rational combinations in neoadjuvant and/or adjuvant settings, many questions remain. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal timing and duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? These and other essential topics are addressed by two leading experts in thoracic surgery in this PeerView Live Seminar and Case Forum. Watch this stimulating discussion of practice-changing data on perioperative immunotherapy, surgical implications and applicability to practice, and how to make the most of ICIs as part of multimodal management of resectable NSCLC to reduce the risk of recurrence and improve cure rates. You will also be able to watch an intriguing debate of real cases selected to highlight the practicalities and challenges of integrating perioperative immunotherapy into practice. Upon completion of this CE activity, participants will be able to: Review the mechanistic aspects of immune checkpoint inhibition, rationale for their use as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapies in these settings, Describe the latest evidence on surrogate endpoints, such as pathologic response criteria, to assess treatment response and gain perspective on the prognosis of patients with resectable lung cancer receiving immunotherapy, Select appropriate resectable NSCLC patients for perioperative immunotherapy, weighing the benefits/limitations and surgical implications based on critical analysis of clinical trial findings and persisting misperceptions, Implement best practices for multidisciplinary communication and collaboration to ensure integration of immunotherapies into multimodal treatment plans for appropriate patients with stage I-III resectable NSCLC.

Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options Apr 01, 2022

Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.

Stephen V. Liu, MD - Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naïve and Pretreated Fusion-Positive NSCLC and Other Tumors Mar 31, 2022

Go online to PeerView.com/BNK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the expanding role of macrocyclic TKIs in the treatment of fusion-positive NSCLC and other solid tumors. Upon completion of this activity, participants should be better able to: Discuss the structure and mechanisms of action of macrocyclic tyrosine kinase inhibitors (TKIs) and their role in the treatment of fusion-positive non–small cell lung cancer (NSCLC) and other solid tumors, Compare the characteristics, efficacy, and safety of macrocyclic TKIs with those of standard TKIs in the treatment fusion-positive NSCLC and other solid tumors, including in treatment-naïve and pretreated populations, Implement best practices for identifying patients with fusion-positive NSCLC or other solid tumors who might benefit from the use of macrocyclic TKIs in the context of clinical practice or clinical trials.

Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults Mar 30, 2022

Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for an expert-led event designed to answer important questions on prostate cancer treatment in the modern era. Combining insight on relevant data from important trials with practical guidance on using guideline-recommended strategies in clinical practice, this event will help clinicians provide optimal personalized care informed by relevant patient-, tumor-, and treatment-related factors and address AEs related to newer therapies and combinations. Upon completion of this CE activity, participants will be able to: Apply current guideline recommendations for germline and tumor testing for clinically relevant biomarkers in patients with prostate cancer, Integrate novel treatment regimens into the management of patients with advanced prostate cancer, based on recent evidence, genetic/molecular features, current guideline recommendations, and individual patient needs and preferences, Employ evidence- and team-based approaches to proactively mitigate and manage treatment-related AEs that may arise in patients receiving novel therapies and combinations for advanced prostate cancer.

Mark S. Freedman, MD - Leveraging S1PR Modulators to Provide Patient-Centered MS Care: An Expert-Driven Review of the Data Mar 29, 2022

Go online to PeerView.com/KAP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.In this expert-led activity, you will learn to leverage S1PR modulators to provide patient-centered MS care Upon completion of this activity, participants should be better able to: Identify the mechanisms of action for S1PR modulators approved for the treatment of multiple sclerosis in the context of disease pathophysiology. Assess the benefits and risks associated with S1PR modulators based on the most recent clinical data,Apply the latest clinical data on S1PR modulators to individualized MS treatment plans

Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape Mar 29, 2022

Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on disease stage and patient factors. To ensure that clinicians are providing optimal care to their patients with HCC, this PeerView Live Seminar and Tumor Board program will pair insightful commentary on cutting-edge science that has validated innovative systemic options in HCC with clinical insights from different disciplines. Each discussion will feature reflective case-centered discussions on the increasingly important role of multidisciplinary treatment across the HCC continuum. Register today to hear an in-depth examination of how the HCC management team can successfully collaborate to offer the best possible care for their patients! Upon completion of this CE activity, participants will be able to: Evaluate current clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immuno-oncology agents, and novel combination regimens, for patients with advanced HCC, Sequence appropriate therapeutic options across multiple lines of therapy for patients with HCC based on the available evidence, guideline recommendations, and patient-, disease-, and treatment-specific factors, Recommend ongoing clinical trials assessing innovative strategies, including combinations of locoregional therapies with systemic therapies, in HCC patients in different disease and treatment settings, Incorporate multidisciplinary care approaches, including strategies to maximize treatment efficacy, safety/tolerability, and patient quality of life, for the optimal assessment and management of patients with HCC across the disease continuum]

Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do Mar 16, 2022

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Anthony R. Mato - The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers Mar 16, 2022

Go online to PeerView.com/CZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Covalent BTK inhibitors have transformed the care of B-cell cancers such as CLL/SLL and MCL, but challenges to optimal care remain. How well do you understand the barriers to consistent, efficacious treatment with BTK-based treatment and what that means for treatment planning across multiple lines of therapy? During this activity, experts will tackle these questions and demonstrate how to strategically plan for and implement management protocols that address clinical problems such as BTK inhibitor resistance and intolerance. Throughout, the panelists will share insights on evidence-based and effective sequential therapy (including with second-generation covalent BTK inhibitors, noncovalent BTK options, and non–BTK inhibitor agent classes) and use case-based discussion to illustrate how therapeutic challenges associated with BTK inhibitor therapy can be overcome. Upon completion of this CE activity, participants will be able to: Develop plans to capture therapeutic intolerance or BTK resistance mutations before or at disease progression in patients receiving treatment with covalent BTK inhibitors, Select evidence-based sequential therapy for patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations, Recommend appropriate sequential options for patients with B-cell cancers who exhibit therapeutic intolerance to BTK inhibitors in order to maximize safety, ensure continued efficacy, and augment patient quality of life.

Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition Mar 15, 2022

Go online to PeerView.com/SWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.

Tammie L.S. Benzinger - The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Management: Is Radiology Prepared for New Challenges? Mar 01, 2022

Go online to PeerView.com/KZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A multidisciplinary panel of experts discuss the expanding role of neuroimaging in the diagnosis and management of Alzheimer’s disease. Upon completion of this CE activity, participants will be able to: Assess the relative utility of the structural, functional, and molecular neuroimaging techniques used in AD diagnosis and management, Implement an evidence-based, guideline-directed approach to using neuroimaging to assess amyloid burden when confirming a diagnosis of AD or determining patient eligibility for use of amyloid-lowering therapy, Apply validated neuroimaging techniques and biomarkers to monitor for treatment response, disease progression, and ARIA or other adverse events in patients being treated for AD, Employ a patient-centered, multidisciplinary approach to patient care in AD

Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH Mar 01, 2022

Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team Feb 23, 2022

Go online to PeerView.com/CPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in later-line settings and are now being tested in earlier-stage disease. While oncologists, oncology nurses, and other members of the interdisciplinary cancer care team have new opportunities for increasing survival and improving QOL in their patients with unresectable/metastatic GIST, they are also faced with more complex treatment paradigms that must account for mutation profiling, treatment selection/sequencing, symptom and AE management, psychological support, and nutritional considerations. Join our experts to hear how all members of the cancer care team can work together to effectively incorporate these modern TKIs into clinical practice. Upon completion of this CE activity, participants will be able to: Summarize current clinical evidence on established (ie, standard and newly available) and emerging TKI strategies (ie, modern TKIs in early-line settings) for unresectable/metastatic GIST, Sequence appropriate targeted therapy over multiple lines of treatment for patients with unresectable/metastatic GIST, Develop personalized treatment plans that address effective safety, dosing, and QOL strategies associated with the use of TKIs with an interprofessional team of clinicians who care for patients with unresectable/metastatic GIST.

William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options Feb 23, 2022

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Christian B. Ramers, MD, MPH, AAHIVS - A Closer Look at Telehealth for HIV: Best Practices for Patient Management in a Unique Era of Care Feb 22, 2022

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Suzanne Lentzsch, MD, PhD - A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey Feb 22, 2022

Go online to PeerView.com/HYJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibodies have allowed clinicians to bring their “A” game when managing multiple myeloma (MM). To see how this happened, watch this activity, developed in collaboration with HealthTree Foundation, to view how experts have rapidly integrated CD38, SLAMF7, and BCMA antibodies into the management of newly diagnosed and relapsed/refractory disease. Each case-based lecture also includes a video testimonial from a patient with MM on how treatment with novel antibodies has made a difference in their lives. Upon completion of this CE activity, participants will be able to: Cite updated evidence on the use of novel antibody platforms targeting CD38, SLAMF7, and BCMA in NDMM and RRMM, Integrate antibody-based therapies, including triplet and quadruplet regimens, into the management of patients with NDMM, Recommend appropriate antibody options for the management of RRMM, including for patients with early relapse or heavily pretreated disease, Develop strategies addressing practical aspects of antibody therapy in MM, including issues related to dosing/scheduling and unique safety considerations, such as neutropenia, infection, and ocular toxicity.

Carlos M. de Castro, MD - Upstream and Downstream Targeting of the Complement Pathway to Manage PNH: Current and Emerging Inhibitors Feb 17, 2022

Go online to PeerView.com/YQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hematology-oncology provides an overview of paroxysmal nocturnal hemoglobinuria (PNH) and discusses current and emerging treatment options for managing PNH. Upon completion of this CE activity, participants will be able to: Discuss the complement pathway and its mechanistic relationship to paroxysmal nocturnal hemoglobinuria (PNH), Summarize efficacy and safety data surrounding complement pathway inhibitors, including factor B inhibitors, to treat PNH, Manage the unique adverse events associated with complement pathway inhibitors for PNH.

Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care Feb 15, 2022

Go online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series of alternating case-based discussions and mini-lectures, the panelists use recent science to explore the practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; appropriate safety management and monitoring strategies; and the emergence of novel immunotherapy options in the form of bispecific antibodies. Upon completion of this CE activity, participants will be able to: Summarize the treatment role of novel antibodies and CAR-T options in the management of relapsed diffuse large b-cell lymphoma (DLBCL) as supported by current evidence and clinical practice guidelines, Integrate novel antibody and cellular therapy options, including as sequential therapy, in the management of patients with relapsed/refractory DLBCL, Manage practical considerations associated with antibody and cellular therapy in DLBCL, including confirmation of patient eligibility for treatment, referral to specialized care centers when appropriate, and strategies for mitigating or managing adverse events in patients receiving therapy.

Anita H. Clayton, MD - Recent Advances and Novel Options in Depression: Reviewing the Evidence for GABA-Modulating Neuroactive Steroids for Major Depressive Disorder Feb 15, 2022

Go online to PeerView.com/TTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the evidence for the use of GABA-modulating neuroactive steroids for major depressive disorder. Upon completion of this CE activity, participants will be able to: Summarize the evidence supporting a role for GABAergic dysfunction and altered neuroactive steroid signaling in major depressive disorder (MDD), Recognize the burden of MDD and the impact of delayed or suboptimal treatment on patient outcomes, Evaluate recent safety and efficacy data related to emerging treatment options for MDD, recognizing potential implications for the future treatment landscape.

George L. Bakris, MD / Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF - Advancing the Standard of Care for Patients with Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice Feb 09, 2022

Go online to PeerView.com/YVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hyperkalemia is a potentially life-threatening condition caused by the inability of the kidneys to excrete potassium sufficiently. Excessive potassium levels can lead to cardiac arrhythmias and sudden cardiac death. Hyperkalemia is often encountered in hospitalized patients and frequently recurs after discharge. The problem is further complicated by the fact that guideline-directed medical therapies frequently used to reduce cardiorenal risks in patients with heart failure (HF) or chronic kidney disease (CKD) can increase the risk of hyperkalemia. Newer potassium binders may allow these patients to better tolerate guideline-directed therapies, as well as reduce the risk of hyperkalemia recurrence. Interprofessional models of care, such as those involving the pharmacist in transition-of-care interventions, have also been shown to improve patient outcomes. In this activity, based on a recent live web broadcast, an interprofessional expert panel examines the diagnostic thresholds for hyperkalemia, the factors that contribute to its risk in patients with HF, CKD, or diabetes, and the associations between hyperkalemia and poor patient outcomes. The experts also explore the latest evidence for modern potassium binders, share evidence-based strategies for integrating these agents into patient-centered treatment plans, and consider how interprofessional approaches to care can improve patient outcomes and potentially reduce readmission rates. Upon completion of this CE activity, participants will be able to: Recognize thresholds for mild, moderate, and severe hyperkalemia and their implications for recurrent hospital admissions and mortality, Describe the burden of hyperkalemia in patients with HF and CKD and its association with renin-angiotensin-aldosterone system (RAAS) inhibitors, Differentiate agents for managing hyperkalemia according to their mechanisms of action, indications, and pharmacologic characteristics, Apply evidence-based strategies to manage hyperkalemia, optimize care transitions, and potentially reduce hyperkalemia-related hospital readmissions in patients with HF or CKD.

Sara M. Tolaney, MD, MPH - New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy Feb 03, 2022

Go online to PeerView.com/AGM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The orally bioavailable CDK4 and 6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been established standard-of-care options in HR+/HER2- metastatic breast cancer for a while, and recently, abemaciclib was also approved in the adjuvant setting for the treatment of patients with early breast cancer (EBC) at high risk of early recurrence. This brings new hope to a group of patients with EBC who have been underserved by existing therapeutic options and have faced an unacceptably high risk of recurrence. With great progress in clinical research come questions about how to translate it into improvements in clinical practice. Which patients are/are not candidates for adjuvant CDK4 and 6 inhibition based on the recent FDA approval and updated ASCO recommendations? What is the role of Ki-67 testing in determining patient eligibility for treatment? How should risk be assessed to inform treatment selection and improve outcomes in patients with HR+/HER2- EBC? These questions and others are answered in this succinct educational activity to help make the most of this new adjuvant therapy option for the benefit of patients. Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence. Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 and 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease. Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team-based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Biree Andemariam, MD - The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities Feb 01, 2022

Go online to PeerView.com/CMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in sickle cell disease discuss current and future disease management strategies, including recent safety, efficacy, and tolerability data for currently approved and emerging therapies. Upon completion of this CE activity, participants will be able to: Discuss the disease burden, etiopathogenesis, complications, and unmet needs associated with SCD, Appraise recent safety, efficacy, and tolerability data associated with currently approved and emerging therapies for SCD including anti-adhesion agents, antisickling agents, and pyruvate kinase-R (PKR) activators among others, Develop treatment plans to prevent and/or reduce veno-occlusive crises and end-organ damage in patients with SCD, Implement collaborative strategies and shared decision-making practices to ensure patient engagement in treatment decisions and management of therapy-related adverse events.

Erika Hamilton, MD - Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies Jan 28, 2022

Go online to PeerView.com/HCA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in breast cancer discuss the latest advances in the management of patients with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) breast cancer, including the rapidly accumulating evidence supporting the use of novel therapies such as selective estrogen receptor degraders (SERDs), selective estrogen receptor modulators (SERMs), selective estrogen receptor covalent antagonists (SERCAs), complete estrogen receptor antagonists (CERANs), and proteolysis-targeting chimeras (PROTACs), among others. In addition to analyzing the recent data from clinical trials with these ER-targeted therapies, patient case scenarios are presented to illustrate their potential role and use, and how to incorporate these novel treatments into the current management paradigm to improve outcomes in patients with ER+ breast cancer. Upon completion of this CE activity, participants will be able to: Cite the rationale for use, mechanism of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Incorporate the most recent efficacy, safety, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations into treatment regimens for eligible patients with HR+ breast cancer in the context of clinical practice or via clinical trial participation.

Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care Jan 26, 2022

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.

Neal K. Lakdawala, MD - Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment Jan 26, 2022

Go online to PeerView.com/TCX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is a clinically complex disease that is often undiagnosed or misdiagnosed. The mechanisms behind its pathophysiology are not yet fully understood, but HCM has multiple underlying drivers, including cardiac muscle hypercontractility. It is the most common genetic heart disease and follows an autosomal dominant pattern with a poorly defined prevalence, age-dependent penetrance, and widely variable outcomes, as no medications are specifically indicated for its treatment. Encouragingly, recent advances in precision medicine and emerging treatment strategies, such as targeted therapy with small molecules, have demonstrated improvements in imaging parameters and quality of life. In this engaging activity, based on a recent live web broadcast, leading experts examine the pathophysiology of HCM, current guideline recommendations, and patient-centered care, as they explore the latest evidence for myosin inhibitors. Compelling videos of patients with HCM are shown to articulate first-person perspectives on how this condition affects individuals and their families. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance and recent advances in testing and technology to promote early recognition, Recognize the burdens that patients with HCM experience and the effects that diagnosis and treatments can have on their lifestyle, activity level, and emotional well-being, Select from among current and emerging therapeutic strategies based on their efficacy, safety, and ability to address the underlying pathophysiology of HCM, Collaborate with multidisciplinary and interprofessional care colleagues to personalize HCM management plans consistent with new recommendations, including imaging and genetic testing, medical therapies, sudden cardiac death risk assessment and prevention, and lifestyle considerations, such as referring patients to HCM centers.

Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease Jan 24, 2022

Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.

Christopher Baugh, MD, MBA & Mark M. Awad, MD, PhD - Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice Jan 20, 2022

Go online to PeerView.com/KKF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with cancer often present to the ED in an acutely ill state with complications from their cancer or treatments used, but a broadening use of a new class of cancer immunotherapies has changed the types of complications experienced by these patients. This spectrum of unique toxicities, termed immune-related adverse events (irAEs), is less well known, and commonly, they are overlooked, misdiagnosed, and not appropriately managed in ED settings. Standard algorithms for diagnosis and treatment no longer apply, as irAEs require a distinct approach. Are you prepared to handle the new category of oncologic emergencies you are likely to increasingly encounter in your ED? This activity will help you get up to date and change your practice. Emergency medicine and oncology experts will join forces to provide practical, case-based guidance for timely and accurate recognition, triage, diagnosis, and management of irAEs associated with novel immunotherapies in patients with cancer who present to the ED. Upon completion of this CE activity, participants will be able to: Review the biologic reasons and mechanisms that drive the development of immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Describe the spectrum of irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED), Implement latest recommendations for identification, assessment, diagnosis/differential diagnosis, and management of irAEs in ED settings, Integrate team-based approaches to triage, evaluate, diagnose, and manage pertinent irAEs in the ED in collaboration with oncology professionals.

John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management Jan 20, 2022

Go online to PeerView.com/HZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView ”Clinical Consults” offers a window into how experts customize BTK inhibitor therapy to achieve optimal CLL care—and represents a timely and relevant guide to using potent therapies that have transformed patient management. Throughout, the experts will debate real-world clinical scenarios (supported by mini-lectures) designed to explore the use of first- and second-generation BTK inhibitors and address issues such as: selectivity and safety differences among BTK inhibitors; choosing a BTK option in treatment-naïve CLL; using phase 3 head-to-head safety evidence to guide therapy selection; agent sequencing in relapsed CLL and BTK-intolerant settings; and the management of BTK-related adverse events. Upon completion of this CE activity, participants will be able to: Contrast the selectivity and safety profiles of first- and second-generation BTK inhibitors with therapeutic applications in CLL, Summarize recent clinical evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Develop a management plan for adverse events associated with first- and second- generation BTK inhibitors used to treat CLL.

Bradley S. Miller, MD, PhD - Advances in Pediatric Growth Hormone Therapy: Visualizing the Impact on Individualized Care Jan 20, 2022

Go online to PeerView.com/VUG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric growth hormone deficiency (pGHD) discusses the latest advances in treatment and patient-centered approaches to care. Upon completion of this activity, participants should be better able to: Identify appropriate pediatric candidates for growth hormone (GH) therapy based on approved indications, current recommendations, and relevant diagnostic test results, Evaluate evidence regarding the clinical characteristics (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) of available and emerging GH therapies, Individualize pediatric GH therapy to include efforts that address patient needs and preferences, such as personalized dosing, therapeutic monitoring, and assistance with care transitions.

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management Jan 12, 2022

Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Jennifer Wargo, MD, MMSc - Leveraging Neoadjuvant and Adjuvant Immunotherapy to Break Through the Outcomes Plateau, Prevent Recurrences, and Improve Curability in Early-Stage Cancers Jan 11, 2022

Go online to PeerView.com/DVD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, multidisciplinary oncology experts discuss immunotherapy advances, focusing on transitioning immunotherapies to earlier disease settings to improve outcomes, prevent recurrences, and increase curability in early-stage cancers. Upon completion of this CE activity, participants will be able to: Describe the rationale for using neoadjuvant, adjuvant, or perioperative immunotherapy in early-stage cancers, key trials and relevant endpoints, and evolving evidence supporting ICI use in different early-stage solid tumors, Implement best practices for multidisciplinary/interprofessional patient and tumor evaluation as well as coordination of care when managing patients with early-stage cancers, Integrate immunotherapies into individualized, multimodal treatment plans for appropriate patients with early-stage cancers in clinical practice or through clinical trial participation, Assess the risks and benefits associated with neoadjuvant/adjuvant/perioperative immunotherapy use to ensure safe, optimally selected, and appropriately timed delivery of systemic and local multimodal therapies to patients with early-stage solid tumors.

Lenard A. Adler, MD / Oren Mason, MD - Overcoming Challenges in the Recognition and Management of Adult ADHD in Primary Care: Optimizing Outcomes to Reduce Disease Burden and Improve Quality of Life Jan 11, 2022

Go online to PeerView.com/CQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in attention-deficit/hyperactivity disorder (ADHD) discuss overcoming challenges in the recognition and management of adult ADHD in primary care. Upon completion of this CE activity, participants will be able to: Evaluate the association between attention-deficit/hyperactivity disorder (ADHD) symptoms and functional impairment in adulthood, Utilize evidence-based tools to identify and diagnose adult ADHD, Engage in shared decision-making to optimize ADHD treatment selection and management considering the latest clinical evidence as well as the patient’s ADHD symptoms, psychiatric and medical comorbidities, and individual preferences.

Robert Dreicer, MD, MS, MACP, FASCO/Pedro C. Barata, MD, MSc - Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer Jan 11, 2022

Go online to PeerView.com/TGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the multidisciplinary relationship between urologic oncologists and advanced practice clinicians in the management of patients with prostate cancer has become increasingly more important in providing the best patient care. During this video, an expert panel highlights how a multidisciplinary team can use the latest clinical evidence, treatment guidelines, and expert consensus recommendations to improve care for patients with prostate cancer and gives practical insights on applying next-generation anti-androgen agents, PARP inhibitors, and chemotherapy to the prostate cancer treatment landscape. The experts also provide meaningful guidance to assist clinicians in optimizing treatment planning based on a modern understanding of prostate cancer biology, best treatment practices, and the expanding opportunities for treatment personalization across the disease continuum. Upon completion of this CE activity, participants will be able to: Implement guideline recommendations related to genetic testing when managing patients with prostate cancer, Apply current evidence about available and emerging anti-androgen and non-hormonal agents when deciding on treatment for prostate cancer, Integrate appropriate anti-androgen and non-hormonal strategies into treatment plans for patients with prostate cancer.

Emma Guttman-Yassky, MD, PhD - Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis Jan 10, 2022

Go online to PeerView.com/AYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts will review the presentation and diagnosis of AD and discuss the current evidence and guidelines for treatment selection for pediatric and adult patients. The faculty will also offer their thoughts on engaging with patients to provide personalized care and improved outcomes. Learn from the data and the experts in this informative, engaging discussion. Upon completion of this activity, participants should be better able to: Summarize underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of atopic dermatitis (AD), Assess the severity of AD in pediatric and adult patients according to evidence-based practice guidelines, Select treatment for pediatric and adult patients with AD according to current evidence and guidelines, identifying patients with moderate to severe disease who would likely benefit from targeted therapy, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of AD and engage them in their care.

David Malebranche, MD, MPH - Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient Jan 06, 2022

Go online to PeerView.com/ZWH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite a widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, there has been unequal progress with increasing access to treatment and reducing the number of new HIV infections and AIDS-related deaths, resulting in several vulnerable populations being left behind. Stigma and discrimination, together with other social inequalities and exclusion, are proving to be key barriers in battling this epidemic. In this activity, based on a recent live web broadcast, provider and patient perspectives on overcoming barriers to modern HIV treatment strategies will be examined. Additionally, the engaging panel will discuss the importance of establishing strong patient–provider relationships and demonstrating an understanding of the unique challenges faced by each individual patient living with HIV. Upon completion of this CE activity, participants should be better able to: Apply updated evidence-based guidelines and recent clinical data when recommending initial antiretroviral therapy (ART) regimens and switch strategies for individual patients infected with HIV, Assess the potential impact of clinical trial data related to emerging therapeutic strategies for HIV, Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, ART, and comorbidities, Establish strong patient–provider relationships, and demonstrate an understanding of the unique challenges faced by each individual patient living with HIV, Develop strategies within the healthcare team to link people living with HIV to essential HIV care, treatment, and support services.

Sumanta Kumar Pal, MD, FASCO - Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients? Jan 06, 2022

Go online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI partners. Despite recent regulatory approvals, guideline updates, and abundant evidence, many medical and urologic oncologists find it challenging to bring these novel immune and targeted strategies into clinical practice. Designed to bridge the gap between theory and practice, this educational activity features expert guidance on how oncologists and urologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Featuring cases drawn from practice, participants will hear how peers resolve clinical issues as the faculty present best practices for individualized RCC treatment. Upon completion of this CE activity, participants will be able to: Choose appropriate, personalized treatment regimens that make use of recent clinical research findings on validated immune and targeted therapies for patients across the disease spectrum, including resectable disease, newly diagnosed metastatic, or previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for patients with RCC in different disease and treatment settings, Incorporate practical strategies to mitigate and manage AEs related to targeted and immune-based therapies for patients with RCC.

Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies Dec 20, 2021

Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, and locoregional combinations with systemic therapies, across the HCC disease spectrum, Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors, Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities.

David R. Jones, MD - Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC Dec 20, 2021

Go online to PeerView.com/MHD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team? This PeerView Live Candid Conversations & Clinical Consults, based on a recent web broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances, as well as provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, the importance of identifying patients with EGFR mutations in earlier disease settings, and the role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Optimize sample collection and EGFR testing in early-stage NSCLC to identify patients with EGFR mutations who might benefit from EGFR-targeted therapy, Apply the latest evidence and guidelines on EGFR-targeted therapies to select optimal therapy for patients with early-stage EGFR-mutated NSCLC, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and safely integrate adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC in clinical practice or through clinical trial enrollment.

Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared? Dec 16, 2021

Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Summarize the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse effects (irAEs) during or after treatment with cancer immunotherapies, Utilize algorithms and practical tools based on the latest clinical evidence and recommendations for identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs, Integrate shared decision-making, team-based approaches, and telemedicine to facilitate multidisciplinary and interprofessional collaboration and care coordination and improve clinician-patient communication and patient outcomes.

Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors Dec 16, 2021

Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the application of these agents using individualized treatment plans and effective multidisciplinary collaboration. Upon completion of this CE activity, participants will be able to: Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence, Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 & 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease, Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.

Steven E. Carsons, MD - Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade Dec 16, 2021

Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management Dec 10, 2021

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatment plans in order to optimize health outcomes and promote long-term weight loss. Upon completion of this CE activity, participants will be able to: Recognize the role of weight-loss pharmacotherapy used adjunct to other treatment approaches for addressing obesity pathophysiology, including metabolic adaptation, Assess available evidence on current and emerging GLP-1–based weight-loss pharmacotherapies, including long-term efficacy and safety data, Incorporate GLP-1–based weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options Dec 09, 2021

Go online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which provide a new option for managing relapsed disease. In this animated, visually enhanced activity, a hematology-oncology expert outlines the clinically relevant mechanistic aspects of covalent and noncovalent BTK inhibitors, mechanisms and patterns of resistance to covalent agents, and rationale for integrating novel approaches to combatting resistance and intolerance. Upon completion of this CE activity, participants will be able to: Summarize the mechanistic and selectivity differences among covalent and noncovalent BTK inhibitors, including their implications for off-target effects, agent safety profiles, and therapeutic intolerance, Describe the mechanisms of BTK inhibitor resistance, including core mechanisms of acquired resistance to covalent agents and how noncovalent inhibitors can overcome resistance mutations.

R. Sharon Chinthrajah, MD - Fulfilling Unmet Treatment Needs for Patients With IgE-Mediated Food Allergies: An Animated Exploration of Emerging Targeted Therapy Dec 09, 2021

Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of action of current and emerging treatments for IgE-mediated food allergies, Identify patients with IgE-mediated food allergies who would likely derive benefit from treatment with IgE-blocking therapies.

Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers Dec 08, 2021

Go online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in terms of clinical efficacy and minimal toxicity in solid tumors. Approved for the therapeutic management of recurrent and newly diagnosed glioblastoma multiforme (GBM) as well as unresectable, previously untreated malignant pleural mesothelioma (MPM), TTFields therapy in combination with other conventional cancer treatments is being explored in a number of ongoing clinical trials in patients with a range of solid tumors, including lung, pancreatic, gastric, liver, and ovarian cancers. This CME-accredited activity features a review of the latest advancements in cancer technology, along with expert insights and case discussions on the optimal integration and use of recently validated locoregional therapies, such as TTFields, in the clinic. The expert panel will also discuss key safety and efficacy data from recent pivotal clinical trials studying multimodal treatment strategies in GBM, MPM, and other solid tumor types. Upon completion of this CE activity, participants will be able to: Describe the mechanistic rationale and clinical evidence for validated locoregional therapies, such as tumor treating fields (TTFields), for glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM), Appraise new clinical evidence on investigational multimodal strategies with synergistic mechanisms of action (eg, TTFields in combination with systemic therapy, radiotherapy, or other modalities) across a range of solid tumor types, including lung, pancreatic, gastric, liver, and ovarian cancers, Integrate novel locoregional therapies into the therapeutic management of appropriately selected patients with GBM, MPM, or other solid tumors, including via clinical trial enrollment, Implement team-based strategies to minimize and manage adverse events associated with novel therapeutic modalities in patients with solid tumors.

Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings Dec 08, 2021

Go online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have recently been approved by the FDA for those with less common but highly important EGFR exon 20 insertion mutations. Furthermore, EGFR-targeted therapy is now also transitioning from the advanced to early-stage settings of lung cancer, with the first regulatory approval granted for adjuvant therapy so far, and further developments are anticipated. The expansion of the treatment arsenal means that appropriate biomarker testing is increasingly more important, including the selection and use of correct testing methodologies to identify all patients with diverse EGFR mutations who can benefit from novel targeted therapies. Are you prepared for the enhanced precision and granularity in testing and treatment that is now required? This PeerView activity highlights all the recent need-to-know advances in EGFR-targeted therapy, along with the implications for pathology and oncology practice. Top experts will also provide useful, case-based guidance on what, how, and when to test, and how to accurately interpret the complex results of EGFR mutation testing to guide individualized treatment decisions for patients with EGFR-mutated NSCLC. Upon completion of this CE activity, participants will be able to: Describe the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that serve as therapeutic targets and help to inform treatment decisions regarding targeted therapies, including in earlier disease stages, Apply the latest recommendations and best practices for biomarker testing to detect common and less common EGFR mutations in NSCLC, Implement multidisciplinary strategies for biomarker testing and individualized treatment selection throughout the NSCLC disease continuum, Integrate established, new, and investigational targeted therapies into the treatment of patients with EGFR-mutated NSCLC according to the latest evidence and guidelines and patient needs, values, and preferences.

Benjamin M. Greenberg, MD, MHS & Professor Anthony Traboulsee, MD - Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach Dec 08, 2021

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants will be able to: Recognize characteristics and evidence related to the role of BTK inhibitors in addressing MS pathophysiology, Compare characteristics of BTK inhibitors with other B-cell–targeted therapies, Evaluate available data on the efficacy, safety, and tolerability of BTK inhibitors in the context of addressing the treatment needs of patients with MS.

Donna E. Sweet, MD, AAHIVS, MACP - The HIV Prevention–Certified Provider Program: A Training and Certificate Program Designed to Improve Competencies and Expand the HIV Prevention Workforce Dec 08, 2021

Go online to PeerView.com/VQJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. No single prevention method or approach can stop the HIV epidemic on its own. Several interventions have proved highly effective in reducing the risk of, and protecting against, HIV infection, including male and female condoms, the use of antiretroviral medicines as pre-exposure prophylaxis (PrEP), and the treatment of people living with HIV, to reduce viral load and prevent onward transmission. Despite the availability of this widening array of effective HIV prevention tools and a massive scale-up of HIV treatment in recent years, new infections among adults globally have not decreased sufficiently, and infections have actually increased in the United States among African American gay and bisexual men and Hispanic/Latino gay and bisexual men. Although the Centers for Disease Control and Prevention has issued clinical practice guidelines for PrEP use in the United States, numerous implementation barriers remain, including questions about the effectiveness of PrEP, optimal settings for provision, cost, and the most effective ways to motivate healthcare practitioners to prescribe PrEP. Protocols to identify individuals who are most likely to benefit from PrEP have been developed, but addressing racial, ethnic, and socioeconomic disparities poses additional challenges. This activity will marry Dr. Donna Sweet’s personal experiences in clinical utilization of HIV prevention strategies with practical, evidence-based guidance for patient care decisions, to provide additional motivation and rationale for participants to review their own current management strategies and adjust them as needed to optimize patient care. Upon completion of this CE activity, participants will be able to: Effectively engage clients in conversations about sexual health practices to assess HIV risk factors and support their ability to have healthy sex lives, Develop a set of comprehensive competencies (with a focus on PrEP interventions) based on a provider’s individual client needs, Apply current evidence with individual client needs/preferences when integrating HIV prevention options (eg, PrEP, PEP, viral suppression, female condoms) into practice, Employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among clients at increased risk for HIV infection, Facilitate access to HIV prevention options by effectively connecting clients to available resources, support, and assistance, Describe currently available and emerging tools that have been shown to significantly reduce the risk of HIV transmission or acquisition, Describe currently available methods for client-friendly diagnostic tests that measure and improve adherence to medications.

Richard Elion, MD / Rupa R. Patel, MD, MPH, DTM&H - PrEP for All Ages: A Comprehensive Look at Employing HIV Prevention Strategies Across All Age Groups Nov 29, 2021

Go online to PeerView.com/HNA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in infectious diseases discuss employing PrEP and HIV prevention strategies across all age groups. Upon completion of this activity, participants should be better able to: Describe the biologic principles and HIV prevention benefit of PrEP, Discuss clinical data to support PrEP use in different age groups (eg, youth, adults, and older adults), Develop strategies for the healthcare team to employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection across the lifespan, Facilitate access to PrEP among youth, adults, and individuals aged 50 and older.

Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next? Nov 29, 2021

Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what’s showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.

Carl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy Nov 26, 2021

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Bruce Cree, MD, PhD, MAS - Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis Nov 22, 2021

Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completion of this CE activity, participants will be able to: Describe the mechanisms of action for S1PR modulators approved for the treatment of MS in the context of disease pathophysiology, Recognize the therapeutic effects of S1PR modulators approved for the treatment of MS, including efficacy, safety, and tolerability, and the potential impact on emerging disease state markers (eg, brain atrophy, neurofilament protein, cognition), Use S1PR modulators appropriately, according to current recommendations and evidence, to meet treatment needs of individuals with MS.

Jonathan A. Bernstein, MD - Visualizing Progress in the Management of Chronic Spontaneous Urticaria: Harnessing the Clinical Potential of New and Novel Therapies to Address Unmet Patient Needs Nov 19, 2021

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care Nov 16, 2021

Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.

Timothy Berger, MD - Changing the Game for Patients With Prurigo Nodularis: Best Practices to Achieve Treatment Goals and Improve Quality of Life Nov 12, 2021

Go online to PeerView.com/AXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses best practices to achieve treatment goals and improve quality of life for patients with prurigo nodularis and a patient provides a firsthand account concerning the great impact the disease can have. Upon completion of this CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN), Discuss advances in the underlying pathophysiology of PN that have led to the identification of new therapeutic targets, Describe the clinical profiles of emerging treatment options for PN, Develop treatment plans for PN that are tailored to the individual needs of each patient, considering clinical presentation, comorbidities, and response to prior therapies.

Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team Nov 09, 2021

Go online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial. Upon completion of this CE activity, participants will be able to: Interpret the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Utilize multidisciplinary management strategies for localized and diffuse TGCT that include collaboration between oncologists, orthopedic surgeons, advanced practice clinicians, and other relevant professionals, Apply clinical evidence for the use of targeted options as part of the multimodal management of TGCT, including for patients for whom continued surgery is unlikely to produce clinical benefits, Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Kurt A. Schalper, MD, PhD - Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy Nov 05, 2021

Go online to PeerView.com/QRC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss IO biomarkers. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for and practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for multidisciplinary collaboration and coordination among pathologists, oncologists, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.

Lisa A. Beck, MD - Integrating the Latest Evidence Into Practice: Expert Insights on Targeted Biologic Therapy for Pediatric and Adult Patients With Moderate to Severe Atopic Dermatitis Nov 03, 2021

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

Philip J. Mease, MD, MACR - Improving the Recognition and Effective Management of Axial Spondyloarthritis: Practical Guidance for the Primary Care Provider Oct 25, 2021

Go online to PeerView.com/JTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the recognition and management of axial spondyloarthritis (axSpA). Upon completion of this accredited CE activity, participants should be better able to: Describe axial spondyloarthritis (axSpA) pathophysiology and epidemiology and complications associated with diagnostic and treatment delays, Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Assess efficacy and safety data related to novel treatment options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences, Recognize the importance of collaborating with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.

Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics Oct 19, 2021

Go online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and clinical presentation of myelofibrosis, Evaluate the latest safety, efficacy, and tolerability data supporting the use of JAK inhibitors and other novel strategies, including JAK inhibitor–based combinations or sequencing approaches for managing transplant-eligible and transplant-ineligible patients with myelofibrosis, Address practical aspects of individualized care and risk-adapted therapy in myelofibrosis for managing lower- and higher-risk patients, including those failing prior JAK inhibitor therapy, Educate patients on the treatment strategies, what to expect when undergoing treatment with JAK inhibitor or JAK inhibitor–based combinations, and how they can effectively collaborate with the oncology team to monitor and manage therapy-related adverse events.

Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC Oct 19, 2021

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Daniel Jacoby, MD - Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology Oct 19, 2021

Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options to patients with HCM. Upon completion of this activity, participants should be better able to: Recognize HCM’s pathophysiology and the associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Apply the latest recommendations and guidance for diagnosing, evaluating, and monitoring patients with HCM in a team-based manner, Evaluate current and emerging strategies for managing HCM in terms of efficacy, safety, and effects on burden of disease, Collaborate with patients to identify their individual goals and counsel them about the benefits and risks of testing and treatment.

Nicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care Oct 19, 2021

Go online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor usage based on changing circumstances, patient features, and safety considerations. Upon completion of this accredited CE activity, participants should be better able to: Review the selectivity and safety differences between first- and second-generation BTK inhibitors with therapeutic applications in CLL, Cite updated evidence surrounding the efficacy and safety of BTK inhibitors in treatment-naïve and relapsed/refractory CLL as monotherapy or as part of novel combination regimens, Recommend single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, Manage the unique spectrum of adverse events associated with first- and second-generation BTK inhibitors used to treat CLL.

Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies Oct 14, 2021

Go online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events. Upon completion of this accredited CE activity, participants should be better able to: Cite current evidence and guidelines supporting a treatment role for targeted agents, including BTK and BCL-2 inhibitors, in the management of B-cell malignancies, Identify the unique spectrum of adverse events associated with the use of targeted agents in B-cell malignancies, including hypertension, bleeding, cardiac events, TLS, neutropenia, fatigue, and others, Develop team-based management strategies to address the emergence of adverse events in patients with B-cell malignancies receiving therapy with novel agents, Utilize team-based educational and counseling strategies detailing therapeutic and safety expectations for patients with MCL, CLL, or other B-cell malignancies.

Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care Oct 13, 2021

Go online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ultimately improve care for their patients with MM. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence about the use of novel antibody platforms targeting CD38 and BCMA in relapsed/refractory multiple myeloma (RRMM), including in heavily pretreated disease, Integrate antibody-based therapies into team treatment plans for the management of patients with RRMM, Develop team-based strategies addressing practical aspects of antibody therapy in RRMM, including issues related to dosing/scheduling, unique safety considerations such as neutropenia, infection, and ocular toxicity, and patient and staff education on drug safety/delivery.

Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice Oct 12, 2021

Go online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options and hope for improved outcomes for these patients. This educational activity provides a grand tour through the exciting changes in the treatment arsenal for SCLC, including the impact of chemo-immunotherapy in the first-line setting and the emergence of the transcription inhibitor lurbinectedin as the new standard of care in the second-line setting, as well as a sneak peek into the future, focusing on what’s looking promising on the horizon based on findings from ongoing research efforts. The exploration of the treatment advances are framed by cases to illustrate how to integrate the new therapeutic options into practice and what factors to consider when constructing individualized treatment plans. Progress is inconsequential if it doesn’t rapidly translate into practice. Are you prepared to take all the necessary steps to improve outcomes for your patients with SCLC? Upon completion of this activity, participants should be better able to: Review the role and rationale for integrating novel therapies into the SCLC treatment arsenal, Assess the safety and efficacy data evaluating established and newly approved treatment options, including transcription inhibition as a novel therapeutic approach, for patients with SCLC, Integrate approved and emerging therapies into individualized management plans for patients with SCLC taking into consideration the latest findings, current guidelines and recommendations, and patient needs and preferences.

Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care Oct 12, 2021

Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, for patients with advanced biliary cancers, Apply practice-changing clinical trial evidence to personalize the management of patients with advanced biliary cancers, utilizing molecular testing and established and emerging targeted options based on individual tumor characteristics.

Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment Oct 11, 2021

Go online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, and other team members can collaborate to overcome the many challenges of VOD/SOS. Upon completion of this activity, participants should be better able to: Explain the clinical signs, symptoms, and medical burden of VOD/SOS to patients preparing for transplantation, Apply team-based approaches to risk assessment and diagnostic confirmation of VOD/SOS, including interpretation of clinical symptoms/disease onset and use of techniques such as ultrasound imaging or other strategies as appropriate, Use modern adverse event severity grading models to determine the presence and severity of organ dysfunction in patients with a VOD/SOS diagnosis, Recommend appropriate team management options for adult and pediatric patients with VOD/SOS in the post-HCT setting.

Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL Oct 11, 2021

Go online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to plan for and proactively capture the emergence of BTK resistance and intolerance, address the medical challenges of selecting effective sequential therapy, and prepare for the emergence of newer non-covalent BTK options. Throughout, our experts share sound, evidence-based treatment plans designed to address the medical needs of patients progressing on or unable to tolerate BTK covalent inhibitor therapy in the CLL/SLL and MCL settings. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence on the mechanistic properties, safety, and efficacy of covalent and non-covalent BTK inhibitors with therapeutic applications in B-cell malignancies, including in settings where therapeutic intolerance or resistance mutations are present, Develop management models for capturing therapeutic intolerance or BTK resistance mutations at disease progression in patients receiving treatment with covalent BTK inhibitors, Recommend evidence-based management plans addressing the therapeutic and safety needs of patients with CLL/SLL or MCL who are progressing on a covalent BTK inhibitor with resistance mutations or who are unable to continue on therapy due to adverse events.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy Oct 08, 2021

Go online to PeerView.com/WST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of pharmacy experts in multiple myeloma management discusses the latest evidence on novel antibody and CAR-T options and link key take-homes from the data to core aspects of pharmacy practice, from minimizing adverse events/drug interactions to educating patients and staff while addressing other pharmacy considerations. Upon completion of this accredited CE activity, participants should be better able to: Identify the current treatment role and regulatory status of novel antibodies and cell-based therapy for multiple myeloma, Summarize efficacy and safety evidence related to the use of CD38, SLAMF7, and BCMA-targeting antibodies and BCMA CAR-T therapy in newly diagnosed and relapsed multiple myeloma, Develop educational plans for staff and patients surrounding safety, dosing, and potential drug interactions associated with novel antibodies and cell therapy in multiple myeloma, Apply team-based management strategies for the integration of novel antibodies and cell therapy into existing treatment protocols for multiple myeloma, including addressing formulary concerns or developing intrainstitutional therapeutic algorithms.

Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical Oct 06, 2021

Go online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncologist, as well as a thoracic surgeon, among other specialists. Effective communication and coordination of care are also essential in the management of patients with unresectable stage III non–small cell lung cancer (NSCLC) deemed to be good candidates for consolidation ICI therapy after chemoradiation. How should this be operationalized in real-world settings? Learn useful strategies from this PeerView MasterClass and Tumor Board based on a recent web broadcast, which delivers evidence-based guidance on the best practices related to multidisciplinary patient assessment and treatment planning to help you improve outcomes in your patients with stage III NSCLC. Our panel of experts navigates through the latest evidence, key challenges, and controversies, as well as debates a series of real cases to demonstrate how to individualize patient care in the midst of rapid research and clinical advances. Upon completion of this activity, participants should be better able to: Discuss the latest clinical evidence on cancer immunotherapy in unresectable stage III NSCLC, Collaborate with relevant specialists to stage lung cancer, assess tumor resectability, and develop individualized treatment plans for patients with stage III NSCLC, Integrate cancer immunotherapies into the management of patients with unresectable stage III NSCLC according to the latest evidence and guidelines, multidisciplinary/interprofessional perspectives, and patient treatment and quality of life goals, Apply effective strategies to identify and manage immune-related adverse events in patients receiving cancer immunotherapy for unresectable stage III NSCLC treatment.

Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential Oct 01, 2021

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach Sep 30, 2021

Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.

Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC Sep 29, 2021

Go online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs and rational combinations are starting to show promising activity as neoadjuvant and adjuvant therapies for patients with resectable stage I-III NSCLC as well. Optimal approaches are still being determined, and many questions and controversies remain, but it is essential for oncologists, thoracic surgeons, and other multidisciplinary specialists to work together to make these therapies available to patients with earlier stages of lung cancer. This PeerView educational activity, based on a recent web broadcast, provides essential updates on the evolving science supporting the use of ICIs in multimodal treatment of unresectable and resectable stage I-III NSCLC. Multidisciplinary perspectives on how to make the most of immunotherapies and rational combinations in curative-intent settings are shared as well. Upon completion of this accredited CE activity, participants should be better able to: Characterize the rationale for using immunotherapy as a component of multimodal therapy in locally advanced or earlier stages of non–small cell lung cancer (NSCLC), Review key clinical trials and available efficacy/safety data on immunotherapies and immune-based combinations in locally advanced and earlier stages of NSCLC, Determine the best assessment and treatment approaches for diverse populations of patients with stage I-III NSCLC as part of clinical practice or clinical trials based on the latest evidence and recommendations, effective multidisciplinary and interprofessional collaboration and care coordination, and patient needs, values, and preferences.

Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment Sep 29, 2021

Go online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from these therapies, and thus, broad biomarker testing is essential to identify these patients, as is making the best rational therapies available to them. Many barriers to biomarker testing and appropriate biomarker-driven treatment exist, and there are also significant disparities in lung cancer clinical care and research, but effective steps can be taken to overcome them. An essential component of modern lung cancer management is patient education, which allows patients to become well-informed participants in their care and participate in shared decision-making with their multidisciplinary clinical teams. This PeerView educational activity, based on a recent web broadcast and developed in collaboration with the LUNGevity Foundation, brings together leading experts in lung cancer, patients, and advocates who engage in candid conversations and clinical consultations focused on how to navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer, and provide the best possible care to all patients. Upon completion of this accredited CE activity, participants should be better able to: Describe established, new, and emerging genomic alterations with potential for therapeutic targeting in NSCLC, Discuss the increasing importance of broad biomarker testing for clinical decision-making and the latest methods for identifying genomic alterations in NSCLC, Compare the mechanisms of action, efficacy, and safety of precision therapies targeting established, new, and emerging molecular alterations in NSCLC, Implement best practices, collaborative strategies, and shared decision-making to ensure widespread biomarker testing, precision treatment, and equitable care of diverse populations of patients with NSCLC in the context of clinical practice or clinical trials.

Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care Sep 28, 2021

Go online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions designed to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite evidence surrounding the efficacy of regimens with novel proteasome inhibitors, immunomodulatory drugs, antibodies, targeted therapies, and cell therapies across multiple myeloma (MM) treatment settings, including smoldering MM, newly diagnosed MM, and relapsed/refractory MM, Select evidence-based regimens with novel components for the management of patients with newly diagnosed MM, Develop treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options, Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.

Peter A. Lio, MD - Overcoming Challenges in the Management of Moderate to Severe Atopic Dermatitis: Practical Strategies for Selecting Treatment for Pediatric and Adult Patients Sep 20, 2021

Go online to PeerView.com/XAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients. Upon completion of this accredited CE activity, participants should be better able to: Summarize the pathophysiologic mechanisms and risk factors that contribute to the development of atopic dermatitis, Discuss the clinical evidence and mechanistic rationale for the use of biologic therapies in the treatment of moderate to severe atopic dermatitis, Develop treatment plans for adult and pediatric patients with moderate to severe atopic dermatitis to prevent flare-ups, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects, Employ strategies to communicate and collaborate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence.

Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care Sep 13, 2021

Go online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care. Upon completion of this accredited CE activity, participants should be better able to: Discuss genetic/molecular, clinical, or patient-related factors that can guide therapeutic selection in patients with treatment-naïve or relapsed/refractory CLL, Summarize current safety and efficacy evidence related to the use of novel and emerging therapeutics, including BTK, PI3K, and BCL-2 inhibitors and novel antibodies, across the spectrum of CLL, Select personalized initial or sequential treatment regimens with novel and emerging components for patients with treatment-naïve or relapsed/refractory CLL, including in the context of a clinical trial.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies Aug 31, 2021

Go online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon completion of this accredited CE activity, participants should be better able to: Identify the clinical signs of AML, relevant prognostic factors, and patient- or disease-related features that influence treatment selection, Discuss efficacy and safety evidence surrounding novel cytotoxic, targeted, and epigenetic therapies for AML, Develop educational strategies for patients with AML related to therapeutic expectations, adherence, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with AML receiving novel cytotoxic, targeted, and epigenetic therapies.

Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes Aug 17, 2021

Go online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the global disease burden, etiopathogenesis, risk factors, and stratification scores for cancer-associated VTE using established diagnostic tools, Review safety & efficacy evidence, clinical trial data, and practice guidelines for currently available treatment options for managing cancer-associated VTE, Employ guideline-concordant, evidence-based care and shared decision-making strategies including multidisciplinary and interprofessional collaboration for prevention and treatment of cancer-associated VTE in routine clinical practice.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected